{ "data": { "eventsdetail": [ { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates", "npi_num": "", "hcp_pin_alias": "1146513", "session_name": "Agnostic ADCs (TROP2 and other combinations)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1146513", "first_name": "Paolo", "middle_name": "", "last_name": "Bironzo", "org_name": "University of Turin", "Country": "Italy", "Region": "Piemonte", "City": "Torino", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Agnostic ADCs (TROP2 and other combinations)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunoconjugates", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Paolo Bironzo", "kol_full_name": "Paolo Bironzo" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Early Detection Of Cancer | Health Policy", "npi_num": "", "hcp_pin_alias": "1146502", "session_name": "Policy and preventive strategies,The dark age of single cancer screening is over", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1146502", "first_name": "Dario", "middle_name": "", "last_name": "Trapani", "org_name": "Istituto Europeo Di Oncologia", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Policy and preventive strategies", "rest_events_session_count": 1, "rest_events_session": "The dark age of single cancer screening is over", "events_topic": "Early Detection Of Cancer | Health Policy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dario Trapani", "kol_full_name": "Dario Trapani" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Liquid Biopsy", "npi_num": "", "hcp_pin_alias": "1146489", "session_name": "Latest liquid biopsy techniques", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1146489", "first_name": "Nicola", "middle_name": "", "last_name": "Normanno", "org_name": "Istituto Nazionale Tumori IRCCS Fondazione G. Pascale", "Country": "Italy", "Region": "Campania", "City": "Napoli", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Latest liquid biopsy techniques", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Liquid Biopsy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nicola Normanno", "kol_full_name": "Nicola Normanno" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Whole Genome Sequencing | Genital Neoplasms, Female", "npi_num": "", "hcp_pin_alias": "1145286", "session_name": "Gynaecological cancers,Whole genome sequencing: What are the benefits?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1145286", "first_name": "Charlie", "middle_name": "", "last_name": "Gourley", "org_name": "Cancer Research UK Scotland Centre, University of Edinburgh", "Country": "United Kingdom", "Region": "Scotland", "City": "Edinburgh", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gynaecological cancers", "rest_events_session_count": 1, "rest_events_session": "Whole genome sequencing: What are the benefits?", "events_topic": "Whole Genome Sequencing | Genital Neoplasms, Female", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Charlie Gourley", "kol_full_name": "Charlie Gourley" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genital Neoplasms, Female | Carcinoma, Ovarian Epithelial", "npi_num": "", "hcp_pin_alias": "1145165", "session_name": "Gynaecological cancers,Epithelial ovarian cancer: Discussion", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1145165", "first_name": "Antonio", "middle_name": "", "last_name": "Gonzalez-Martin", "org_name": "Clinica Universidad de Navarra", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gynaecological cancers", "rest_events_session_count": 1, "rest_events_session": "Epithelial ovarian cancer: Discussion", "events_topic": "Genital Neoplasms, Female | Carcinoma, Ovarian Epithelial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Antonio Gonzalez-Martin", "kol_full_name": "Antonio Gonzalez-Martin" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Ovarian Neoplasms | Datopotamab Deruxtecan | Standard Of Care | Endometrial Neoplasms", "npi_num": "", "hcp_pin_alias": "1145145", "session_name": "What we know and what we should know on immunotherapy and endometrial cancer (EC),Should IO be considered the new standard of care in advanced EC?,Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the Phase 2 TROPION-PanTumor03 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1145145", "first_name": "Ana", "middle_name": "", "last_name": "Oaknin", "org_name": "Vall d'Hebron Barcelona Hospital Campus", "Country": "Spain", "Region": "Cataluña", "City": "Barcelona", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What we know and what we should know on immunotherapy and endometrial cancer (EC)", "rest_events_session_count": 2, "rest_events_session": "Should IO be considered the new standard of care in advanced EC?,Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the Phase 2 TROPION-PanTumor03 study", "events_topic": "Immunotherapy | Ovarian Neoplasms ", "rest_events_topic_count": 3, "rest_events_topic": " Datopotamab Deruxtecan | Standard Of Care | Endometrial Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ana Oaknin", "kol_full_name": "Ana Oaknin" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Placebos | Atezolizumab | Ovarian Neoplasms | Drug Therapy | Genital Neoplasms, Female | Bevacizumab", "npi_num": "", "hcp_pin_alias": "1145113", "session_name": "Gynaecological cancers,Final overall survival (OS) from the Phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1145113", "first_name": "Jean-Emmanuel", "middle_name": "", "last_name": "Kurtz", "org_name": "Institut de cancerologie Strasbourg Europe - ICANS", "Country": "France", "Region": "Alsace", "City": "Strasbourg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gynaecological cancers", "rest_events_session_count": 1, "rest_events_session": "Final overall survival (OS) from the Phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)", "events_topic": "Placebos | Atezolizumab ", "rest_events_topic_count": 4, "rest_events_topic": " Ovarian Neoplasms | Drug Therapy | Genital Neoplasms, Female | Bevacizumab", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jean-Emmanuel Kurtz", "kol_full_name": "Jean-Emmanuel Kurtz" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genital Neoplasms, Female", "npi_num": "", "hcp_pin_alias": "1145073", "session_name": "Gynaecological cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1145073", "first_name": "Alexandra", "middle_name": "", "last_name": "Leary", "org_name": "Institut de Cancérologie Gustave Roussy", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gynaecological cancers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Genital Neoplasms, Female", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alexandra Leary", "kol_full_name": "Alexandra Leary" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Decision-Making", "npi_num": "", "hcp_pin_alias": "1145047", "session_name": "Prognostic and predictive factors for clinical decision making", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1145047", "first_name": "Nadia", "middle_name": "", "last_name": "Harbeck", "org_name": "LMU Hospital", "Country": "Germany", "Region": "Bayern", "City": "Munich", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Prognostic and predictive factors for clinical decision making", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Decision-Making", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nadia Harbeck", "kol_full_name": "Nadia Harbeck" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms | Biomarkers", "npi_num": "", "hcp_pin_alias": "1144949", "session_name": "Biomarkers in the treatment of breast cancer: Importance and pitfalls", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1144949", "first_name": "Fabrice", "middle_name": "", "last_name": "Andre", "org_name": "CLCC Institut Gustave Roussy", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Biomarkers in the treatment of breast cancer: Importance and pitfalls", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms | Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fabrice Andre", "kol_full_name": "Fabrice Andre" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Avelumab | Trophoblastic Neoplasms | Methotrexate | Pregnancy", "npi_num": "", "hcp_pin_alias": "1144941", "session_name": "Avelumab + methotrexate to eradicate low-risk gestational trophoblastic tumors in 1st-line setting: TROPHAMET phase I/II trial.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1144941", "first_name": "Benoit", "middle_name": "", "last_name": "You", "org_name": "Hospices Civils de Lyon", "Country": "France", "Region": "Rhone-Alpes", "City": "Lyon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Avelumab + methotrexate to eradicate low-risk gestational trophoblastic tumors in 1st-line setting: TROPHAMET phase I/II trial.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Avelumab | Trophoblastic Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Methotrexate | Pregnancy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Benoit You", "kol_full_name": "Benoit You" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Pembrolizumab | Radiotherapy | Chemoradiotherapy | Uterine Cervical Neoplasms | Ovarian Neoplasms", "npi_num": "", "hcp_pin_alias": "1144935", "session_name": "Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study,ADCs in ovarian cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1144935", "first_name": "Domenica", "middle_name": "", "last_name": "Lorusso", "org_name": "Humanitas University", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized", "rest_events_session_count": 3, "rest_events_session": " double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study,ADCs in ovarian cancer", "events_topic": "Immunoconjugates | Pembrolizumab ", "rest_events_topic_count": 4, "rest_events_topic": " Radiotherapy | Chemoradiotherapy | Uterine Cervical Neoplasms | Ovarian Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Domenica Lorusso", "kol_full_name": "Domenica Lorusso" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Rectal Neoplasms", "npi_num": "", "hcp_pin_alias": "1144676", "session_name": "Rectal cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1144676", "first_name": "Eric", "middle_name": "", "last_name": "Van Cutsem", "org_name": "KU Leuven", "Country": "Belgium", "Region": "Brussels", "City": "Leuven", "num_sess": "1", "opt_in_out_status": "0", "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Rectal cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Rectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eric Van Cutsem", "kol_full_name": "Eric Van Cutsem" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Amivantamab | Gastrointestinal Neoplasms | Colorectal Neoplasms", "npi_num": "2024060001", "hcp_pin_alias": "1144656", "session_name": "GI tumours, upper digestive,Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1144656", "first_name": "Filippo", "middle_name": "", "last_name": "Pietrantonio", "org_name": "Fondazione IRCCS Istituto Nazionale dei Tumori", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "2", "opt_in_out_status": "0", "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 4, "rest_events_session": " upper digestive,Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study", "events_topic": "Amivantamab | Gastrointestinal Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Colorectal Neoplasms", "kol_name": "Filippo Pietrantonio", "kol_full_name": "Filippo Pietrantonio" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Immunotherapy | Colonic Neoplasms", "npi_num": "", "hcp_pin_alias": "1144646", "session_name": "Neoadjuvant treatment for colon cancer: Building upon the existing data,Neoadjuvant immunotherapy in colon cancer: Are we there yet?,Should we try immunotherapy for all patients with advanced cancer? - Yes", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1144646", "first_name": "Myriam", "middle_name": "", "last_name": "Chalabi", "org_name": "Nederlands Kanker Instituut-Antoni van Leeuwenhoek", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "3", "opt_in_out_status": "0", "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neoadjuvant treatment for colon cancer: Building upon the existing data", "rest_events_session_count": 2, "rest_events_session": "Neoadjuvant immunotherapy in colon cancer: Are we there yet?,Should we try immunotherapy for all patients with advanced cancer? - Yes", "events_topic": "Neoadjuvant Therapy | Immunotherapy ", "rest_events_topic_count": 1, "rest_events_topic": " Colonic Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Myriam Chalabi", "kol_full_name": "Myriam Chalabi" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tertiary Lymphoid Structures | Solid Tumors | Immunotherapy", "npi_num": "", "hcp_pin_alias": "1113730", "session_name": "Atlas of Tertiary Lymphoid Structures in Solid Tumors: Genomic Features and Prediction of Response to Immunotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1113730", "first_name": "Antoine", "middle_name": "", "last_name": "Italiano", "org_name": "Institut Bergonié Bordeaux", "Country": "France", "Region": "Aquitaine", "City": "Bordeaux", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Atlas of Tertiary Lymphoid Structures in Solid Tumors: Genomic Features and Prediction of Response to Immunotherapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Tertiary Lymphoid Structures | Solid Tumors ", "rest_events_topic_count": 1, "rest_events_topic": " Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Antoine Italiano", "kol_full_name": "Antoine Italiano" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Head And Neck Neoplasms", "npi_num": "", "hcp_pin_alias": "1111649", "session_name": "Personalised immunotherapy strategies for head and neck cancers,Latest developments in virus targeting approaches for the management of head and neck cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1111649", "first_name": "Amanda", "middle_name": "", "last_name": "Psyrri", "org_name": "National Kapodistrian University of Athens", "Country": "Greece", "Region": "Attiki", "City": "Athens", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Personalised immunotherapy strategies for head and neck cancers", "rest_events_session_count": 1, "rest_events_session": "Latest developments in virus targeting approaches for the management of head and neck cancers", "events_topic": "Immunotherapy | Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Amanda Psyrri", "kol_full_name": "Amanda Psyrri" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thoracic Neoplasms | Carcinoma, Non-Small-Cell Lung", "npi_num": "", "hcp_pin_alias": "1088209", "session_name": "Non-metastatic NSCLC and other thoracic malignancies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1088209", "first_name": "Alfredo", "middle_name": "", "last_name": "Addeo", "org_name": "Hopitaux Universitaires De Geneve", "Country": "Switzerland", "Region": "Geneve", "City": "Geneva", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Non-metastatic NSCLC and other thoracic malignancies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Thoracic Neoplasms | Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alfredo Addeo", "kol_full_name": "Alfredo Addeo" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Artificial Intelligence", "npi_num": "1528057155", "hcp_pin_alias": "1077835", "session_name": "Application of GigaPath, an open-weight billion-parameter AI foundation model based on a novel vision transformer architecture for cancer mutation prediction and TME analysis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1077835", "first_name": "Carlo", "middle_name": "Bruno", "last_name": "Bifulco", "org_name": "Providence Health And Services Oregon", "Country": "United States", "Region": "Oregon", "City": "Portland", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Application of GigaPath", "rest_events_session_count": 1, "rest_events_session": " an open-weight billion-parameter AI foundation model based on a novel vision transformer architecture for cancer mutation prediction and TME analysis", "events_topic": "Artificial Intelligence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Carlo Bruno Bifulco", "kol_full_name": "Carlo Bruno Bifulco" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "", "hcp_pin_alias": "1047253", "session_name": "Breast cancer, early stage", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "1047253", "first_name": "Bidard", "middle_name": "Francois", "last_name": "Clement", "org_name": "Institut Curie", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 1, "rest_events_session": " early stage", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bidard Francois Clement", "kol_full_name": "Bidard Francois Clement" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genital Neoplasms, Female | Mechanism Of Action | Immunoconjugates", "npi_num": "", "hcp_pin_alias": "976434", "session_name": "Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?,Visiting the basics: Rationale and MoA", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "976434", "first_name": "Susana", "middle_name": "", "last_name": "Banerjee", "org_name": "The Royal Marsden NHS Foundation Trust", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?", "rest_events_session_count": 1, "rest_events_session": "Visiting the basics: Rationale and MoA", "events_topic": "Genital Neoplasms, Female | Mechanism Of Action ", "rest_events_topic_count": 1, "rest_events_topic": " Immunoconjugates", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Susana Banerjee", "kol_full_name": "Susana Banerjee" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Colorectal Neoplasms", "npi_num": "", "hcp_pin_alias": "975998", "session_name": "New technology, new ideas: What is on the horizon for colorectal cancer?,Novel systemic therapeutic approaches in mCRC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "975998", "first_name": "Maria", "middle_name": "MF", "last_name": "Fernandez", "org_name": "St George's Hospital", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New technology", "rest_events_session_count": 2, "rest_events_session": " new ideas: What is on the horizon for colorectal cancer?,Novel systemic therapeutic approaches in mCRC", "events_topic": "Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria MF Fernandez", "kol_full_name": "Maria MF Fernandez" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "", "hcp_pin_alias": "926891", "session_name": "Breast cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "926891", "first_name": "Joseph", "middle_name": "", "last_name": "Gligorov", "org_name": "Hôpital Tenon AP-HP", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joseph Gligorov", "kol_full_name": "Joseph Gligorov" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Thymus Neoplasms", "npi_num": "", "hcp_pin_alias": "863431", "session_name": "Current standards and advances in radiation for thymic tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863431", "first_name": "Rafal", "middle_name": "", "last_name": "Dziadziuszko", "org_name": "Medical University of Gdansk", "Country": "Poland", "Region": "Pomorskie", "City": "Gdansk", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Current standards and advances in radiation for thymic tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Thymus Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Rafal Dziadziuszko", "kol_full_name": "Rafal Dziadziuszko" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung | ErbB Receptors | Drug Therapy", "npi_num": "", "hcp_pin_alias": "863383", "session_name": "A Phase II Safety and Efficacy Study of PM8002/BNT327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863383", "first_name": "Yi-Long", "middle_name": "", "last_name": "Wu", "org_name": "Guangdong Provincial People's Hospital", "Country": "China", "Region": "Guangdong", "City": "Guangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Phase II Safety and Efficacy Study of PM8002/BNT327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung | ErbB Receptors ", "rest_events_topic_count": 1, "rest_events_topic": " Drug Therapy", "kol_name": "Yi-Long Wu", "kol_full_name": "Yi-Long Wu" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Systemic Therapy", "npi_num": "", "hcp_pin_alias": "863365", "session_name": "The role of systemic treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863365", "first_name": "Su", "middle_name": "Pin", "last_name": "Choo", "org_name": "Mount Elizabeth Hospital", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of systemic treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Systemic Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Su Pin Choo", "kol_full_name": "Su Pin Choo" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immunogenicity | Colorectal Neoplasms | Optimal Sequencing", "npi_num": "", "hcp_pin_alias": "863357", "session_name": "Metastatic colorectal cancer: Changing paradigms and the relevance for patient care,Optimal sequencing of therapeutic strategies in immunogenic CRC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863357", "first_name": "Sara", "middle_name": "", "last_name": "Lonardi", "org_name": "IOV Istituto Oncologico Veneto", "Country": "Italy", "Region": "Veneto", "City": "Padova", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Metastatic colorectal cancer: Changing paradigms and the relevance for patient care", "rest_events_session_count": 1, "rest_events_session": "Optimal sequencing of therapeutic strategies in immunogenic CRC", "events_topic": "Immunogenicity | Colorectal Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Optimal Sequencing", "kol_name": "Sara Lonardi", "kol_full_name": "Sara Lonardi" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung | Molecular Targeted Therapy", "npi_num": "", "hcp_pin_alias": "863341", "session_name": "Treating KRAS-mutated NSCLC,G12C targeted therapies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863341", "first_name": "Natasha", "middle_name": "B.", "last_name": "Leighl", "org_name": "Princess Margaret Cancer Centre", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treating KRAS-mutated NSCLC", "rest_events_session_count": 1, "rest_events_session": "G12C targeted therapies", "events_topic": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung ", "rest_events_topic_count": 1, "rest_events_topic": " Molecular Targeted Therapy", "kol_name": "Natasha B. Leighl", "kol_full_name": "Natasha B. Leighl" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Gastrointestinal Neoplasms", "npi_num": "", "hcp_pin_alias": "863338", "session_name": "GI tumours, lower", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863338", "first_name": "Michel", "middle_name": "", "last_name": "Ducreux", "org_name": "Gustave Roussy Cancer Institute", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 1, "rest_events_session": " lower", "events_topic": "Gastrointestinal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Michel Ducreux", "kol_full_name": "Michel Ducreux" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Oncogenes | Carcinoma, Non-Small-Cell Lung", "npi_num": "", "hcp_pin_alias": "863329", "session_name": "Promises and pitfalls in earlier stage NSCLC,Oncogene-addicted earlier stage NSCLC: Current standards, debates, and open questions", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863329", "first_name": "Laura", "middle_name": "", "last_name": "Mezquita", "org_name": "Hospital Clínic de Barcelona", "Country": "Spain", "Region": "Cataluña", "City": "Barcelona", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Promises and pitfalls in earlier stage NSCLC", "rest_events_session_count": 3, "rest_events_session": "Oncogene-addicted earlier stage NSCLC: Current standards, debates, and open questions", "events_topic": "Oncogenes | Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Laura Mezquita", "kol_full_name": "Laura Mezquita" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Neoadjuvant Therapy", "npi_num": "", "hcp_pin_alias": "863319", "session_name": "What’s next? Clinical and translational opportunities in the neoadjuvant setting", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863319", "first_name": "Julien", "middle_name": "", "last_name": "Taieb", "org_name": "European Hospital Georges Pompidou AP-HP", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What’s next? Clinical and translational opportunities in the neoadjuvant setting", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoadjuvant Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Julien Taieb", "kol_full_name": "Julien Taieb" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Cancer Prevention", "npi_num": "", "hcp_pin_alias": "863316", "session_name": "Are you really up-to-date on cancer prevention?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863316", "first_name": "Josep", "middle_name": "", "last_name": "Tabernero", "org_name": "Vall d'Hebron University Hospital", "Country": "Spain", "Region": "Cataluña", "City": "Barcelona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Are you really up-to-date on cancer prevention?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Josep Tabernero", "kol_full_name": "Josep Tabernero" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Colonic Neoplasms | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Gastrointestinal Neoplasms", "npi_num": "", "hcp_pin_alias": "863310", "session_name": "GI tumours, lower,Neoadjuvant chemotherapy in colon cancer: Who, what and for how long?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863310", "first_name": "Jenifer", "middle_name": "", "last_name": "Seligmann", "org_name": "University of Leeds School of Medicine", "Country": "United Kingdom", "Region": "England", "City": "Leeds", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 3, "rest_events_session": " lower,Neoadjuvant chemotherapy in colon cancer: Who, what and for how long?", "events_topic": "Colonic Neoplasms | Neoadjuvant Therapy ", "rest_events_topic_count": 2, "rest_events_topic": " Chemotherapy, Adjuvant | Gastrointestinal Neoplasms", "kol_name": "Jenifer Seligmann", "kol_full_name": "Jenifer Seligmann" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Colorectal Neoplasms", "npi_num": "", "hcp_pin_alias": "863294", "session_name": "Metastatic colorectal cancer: Discussion", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863294", "first_name": "Erika", "middle_name": "", "last_name": "Martinelli", "org_name": "Università degli studi della Campania Luigi Vanvitelli", "Country": "Italy", "Region": "Campania", "City": "Caserta", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Metastatic colorectal cancer: Discussion", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Erika Martinelli", "kol_full_name": "Erika Martinelli" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Gastrointestinal Neoplasms", "npi_num": "", "hcp_pin_alias": "863288", "session_name": "GI tumours, lower,Gastrointestinal tumours, lower digestive", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863288", "first_name": "Dirk", "middle_name": "", "last_name": "Arnold", "org_name": "Asklepios Clinic Altona", "Country": "Germany", "Region": "Hamburg", "City": "Hamburg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 3, "rest_events_session": " lower,Gastrointestinal tumours, lower digestive", "events_topic": "Gastrointestinal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Dirk Arnold", "kol_full_name": "Dirk Arnold" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Receptor, ErbB-3 | Encorafenib | Proto-Oncogene Proteins B-raf | Carcinoma, Non-Small-Cell Lung | Immunoconjugates | Binimetinib", "npi_num": "", "hcp_pin_alias": "863285", "session_name": "Specific ADCs: HER2, HER3, CEACAM5, MET,Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced Non-Small Cell Lung Cancer (NSCLC): an open-label, multicenter phase 2 trial (IFCT-1904 ENCO-BRAF)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863285", "first_name": "David", "middle_name": "", "last_name": "Planchard", "org_name": "Gustave Roussy Cancer Institute", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Specific ADCs: HER2", "rest_events_session_count": 5, "rest_events_session": " HER3, CEACAM5, MET,Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced Non-Small Cell Lung Cancer (NSCLC): an open-label, multicenter phase 2 trial (IFCT-1904 ENCO-BRAF)", "events_topic": "Receptor, ErbB-3 | Encorafenib ", "rest_events_topic_count": 4, "rest_events_topic": " Proto-Oncogene Proteins B-raf | Carcinoma, Non-Small-Cell Lung | Immunoconjugates | Binimetinib", "kol_name": "David Planchard", "kol_full_name": "David Planchard" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Microsatellite Stability | Colorectal Neoplasms | Optimal Sequencing", "npi_num": "", "hcp_pin_alias": "863280", "session_name": "Optimal sequencing of therapeutic strategies in biomarker unselected MSS CRC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863280", "first_name": "Chiara", "middle_name": "", "last_name": "Cremolini", "org_name": "Università di Pisa", "Country": "Italy", "Region": "Toscana", "City": "Pisa", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Optimal sequencing of therapeutic strategies in biomarker unselected MSS CRC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Microsatellite Stability | Colorectal Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Optimal Sequencing", "kol_name": "Chiara Cremolini", "kol_full_name": "Chiara Cremolini" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "KRAS Protein, Human | Solid Tumors", "npi_num": "", "hcp_pin_alias": "863276", "session_name": "Phase 1/2 study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863276", "first_name": "Byoung", "middle_name": "Chul", "last_name": "Cho", "org_name": "Yonsei University College of Medicine", "Country": "Korea, South", "Region": "Kyonggi-do", "City": "Seoul", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase 1/2 study of D3S-001", "rest_events_session_count": 1, "rest_events_session": " a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations", "events_topic": "KRAS Protein, Human | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Byoung Chul Cho", "kol_full_name": "Byoung Chul Cho" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "ROS1 Protein, Human | Zidesamtinib | Solid Tumors | Carcinoma, Non-Small-Cell Lung", "npi_num": "", "hcp_pin_alias": "863275", "session_name": "NSCLC metastatic,Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863275", "first_name": "Benjamin", "middle_name": "", "last_name": "Besse", "org_name": "Gustave Roussy Cancer Institute", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NSCLC metastatic", "rest_events_session_count": 1, "rest_events_session": "Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors", "events_topic": "ROS1 Protein, Human | Zidesamtinib ", "rest_events_topic_count": 2, "rest_events_topic": " Solid Tumors | Carcinoma, Non-Small-Cell Lung", "kol_name": "Benjamin Besse", "kol_full_name": "Benjamin Besse" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Gastrointestinal Neoplasms", "npi_num": "", "hcp_pin_alias": "863273", "session_name": "GI tumours, upper", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863273", "first_name": "Arndt", "middle_name": "", "last_name": "Vogel", "org_name": "Hannover Medical School", "Country": "Germany", "Region": "Niedersachsen", "City": "Hannover", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 1, "rest_events_session": " upper", "events_topic": "Gastrointestinal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Arndt Vogel", "kol_full_name": "Arndt Vogel" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Hepatocellular | Neoadjuvant Therapy", "npi_num": "", "hcp_pin_alias": "863271", "session_name": "Management of adjuvant/neoadjuvant HCC in 2024", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863271", "first_name": "Angela", "middle_name": "", "last_name": "Lamarca", "org_name": "Fundacion Jimenez Diaz University Hospital", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of adjuvant/neoadjuvant HCC in 2024", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Hepatocellular | Neoadjuvant Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Angela Lamarca", "kol_full_name": "Angela Lamarca" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Precision Medicine | Students, Medical", "npi_num": "", "hcp_pin_alias": "863269", "session_name": "Session in collaboration with ASCO: Novel pathways for development of precision therapeutics in molecular oncology,ESMO-ESO Medical Students Course", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "863269", "first_name": "Andrés", "middle_name": "", "last_name": "Cervantes", "org_name": "Hospital Clínico Universitario de Valencia", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Session in collaboration with ASCO: Novel pathways for development of precision therapeutics in molecular oncology", "rest_events_session_count": 1, "rest_events_session": "ESMO-ESO Medical Students Course", "events_topic": "Precision Medicine | Students, Medical", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Andrés Cervantes", "kol_full_name": "Andrés Cervantes" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Proto-Oncogene Proteins B-raf | Solid Tumors | Melanoma | Binimetinib", "npi_num": "", "hcp_pin_alias": "860020", "session_name": "A Phase 1 Clinical Trial Evaluating Exarafenib, a Selective Pan-RAF Inhibitor in Combination with Binimetinib in NRAS-mutant (NRASMut) Melanoma (Mel) & BRAF-Altered Solid Tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "860020", "first_name": "Philippe", "middle_name": "", "last_name": "Cassier", "org_name": "Centre Léon Bérard (CLB)", "Country": "France", "Region": "Rhone-Alpes", "City": "Lyon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Phase 1 Clinical Trial Evaluating Exarafenib", "rest_events_session_count": 1, "rest_events_session": " a Selective Pan-RAF Inhibitor in Combination with Binimetinib in NRAS-mutant (NRASMut) Melanoma (Mel) & BRAF-Altered Solid Tumors", "events_topic": "Proto-Oncogene Proteins B-raf | Solid Tumors ", "rest_events_topic_count": 2, "rest_events_topic": " Melanoma | Binimetinib", "kol_name": "Philippe Cassier", "kol_full_name": "Philippe Cassier" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immunoconjugates", "npi_num": "", "hcp_pin_alias": "860018", "session_name": "What are the ADCs and main AEs?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "860018", "first_name": "Nicolas", "middle_name": "", "last_name": "Girard", "org_name": "Institut Curie", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What are the ADCs and main AEs?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunoconjugates", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Nicolas Girard", "kol_full_name": "Nicolas Girard" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Perioperative Care", "npi_num": "", "hcp_pin_alias": "859998", "session_name": "Incorporating systemic therapy in the perioperative setting", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "859998", "first_name": "Solange", "middle_name": "", "last_name": "Peters", "org_name": "Centre hospitalier universitaire vaudois", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Incorporating systemic therapy in the perioperative setting", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Perioperative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Solange Peters", "kol_full_name": "Solange Peters" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "", "hcp_pin_alias": "859997", "session_name": "Improving outcome in long-term survivors with metastatic NSCLC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "859997", "first_name": "Silvia", "middle_name": "", "last_name": "Novello", "org_name": "University of Turin, S. Luigi Gonzaga Hospital", "Country": "Italy", "Region": "Piemonte", "City": "Turin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Improving outcome in long-term survivors with metastatic NSCLC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Silvia Novello", "kol_full_name": "Silvia Novello" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Cyclin-Dependent Kinases | Breast Neoplasms", "npi_num": "", "hcp_pin_alias": "859991", "session_name": "HR(+)/HER2(-) advanced breast cancer: How can biology inform us on optimising the precision therapeutic strategies in 1L and 2L post progression after endocrine+CDK4/6i?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "859991", "first_name": "Philippe", "middle_name": "", "last_name": "Aftimos", "org_name": "Institut Jules Bordet", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "HR(+)/HER2(-) advanced breast cancer: How can biology inform us on optimising the precision therapeutic strategies in 1L and 2L post progression after endocrine+CDK4/6i?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cyclin-Dependent Kinases | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Philippe Aftimos", "kol_full_name": "Philippe Aftimos" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Triple Negative Breast Neoplasms", "npi_num": "", "hcp_pin_alias": "859895", "session_name": "Triple negative breast cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "859895", "first_name": "Giuseppe", "middle_name": "", "last_name": "Curigliano", "org_name": "Istituto Europeo Di Oncologia", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Triple negative breast cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Triple Negative Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Giuseppe Curigliano", "kol_full_name": "Giuseppe Curigliano" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Ovarian Neoplasms | Endometrial Neoplasms", "npi_num": "1144648478", "hcp_pin_alias": "843486", "session_name": "A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients with Advanced Ovarian or Endometrial Cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "843486", "first_name": "Elizabeth", "middle_name": "Katherine", "last_name": "Lee", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients with Advanced Ovarian or Endometrial Cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Ovarian Neoplasms | Endometrial Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Elizabeth Katherine Lee", "kol_full_name": "Elizabeth Katherine Lee" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Neoplasms | Epidemics", "npi_num": "1285683367", "hcp_pin_alias": "843104", "session_name": "The emerging global epidemic of young age- onset cancer: Nature or nurture?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "843104", "first_name": "Shuji", "middle_name": "", "last_name": "Ogino", "org_name": "Brigham And Women'S Physicians Organization Inc", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The emerging global epidemic of young age- onset cancer: Nature or nurture?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms | Epidemics", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Shuji Ogino", "kol_full_name": "Shuji Ogino" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Pembrolizumab | Programmed Cell Death 1 Receptor | Tumor Microenvironment | Immunotherapy | Head And Neck Neoplasms | Recurrent Respiratory Papillomatosis | Immune Signalling Pathways | Papillomatosis | Genetic Therapy", "npi_num": "1093861429", "hcp_pin_alias": "830809", "session_name": "Targeting innate immune signalling pathways,The Patient Voice: An Analysis of Real-World Data using the Recurrent Respiratory Papillomatosis Foundation/CoRDS Patient Registry (RRPF/CoRDS),Epigenetic therapy modulates the tumor microenvironment to sensitize anti-PD-1 refractory head and neck cancers to immunotherapy,Pembrolizumab for HPV-associated Recurrent Respiratory Papillomatosis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "830809", "first_name": "Sara", "middle_name": "Isabel", "last_name": "Pai", "org_name": "Massachusetts General Hospital", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Targeting innate immune signalling pathways", "rest_events_session_count": 3, "rest_events_session": "The Patient Voice: An Analysis of Real-World Data using the Recurrent Respiratory Papillomatosis Foundation/CoRDS Patient Registry (RRPF/CoRDS),Epigenetic therapy modulates the tumor microenvironment to sensitize anti-PD-1 refractory head and neck cancers to immunotherapy,Pembrolizumab for HPV-associated Recurrent Respiratory Papillomatosis", "events_topic": "Pembrolizumab | Programmed Cell Death 1 Receptor ", "rest_events_topic_count": 7, "rest_events_topic": " Tumor Microenvironment | Immunotherapy | Head And Neck Neoplasms | Recurrent Respiratory Papillomatosis | Immune Signalling Pathways | Papillomatosis | Genetic Therapy", "kol_name": "Sara Isabel Pai", "kol_full_name": "Sara Isabel Pai" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Chemoradiotherapy | Cisplatin | Head And Neck Neoplasms | Carcinoma, Squamous Cell", "npi_num": "", "hcp_pin_alias": "643982", "session_name": "Head and neck cancer,Final Analysis of a Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of the Head and Neck (JCOG1008)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "643982", "first_name": "Makoto", "middle_name": "", "last_name": "Tahara", "org_name": "National Cancer Center Hospital East", "Country": "Japan", "Region": "Chiba", "City": "Chiba", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Head and neck cancer", "rest_events_session_count": 1, "rest_events_session": "Final Analysis of a Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of the Head and Neck (JCOG1008)", "events_topic": "Chemoradiotherapy | Cisplatin ", "rest_events_topic_count": 2, "rest_events_topic": " Head And Neck Neoplasms | Carcinoma, Squamous Cell", "kol_name": "Makoto Tahara", "kol_full_name": "Makoto Tahara" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Retifanlimab | Programmed Cell Death 1 Receptor | Palbociclib | Liposarcoma", "npi_num": "1104246032", "hcp_pin_alias": "643776", "session_name": "A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "643776", "first_name": "Evan", "middle_name": "", "last_name": "Rosenbaum", "org_name": "Memorial Sloan Kettering Cancer Center", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Retifanlimab | Programmed Cell Death 1 Receptor ", "rest_events_topic_count": 2, "rest_events_topic": " Palbociclib | Liposarcoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Evan Rosenbaum", "kol_full_name": "Evan Rosenbaum" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immune Checkpoint Inhibitors | Programmed Cell Death Ligand 1 | SARS-CoV-2", "npi_num": "1881270304", "hcp_pin_alias": "643343", "session_name": "Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "643343", "first_name": "Adam", "middle_name": "", "last_name": "Grippin", "org_name": "UF Health Shands", "Country": "United States", "Region": "Florida", "City": "Gainesville", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immune Checkpoint Inhibitors | Programmed Cell Death Ligand 1 ", "rest_events_topic_count": 1, "rest_events_topic": " SARS-CoV-2", "kol_name": "Adam Grippin", "kol_full_name": "Adam Grippin" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "1053999599", "hcp_pin_alias": "643341", "session_name": "NSCLC metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "643341", "first_name": "Marina Chiara", "middle_name": "C", "last_name": "Garassino", "org_name": "University of Chicago Hospitals", "Country": "United States", "Region": "Illinois", "City": "Chicago", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NSCLC metastatic", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Marina Chiara C Garassino", "kol_full_name": "Marina Chiara C Garassino" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Pembrolizumab | Solid Tumors | Organ Preservation", "npi_num": "1891108221", "hcp_pin_alias": "641439", "session_name": "Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "641439", "first_name": "Kaysia", "middle_name": "", "last_name": "Ludford", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pembrolizumab | Solid Tumors ", "rest_events_topic_count": 1, "rest_events_topic": " Organ Preservation", "kol_name": "Kaysia Ludford", "kol_full_name": "Kaysia Ludford" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Renal Cell", "npi_num": "1841746542", "hcp_pin_alias": "641431", "session_name": "Non-clear cell RCC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "641431", "first_name": "Pedro", "middle_name": "M", "last_name": "Barata", "org_name": "University Hospitals Seidman", "Country": "United States", "Region": "Ohio", "City": "Cleveland", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Non-clear cell RCC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Renal Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Pedro M Barata", "kol_full_name": "Pedro M Barata" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "IGSF8 Protein, Human | Solid Tumors", "npi_num": "1427317403", "hcp_pin_alias": "638263", "session_name": "A phase 1/2, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "638263", "first_name": "Kristopher", "middle_name": "Paul", "last_name": "Wentzel", "org_name": "Cedars Sinai Medical Care Foundation", "Country": "United States", "Region": "California", "City": "Santa Monica", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A phase 1/2", "rest_events_session_count": 1, "rest_events_session": " open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors", "events_topic": "IGSF8 Protein, Human | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Kristopher Paul Wentzel", "kol_full_name": "Kristopher Paul Wentzel" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Pembrolizumab | Futibatinib | Carcinoma, Transitional Cell", "npi_num": "1154684777", "hcp_pin_alias": "637196", "session_name": "Phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "637196", "first_name": "Vadim", "middle_name": "S", "last_name": "Koshkin", "org_name": "UCSF Medical Center", "Country": "United States", "Region": "California", "City": "San Francisco", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pembrolizumab | Futibatinib ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Transitional Cell", "kol_name": "Vadim S Koshkin", "kol_full_name": "Vadim S Koshkin" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Triple Negative Breast Neoplasms", "npi_num": "1053395582", "hcp_pin_alias": "632654", "session_name": "The rapidly changing treatment landscape of early triple negative breast cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "632654", "first_name": "Kalliopi", "middle_name": "P", "last_name": "Siziopikou", "org_name": "Northwestern University Feinberg School of Medicine", "Country": "United States", "Region": "Illinois", "City": "Chicago", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The rapidly changing treatment landscape of early triple negative breast cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Triple Negative Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Kalliopi P Siziopikou", "kol_full_name": "Kalliopi P Siziopikou" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Sequence Analysis", "npi_num": "1831359355", "hcp_pin_alias": "624411", "session_name": "Resistance and sequencing", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "624411", "first_name": "Mark", "middle_name": "M", "last_name": "Awad", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Resistance and sequencing", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Sequence Analysis", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Mark M Awad", "kol_full_name": "Mark M Awad" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Genetically Modified T Cells | Killer Cells, Natural", "npi_num": "1760749204", "hcp_pin_alias": "621907", "session_name": "Gene modified T cells and new players,CAR NK cells", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "621907", "first_name": "Katayoun", "middle_name": "", "last_name": "Rezvani", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gene modified T cells and new players", "rest_events_session_count": 1, "rest_events_session": "CAR NK cells", "events_topic": "Genetically Modified T Cells | Killer Cells, Natural", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Katayoun Rezvani", "kol_full_name": "Katayoun Rezvani" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Transitional Cell | Advanced Illness | Urogenital Neoplasms | Carcinoma, Renal Cell", "npi_num": "1740443852", "hcp_pin_alias": "621127", "session_name": "GU tumours, non-prostate,Addressing uncertainties in the management of urothelial and renal cell carcinomas,What is the role of rechallenge with the same class of agents in advanced disease?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "621127", "first_name": "Petros", "middle_name": "", "last_name": "Grivas", "org_name": "University of Washington Fred Hutchinson Cancer Center", "Country": "United States", "Region": "Washington", "City": "Seattle", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GU tumours", "rest_events_session_count": 3, "rest_events_session": " non-prostate,Addressing uncertainties in the management of urothelial and renal cell carcinomas,What is the role of rechallenge with the same class of agents in advanced disease?", "events_topic": "Carcinoma, Transitional Cell | Advanced Illness ", "rest_events_topic_count": 2, "rest_events_topic": " Urogenital Neoplasms | Carcinoma, Renal Cell", "kol_name": "Petros Grivas", "kol_full_name": "Petros Grivas" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "SMARCA2 Protein, Human | Solid Tumors", "npi_num": "1811308851", "hcp_pin_alias": "617888", "session_name": "First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "617888", "first_name": "Robin", "middle_name": "", "last_name": "Guo", "org_name": "Memorial Hospital For Cancer And Allied Diseases", "Country": "United States", "Region": "New York", "City": "Commack", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "First Clinical Results from A Phase 1 Trial of PRT3789", "rest_events_session_count": 2, "rest_events_session": " a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation", "events_topic": "SMARCA2 Protein, Human | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Robin Guo", "kol_full_name": "Robin Guo" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immunotherapy, Adoptive | Receptors, Chimeric Antigen | Efineptakin Alfa | Lymphoma, Large B-Cell, Diffuse", "npi_num": "1609085356", "hcp_pin_alias": "595020", "session_name": "Phase 1b study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "595020", "first_name": "Armin", "middle_name": "", "last_name": "Ghobadi", "org_name": "Washington University St. Louis Children’s Hospital", "Country": "United States", "Region": "Missouri", "City": "Uckermark", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase 1b study of NT-I7 (efineptakin alfa)", "rest_events_session_count": 2, "rest_events_session": " a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)", "events_topic": "Immunotherapy, Adoptive | Receptors, Chimeric Antigen ", "rest_events_topic_count": 2, "rest_events_topic": " Efineptakin Alfa | Lymphoma, Large B-Cell, Diffuse", "kol_name": "Armin Ghobadi", "kol_full_name": "Armin Ghobadi" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immunotherapy | Head And Neck Neoplasms", "npi_num": "1609002708", "hcp_pin_alias": "594958", "session_name": "Cell-based immunotherapeutic approaches head and neck cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "594958", "first_name": "Christian", "middle_name": "Sutter", "last_name": "Hinrichs", "org_name": "Rutgers Health-Rwj Scleroderma Program", "Country": "United States", "Region": "New Jersey", "City": "New Brunswick", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cell-based immunotherapeutic approaches head and neck cancers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy | Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Christian Sutter Hinrichs", "kol_full_name": "Christian Sutter Hinrichs" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "KRAS Protein, Human | Olaparib | Pembrolizumab | Pancreatic Neoplasms | Carcinoma, Non-Small-Cell Lung | Homologous Recombination", "npi_num": "1457617771", "hcp_pin_alias": "589726", "session_name": "Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum,Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "589726", "first_name": "Wungki", "middle_name": "", "last_name": "Park", "org_name": "Memorial Sloan Kettering Cancer Center", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD)", "rest_events_session_count": 6, "rest_events_session": " (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum,Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)", "events_topic": "KRAS Protein, Human | Olaparib ", "rest_events_topic_count": 4, "rest_events_topic": " Pembrolizumab | Pancreatic Neoplasms | Carcinoma, Non-Small-Cell Lung | Homologous Recombination", "kol_name": "Wungki Park", "kol_full_name": "Wungki Park" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Renal Cell | Radiotherapy", "npi_num": "1376899419", "hcp_pin_alias": "586784", "session_name": "Is there a role for radiation therapy in advanced RCC?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "586784", "first_name": "Chad", "middle_name": "", "last_name": "Tang", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Is there a role for radiation therapy in advanced RCC?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Renal Cell | Radiotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Chad Tang", "kol_full_name": "Chad Tang" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Loss Of Function Mutation | Camonsertib", "npi_num": "1265489371", "hcp_pin_alias": "582422", "session_name": "Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "582422", "first_name": "Benedito", "middle_name": "Arruda", "last_name": "Carneiro Filho", "org_name": "Rhode Island Hospital", "Country": "United States", "Region": "Rhode Island", "City": "Providence", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Loss Of Function Mutation | Camonsertib", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Benedito Arruda Carneiro Filho", "kol_full_name": "Benedito Arruda Carneiro Filho" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Chemoradiotherapy | Biomarkers", "npi_num": "1235388901", "hcp_pin_alias": "581497", "session_name": "Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?,Clinical responders: Option of chemoradiation?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "581497", "first_name": "Leslie", "middle_name": "", "last_name": "Ballas", "org_name": "USC Care Medical Group Inc", "Country": "United States", "Region": "California", "City": "Los Angeles", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?", "rest_events_session_count": 1, "rest_events_session": "Clinical responders: Option of chemoradiation?", "events_topic": "Neoadjuvant Therapy | Chemoradiotherapy ", "rest_events_topic_count": 1, "rest_events_topic": " Biomarkers", "kol_name": "Leslie Ballas", "kol_full_name": "Leslie Ballas" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Poly(ADP-ribose) Polymerase Inhibitors", "npi_num": "1174599930", "hcp_pin_alias": "579143", "session_name": "Beyond PARP inhibition: New preclinical science entering the clinic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "579143", "first_name": "Alan", "middle_name": "David", "last_name": "Dandrea", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Beyond PARP inhibition: New preclinical science entering the clinic", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Poly(ADP-ribose) Polymerase Inhibitors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Alan David Dandrea", "kol_full_name": "Alan David Dandrea" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Basic Science", "npi_num": "1992842280", "hcp_pin_alias": "571738", "session_name": "Basic science rationale", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "571738", "first_name": "Sapna", "middle_name": "P", "last_name": "Patel", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Basic science rationale", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Basic Science", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Sapna P Patel", "kol_full_name": "Sapna P Patel" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Proficient Mismatch Repair", "npi_num": "1972769800", "hcp_pin_alias": "571588", "session_name": "Enhancing the checkpoints' activity in pMMR", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "571588", "first_name": "Vicky", "middle_name": "", "last_name": "Makker", "org_name": "Memorial Sloan Kettering Cancer Center", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Enhancing the checkpoints' activity in pMMR", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Proficient Mismatch Repair", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Vicky Makker", "kol_full_name": "Vicky Makker" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immune Checkpoint Inhibitors | Triple Negative Breast Neoplasms", "npi_num": "1962487330", "hcp_pin_alias": "571473", "session_name": "Novel data in the field of immune checkpoint blockade for eTNBC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "571473", "first_name": "Sara", "middle_name": "M", "last_name": "Tolaney", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": "0", "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Novel data in the field of immune checkpoint blockade for eTNBC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immune Checkpoint Inhibitors | Triple Negative Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Sara M Tolaney", "kol_full_name": "Sara M Tolaney" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "1952497075", "hcp_pin_alias": "571419", "session_name": "Breast cancer, early stage", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "571419", "first_name": "Lisa", "middle_name": "A", "last_name": "Carey", "org_name": "UNC School of Medicine", "Country": "United States", "Region": "North Carolina", "City": "Chapel Hill", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 1, "rest_events_session": " early stage", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Lisa A Carey", "kol_full_name": "Lisa A Carey" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Cyclin-Dependent Kinases | Solid Tumors | Breast Neoplasms | DNA Repair", "npi_num": "1942743216", "hcp_pin_alias": "571336", "session_name": "DDR inhibitor combinations,Phase 1b/2 first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "571336", "first_name": "Timothy", "middle_name": "A", "last_name": "Yap", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "DDR inhibitor combinations", "rest_events_session_count": 1, "rest_events_session": "Phase 1b/2 first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors", "events_topic": "Cyclin-Dependent Kinases | Solid Tumors ", "rest_events_topic_count": 2, "rest_events_topic": " Breast Neoplasms | DNA Repair", "kol_name": "Timothy A Yap", "kol_full_name": "Timothy A Yap" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Precision Medicine", "npi_num": "1891799391", "hcp_pin_alias": "570871", "session_name": "Session in collaboration with ASCO: Novel pathways for development of precision therapeutics in molecular oncology", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "570871", "first_name": "Robin", "middle_name": "T", "last_name": "Zon", "org_name": "American Society of Clinical Oncology", "Country": "United States", "Region": "Virginia", "City": "Alexandria", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Session in collaboration with ASCO: Novel pathways for development of precision therapeutics in molecular oncology", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Precision Medicine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Robin T Zon", "kol_full_name": "Robin T Zon" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Phosphatidylinositol 3-Kinase", "npi_num": "1871822288", "hcp_pin_alias": "570736", "session_name": "PI3Ki: Continued efforts are showing success", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "570736", "first_name": "Komal", "middle_name": "", "last_name": "Jhaveri", "org_name": "Memorial Sloan Kettering Cancer Center", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "PI3Ki: Continued efforts are showing success", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Phosphatidylinositol 3-Kinase", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Komal Jhaveri", "kol_full_name": "Komal Jhaveri" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Botensilimab | Balstilimab | Sarcoma | Immunotherapy", "npi_num": "1861539751", "hcp_pin_alias": "570627", "session_name": "Hot topics in sarcoma,Landmark trials in immunotherapy,Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "570627", "first_name": "Breelyn", "middle_name": "A.", "last_name": "Wilky", "org_name": "University of Colorado Hospital", "Country": "United States", "Region": "Colorado", "City": "Aurora", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Hot topics in sarcoma", "rest_events_session_count": 2, "rest_events_session": "Landmark trials in immunotherapy,Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study", "events_topic": "Botensilimab | Balstilimab ", "rest_events_topic_count": 2, "rest_events_topic": " Sarcoma | Immunotherapy", "kol_name": "Breelyn A. Wilky", "kol_full_name": "Breelyn A. Wilky" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Biomarkers, Pharmacological | Proteolysis", "npi_num": "1841733102", "hcp_pin_alias": "570481", "session_name": "Targeted protein degradation: Pharmacological aspects", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "570481", "first_name": "Jordi", "middle_name": "", "last_name": "Rodon Ahnert", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Targeted protein degradation: Pharmacological aspects", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biomarkers, Pharmacological | Proteolysis", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Jordi Rodon Ahnert", "kol_full_name": "Jordi Rodon Ahnert" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Cyclin-Dependent Kinases | Cyclin-Dependent Kinase 4 | Cyclin-Dependent Kinase 6 | Breast Neoplasms", "npi_num": "1790727709", "hcp_pin_alias": "569965", "session_name": "Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition,A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "569965", "first_name": "Joyce", "middle_name": "Ann", "last_name": "O'shaughnessy", "org_name": "Texas Oncology PA", "Country": "United States", "Region": "Texas", "City": "Dallas", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Hormone-receptor (+)", "rest_events_session_count": 2, "rest_events_session": " HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition,A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition", "events_topic": "Cyclin-Dependent Kinases | Cyclin-Dependent Kinase 4 ", "rest_events_topic_count": 2, "rest_events_topic": " Cyclin-Dependent Kinase 6 | Breast Neoplasms", "kol_name": "Joyce Ann O'shaughnessy", "kol_full_name": "Joyce Ann O'shaughnessy" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Phosphatidylinositol 3-Kinase | Breast Neoplasms", "npi_num": "1669430310", "hcp_pin_alias": "559481", "session_name": "PI3K: Unmet need has driven a succession of targeting attempts,Breast cancer, early stage", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "559481", "first_name": "Kevin", "middle_name": "M", "last_name": "Kalinsky", "org_name": "Emory University Winship Cancer Institute", "Country": "United States", "Region": "Georgia", "City": "Atlanta", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "PI3K: Unmet need has driven a succession of targeting attempts", "rest_events_session_count": 2, "rest_events_session": "Breast cancer, early stage", "events_topic": "Phosphatidylinositol 3-Kinase | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Kevin M Kalinsky", "kol_full_name": "Kevin M Kalinsky" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "1639259872", "hcp_pin_alias": "559249", "session_name": "NSCLC metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "559249", "first_name": "Sai Hong", "middle_name": "I", "last_name": "Ou", "org_name": "UCI Medical Center", "Country": "United States", "Region": "California", "City": "Orange", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NSCLC metastatic", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Sai Hong I Ou", "kol_full_name": "Sai Hong I Ou" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Adolescent And Young Adult Cancer", "npi_num": "1588671762", "hcp_pin_alias": "558781", "session_name": "What clinicians need to successfully treat AYA patient with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "558781", "first_name": "Ann", "middle_name": "Hart", "last_name": "Partridge", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": "0", "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What clinicians need to successfully treat AYA patient with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Adolescent And Young Adult Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Ann Hart Partridge", "kol_full_name": "Ann Hart Partridge" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Solid Tumors | Developmental Therapeutics", "npi_num": "1578876876", "hcp_pin_alias": "558745", "session_name": "Developmental therapeutics,Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "558745", "first_name": "Alexander", "middle_name": "E", "last_name": "Drilon", "org_name": "Memorial Sloan Kettering Cancer Center", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Developmental therapeutics", "rest_events_session_count": 1, "rest_events_session": "Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors", "events_topic": "Solid Tumors | Developmental Therapeutics", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Alexander E Drilon", "kol_full_name": "Alexander E Drilon" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Evidence-Based Practice", "npi_num": "1558323519", "hcp_pin_alias": "558478", "session_name": "Emerging clinical evidence on the efficacy of electric fields in controlling sanctuary metastatic site", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "558478", "first_name": "Minesh", "middle_name": "P.", "last_name": "Mehta", "org_name": "Florida International University Herbert Wertheim College of Medicine", "Country": "United States", "Region": "Florida", "City": "Miami", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Emerging clinical evidence on the efficacy of electric fields in controlling sanctuary metastatic site", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Evidence-Based Practice", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Minesh P. Mehta", "kol_full_name": "Minesh P. Mehta" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Prostatic Neoplasms, Castration-Resistant | Androgen Receptor Pathway Inhibitor | Poor Risk Disease | Receptors, Androgen", "npi_num": "1447221353", "hcp_pin_alias": "557488", "session_name": "Therapeutic options beyond AR pathway inhibitors: What do we choose next?,Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC),Intensification of systemic treatment for poor risk disease", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "557488", "first_name": "Dana", "middle_name": "E", "last_name": "Rathkopf", "org_name": "Memorial Hospital For Cancer And Allied Diseases", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Therapeutic options beyond AR pathway inhibitors: What do we choose next?", "rest_events_session_count": 4, "rest_events_session": "Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC),Intensification of systemic treatment for poor risk disease", "events_topic": "Prostatic Neoplasms, Castration-Resistant | Androgen Receptor Pathway Inhibitor ", "rest_events_topic_count": 2, "rest_events_topic": " Poor Risk Disease | Receptors, Androgen", "kol_name": "Dana E Rathkopf", "kol_full_name": "Dana E Rathkopf" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Central Nervous System Diseases", "npi_num": "1316906498", "hcp_pin_alias": "556335", "session_name": "CNS disease", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "556335", "first_name": "Nancy", "middle_name": "U", "last_name": "Lin", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CNS disease", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Central Nervous System Diseases", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Nancy U Lin", "kol_full_name": "Nancy U Lin" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Solid Tumors", "npi_num": "1275548794", "hcp_pin_alias": "555961", "session_name": "First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "555961", "first_name": "Rachel", "middle_name": "Elizabeth", "last_name": "Sanborn", "org_name": "Providence Cancer Institute Franz Clinic", "Country": "United States", "Region": "Oregon", "City": "Portland", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "First-in-Human (FIH) Phase 1 Data of HST-1011", "rest_events_session_count": 2, "rest_events_session": " an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors", "events_topic": "Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Rachel Elizabeth Sanborn", "kol_full_name": "Rachel Elizabeth Sanborn" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immunoconjugates", "npi_num": "1225028533", "hcp_pin_alias": "555507", "session_name": "Resistance and sequencing to ADCs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "555507", "first_name": "Leif", "middle_name": "William", "last_name": "Ellisen", "org_name": "Massachusetts General Hospital", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Resistance and sequencing to ADCs", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunoconjugates", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Leif William Ellisen", "kol_full_name": "Leif William Ellisen" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Clinical Study", "npi_num": "1144300146", "hcp_pin_alias": "554840", "session_name": "Regulatory sandboxes: How to synchronize safe, timely regulation with scientific breakthroughs in molecular ‘niches’", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "554840", "first_name": "Julie", "middle_name": "R", "last_name": "Gralow", "org_name": "American Society of Clinical Oncology", "Country": "United States", "Region": "Washington", "City": "Edmonds", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Regulatory sandboxes: How to synchronize safe", "rest_events_session_count": 1, "rest_events_session": " timely regulation with scientific breakthroughs in molecular ‘niches’", "events_topic": "Clinical Study", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Julie R Gralow", "kol_full_name": "Julie R Gralow" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Artificial Intelligence", "npi_num": "1962598094", "hcp_pin_alias": "428246", "session_name": "Implementing artificial intelligence in oncology at scale", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "428246", "first_name": "Amy", "middle_name": "", "last_name": "Abernethy", "org_name": "CM Life Sciences III", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Implementing artificial intelligence in oncology at scale", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Artificial Intelligence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Amy Abernethy", "kol_full_name": "Amy Abernethy" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immunoconjugates | Solid Tumors", "npi_num": "1427190115", "hcp_pin_alias": "367123", "session_name": "Phase I, Two-Part, Multicenter First-In-Human (FIH) Study of TORL-1-23, A Novel Claudin 6 (CLDN6) Targeting Antibody Drug Conjugate (ADC) In Patient With Advanced Solid Tumors.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "367123", "first_name": "Gottfried", "middle_name": "E", "last_name": "Konecny", "org_name": "UCLA Health Westwood Cancer Care", "Country": "United States", "Region": "California", "City": "Los Angeles", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase I", "rest_events_session_count": 3, "rest_events_session": " Two-Part, Multicenter First-In-Human (FIH) Study of TORL-1-23, A Novel Claudin 6 (CLDN6) Targeting Antibody Drug Conjugate (ADC) In Patient With Advanced Solid Tumors.", "events_topic": "Immunoconjugates | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Gottfried E Konecny", "kol_full_name": "Gottfried E Konecny" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "T-Cell Engagers | Prostatic Neoplasms", "npi_num": "1417078221", "hcp_pin_alias": "365635", "session_name": "T cell engagers in prostate cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "365635", "first_name": "Neeraj", "middle_name": "", "last_name": "Agarwal", "org_name": "University of Utah Health Center", "Country": "United States", "Region": "Utah", "City": "Salt Lake City", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "T cell engagers in prostate cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "T-Cell Engagers | Prostatic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Neeraj Agarwal", "kol_full_name": "Neeraj Agarwal" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immune Checkpoint Inhibitors | Lung Neoplasms", "npi_num": "1356662803", "hcp_pin_alias": "364430", "session_name": "Racial Disparities in immune-related adverse events in patients with lung cancer treated with Immune checkpoint inhibitors.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "364430", "first_name": "Hina", "middle_name": "", "last_name": "Khan", "org_name": "Brown University Rhode Island Hospital", "Country": "United States", "Region": "Rhode Island", "City": "Providence", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Racial Disparities in immune-related adverse events in patients with lung cancer treated with Immune checkpoint inhibitors.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immune Checkpoint Inhibitors | Lung Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Hina Khan", "kol_full_name": "Hina Khan" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Adolescent And Young Adult Cancer", "npi_num": "1871751867", "hcp_pin_alias": "302184", "session_name": "ESMO in collaboration with SIOPE / ESMO AYA: The greatest need for better outcome of Adolescent and Young Adult Cancer (AYA) with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "302184", "first_name": "David", "middle_name": "C", "last_name": "Starks", "org_name": "Avera McKennan Hospital & University Health Center", "Country": "United States", "Region": "South Dakota", "City": "Sioux Falls", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO in collaboration with SIOPE / ESMO AYA: The greatest need for better outcome of Adolescent and Young Adult Cancer (AYA) with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Adolescent And Young Adult Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "David C Starks", "kol_full_name": "David C Starks" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Genital Neoplasms, Female", "npi_num": "1871680249", "hcp_pin_alias": "302100", "session_name": "Gynaecological cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "302100", "first_name": "Kathleen", "middle_name": "N", "last_name": "Moore", "org_name": "OU Health Stephenson Cancer Center", "Country": "United States", "Region": "Oklahoma", "City": "Oklahoma City", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gynaecological cancers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Genital Neoplasms, Female", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Kathleen N Moore", "kol_full_name": "Kathleen N Moore" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Ovarian Neoplasms | Folate Receptor 1 | Mirvetuximab Soravtansine", "npi_num": "1073531083", "hcp_pin_alias": "238500", "session_name": "Mirvetuximab Soravtansine (MIRV) in Recurrent Platinum-Sensitive Ovarian Cancer (PSOC) with High Folate Receptor-Alpha (FRα) Expression: Results from the PICCOLO Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "238500", "first_name": "Angeles", "middle_name": "A", "last_name": "Secord", "org_name": "Duke University Hospital", "Country": "United States", "Region": "North Carolina", "City": "Durham", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Mirvetuximab Soravtansine (MIRV) in Recurrent Platinum-Sensitive Ovarian Cancer (PSOC) with High Folate Receptor-Alpha (FRα) Expression: Results from the PICCOLO Trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Ovarian Neoplasms | Folate Receptor 1 ", "rest_events_topic_count": 1, "rest_events_topic": " Mirvetuximab Soravtansine", "kol_name": "Angeles A Secord", "kol_full_name": "Angeles A Secord" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Disitamab Vedotin | Pembrolizumab | Carcinoma, Transitional Cell", "npi_num": "1639140668", "hcp_pin_alias": "231524", "session_name": "Preliminary Efficacy And Safety Of Disitamab Vedotin (DV) With Pembrolizumab (P) In Treatment (Tx)-Naive HER2-Expressing, Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): RC48G001 Cohort C", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "231524", "first_name": "Matthew", "middle_name": "David", "last_name": "Galsky", "org_name": "Icahn School of Medicine at Mount Sinai", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Preliminary Efficacy And Safety Of Disitamab Vedotin (DV) With Pembrolizumab (P) In Treatment (Tx)-Naive HER2-Expressing", "rest_events_session_count": 1, "rest_events_session": " Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): RC48G001 Cohort C", "events_topic": "Disitamab Vedotin | Pembrolizumab ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Transitional Cell", "kol_name": "Matthew David Galsky", "kol_full_name": "Matthew David Galsky" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Public Health Surveillance | Case Reports", "npi_num": "1992965735", "hcp_pin_alias": "223819", "session_name": "Experiences from the clinic: a dynamic case study discussion,The importance of surveillance and diagnosis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "223819", "first_name": "Adam", "middle_name": "C", "last_name": "Yopp", "org_name": "University of Texas Southwestern Medical Center", "Country": "United States", "Region": "Texas", "City": "Dallas", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Experiences from the clinic: a dynamic case study discussion", "rest_events_session_count": 1, "rest_events_session": "The importance of surveillance and diagnosis", "events_topic": "Public Health Surveillance | Case Reports", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Adam C Yopp", "kol_full_name": "Adam C Yopp" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Neoplasms | Proteolysis | Developmental Therapeutics", "npi_num": "1982680583", "hcp_pin_alias": "223669", "session_name": "Protein degradation as a novel approach for cancer therapy,Developmental therapeutics", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "223669", "first_name": "Alex", "middle_name": "Asiedu", "last_name": "Adjei", "org_name": "Cleveland Clinic Hospital", "Country": "United States", "Region": "Ohio", "City": "Cleveland", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Protein degradation as a novel approach for cancer therapy", "rest_events_session_count": 1, "rest_events_session": "Developmental therapeutics", "events_topic": "Neoplasms | Proteolysis ", "rest_events_topic_count": 1, "rest_events_topic": " Developmental Therapeutics", "kol_name": "Alex Asiedu Adjei", "kol_full_name": "Alex Asiedu Adjei" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "1932146420", "hcp_pin_alias": "223157", "session_name": "Breast cancer, metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "223157", "first_name": "Patricia", "middle_name": "Mucci", "last_name": "Lorusso", "org_name": "Smilow Cancer Hospital", "Country": "United States", "Region": "Connecticut", "City": "New Haven", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 1, "rest_events_session": " metastatic", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Patricia Mucci Lorusso", "kol_full_name": "Patricia Mucci Lorusso" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Hepatocellular | Gastrointestinal Neoplasms | Case Reports", "npi_num": "1811912074", "hcp_pin_alias": "222141", "session_name": "Experiences from the clinic: a dynamic case study discussion,Pioneering GI cancer treatments and maximising outcomes for patients with HCC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "222141", "first_name": "Richard", "middle_name": "S", "last_name": "Finn", "org_name": "UCLA Santa Monica Medical Center", "Country": "United States", "Region": "California", "City": "Santa Monica", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Experiences from the clinic: a dynamic case study discussion", "rest_events_session_count": 1, "rest_events_session": "Pioneering GI cancer treatments and maximising outcomes for patients with HCC", "events_topic": "Carcinoma, Hepatocellular | Gastrointestinal Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Case Reports", "kol_name": "Richard S Finn", "kol_full_name": "Richard S Finn" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "PD-1 Resistance", "npi_num": "1730109331", "hcp_pin_alias": "221356", "session_name": "Leads for treating PD1 resistance", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "221356", "first_name": "Antoni", "middle_name": "", "last_name": "Ribas", "org_name": "Ronald Reagan UCLA Medical Center", "Country": "United States", "Region": "California", "City": "Los Angeles", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Leads for treating PD1 resistance", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "PD-1 Resistance", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Antoni Ribas", "kol_full_name": "Antoni Ribas" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Drug Therapy | Organ Preservation | Carcinoma, Squamous Cell", "npi_num": "1558479188", "hcp_pin_alias": "219696", "session_name": "Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN Cancer Research Group (EA3163)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "219696", "first_name": "Nabil", "middle_name": "F", "last_name": "Saba", "org_name": "Emory University Hospital", "Country": "United States", "Region": "Georgia", "City": "Atlanta", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN Cancer Research Group (EA3163)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Drug Therapy | Organ Preservation ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Squamous Cell", "kol_name": "Nabil F Saba", "kol_full_name": "Nabil F Saba" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Central Nervous System Neoplasms", "npi_num": "1295271088", "hcp_pin_alias": "217330", "session_name": "CNS tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "217330", "first_name": "Roger", "middle_name": "", "last_name": "Stupp", "org_name": "Northwestern University Feinberg School of Medicine", "Country": "United States", "Region": "Illinois", "City": "Chicago", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CNS tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Central Nervous System Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Roger Stupp", "kol_full_name": "Roger Stupp" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "1215129085", "hcp_pin_alias": "216605", "session_name": "The role of alternating electric fields in the therapeutic management of patients with advanced non-small cell lung cancer,Clinical evidence for efficacy & safety of electric fields therapeutic applications for patients with advanced non-small cell lung cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "216605", "first_name": "Ticiana", "middle_name": "B", "last_name": "Leal", "org_name": "Emory University Winship Cancer Institute", "Country": "United States", "Region": "Georgia", "City": "Atlanta", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of alternating electric fields in the therapeutic management of patients with advanced non-small cell lung cancer", "rest_events_session_count": 1, "rest_events_session": "Clinical evidence for efficacy & safety of electric fields therapeutic applications for patients with advanced non-small cell lung cancer", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Ticiana B Leal", "kol_full_name": "Ticiana B Leal" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Chemoradiotherapy | Uterine Cervical Neoplasms", "npi_num": "1164407540", "hcp_pin_alias": "216058", "session_name": "Surgery for persistent cervical cancer after chemoradiation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "216058", "first_name": "Nadeem", "middle_name": "R", "last_name": "Abu-rustum", "org_name": "Memorial Sloan Kettering Cancer Center", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Surgery for persistent cervical cancer after chemoradiation", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Chemoradiotherapy | Uterine Cervical Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Nadeem R Abu-rustum", "kol_full_name": "Nadeem R Abu-rustum" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Microbiota | Colorectal Neoplasms", "npi_num": "1417185729", "hcp_pin_alias": "150530", "session_name": "Microbiome in colorectal cancer: Ready for primetime?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "150530", "first_name": "Marios", "middle_name": "", "last_name": "Giannakis", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Microbiome in colorectal cancer: Ready for primetime?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Microbiota | Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Marios Giannakis", "kol_full_name": "Marios Giannakis" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Gastrointestinal Neoplasms", "npi_num": "1306003793", "hcp_pin_alias": "150245", "session_name": "GI tumours, upper", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "150245", "first_name": "James", "middle_name": "J", "last_name": "Harding", "org_name": "Memorial Hospital For Cancer And Allied Diseases", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 1, "rest_events_session": " upper", "events_topic": "Gastrointestinal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "James J Harding", "kol_full_name": "James J Harding" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Disease-Free Survival | Pembrolizumab | Carcinoma, Transitional Cell", "npi_num": "1902059124", "hcp_pin_alias": "146661", "session_name": "Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "146661", "first_name": "Andrea", "middle_name": "Borghese", "last_name": "Apolo", "org_name": "National Institutes of Health Hatfield Clinical Research Center", "Country": "United States", "Region": "Maryland", "City": "Bethesda", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Disease-Free Survival | Pembrolizumab ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Transitional Cell", "kol_name": "Andrea Borghese Apolo", "kol_full_name": "Andrea Borghese Apolo" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Progression-Free Survival | Placebos | Cabozantinib | Neuroendocrine Tumors", "npi_num": "1871578823", "hcp_pin_alias": "146375", "session_name": "Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "146375", "first_name": "Jennifer", "middle_name": "A", "last_name": "Chan", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Progression-Free Survival | Placebos ", "rest_events_topic_count": 2, "rest_events_topic": " Cabozantinib | Neuroendocrine Tumors", "kol_name": "Jennifer A Chan", "kol_full_name": "Jennifer A Chan" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Neuroendocrine Tumors | Molecular Targeted Therapy", "npi_num": "1801950704", "hcp_pin_alias": "144924", "session_name": "DLL-3 targeted therapy for neuroendocrine PC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "144924", "first_name": "Himisha", "middle_name": "", "last_name": "Beltran", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "DLL-3 targeted therapy for neuroendocrine PC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neuroendocrine Tumors | Molecular Targeted Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Himisha Beltran", "kol_full_name": "Himisha Beltran" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Artificial Intelligence", "npi_num": "1790955623", "hcp_pin_alias": "144744", "session_name": "Impact of AI Clinical Trial Program on Screening, Matching, and Enrollment of Patients Over 6 Months", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "144744", "first_name": "Dale", "middle_name": "Randall", "last_name": "Shepard", "org_name": "Cleveland Clinic Hospital", "Country": "United States", "Region": "Ohio", "City": "Cleveland", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Impact of AI Clinical Trial Program on Screening", "rest_events_session_count": 2, "rest_events_session": " Matching, and Enrollment of Patients Over 6 Months", "events_topic": "Artificial Intelligence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Dale Randall Shepard", "kol_full_name": "Dale Randall Shepard" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Breast Neoplasms | Weight Loss", "npi_num": "1760459341", "hcp_pin_alias": "143751", "session_name": "Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "143751", "first_name": "Jennifer", "middle_name": "A", "last_name": "Ligibel", "org_name": "Dana Farber Cancer Institute", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms | Weight Loss", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Jennifer A Ligibel", "kol_full_name": "Jennifer A Ligibel" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Thymic Epithelial Tumours | Carcinoma, Non-Small-Cell Lung", "npi_num": "1720137094", "hcp_pin_alias": "142216", "session_name": "Updates on the treatment of thymic epithelial tumours,Non-metastatic NSCLC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "142216", "first_name": "Heather", "middle_name": "Ann", "last_name": "Wakelee", "org_name": "Stanford Health Care", "Country": "United States", "Region": "California", "City": "Palo Alto", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Updates on the treatment of thymic epithelial tumours", "rest_events_session_count": 1, "rest_events_session": "Non-metastatic NSCLC", "events_topic": "Thymic Epithelial Tumours | Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Heather Ann Wakelee", "kol_full_name": "Heather Ann Wakelee" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Cancer Survivors", "npi_num": "1639111065", "hcp_pin_alias": "140781", "session_name": "Who should be responsible for cancer survivorship - Oncologists", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "140781", "first_name": "Maryam", "middle_name": "Beheshti", "last_name": "Lustberg", "org_name": "Smilow Cancer Hospital", "Country": "United States", "Region": "Connecticut", "City": "New Haven", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Who should be responsible for cancer survivorship - Oncologists", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Survivors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Maryam Beheshti Lustberg", "kol_full_name": "Maryam Beheshti Lustberg" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Urogenital Neoplasms", "npi_num": "1548455355", "hcp_pin_alias": "136788", "session_name": "GU, non-prostate", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "136788", "first_name": "Shilpa", "middle_name": "", "last_name": "Gupta", "org_name": "Cleveland Clinic", "Country": "United States", "Region": "Ohio", "City": "Cleveland", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GU", "rest_events_session_count": 1, "rest_events_session": " non-prostate", "events_topic": "Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Shilpa Gupta", "kol_full_name": "Shilpa Gupta" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Colorectal Neoplasms", "npi_num": "1508993957", "hcp_pin_alias": "136782", "session_name": "Profiling the biology of CRC: Actionability and implementability", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "136782", "first_name": "Ryan", "middle_name": "Bruce", "last_name": "Corcoran", "org_name": "Massachusetts General Hospital", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Profiling the biology of CRC: Actionability and implementability", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Ryan Bruce Corcoran", "kol_full_name": "Ryan Bruce Corcoran" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Claudin 6 | Immunoconjugates | DS-9606a", "npi_num": "1457408254", "hcp_pin_alias": "136246", "session_name": "Preliminary results from a Phase 1, first-in-human study of DS-9606a, a Claudin 6 (CLDN6)-directed antibody–drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "136246", "first_name": "Manish", "middle_name": "R", "last_name": "Patel", "org_name": "Florida Cancer Specialists & Research Institute", "Country": "United States", "Region": "Florida", "City": "Sarasota", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Preliminary results from a Phase 1", "rest_events_session_count": 3, "rest_events_session": " first-in-human study of DS-9606a, a Claudin 6 (CLDN6)-directed antibody–drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6", "events_topic": "Claudin 6 | Immunoconjugates ", "rest_events_topic_count": 1, "rest_events_topic": " DS-9606a", "kol_name": "Manish R Patel", "kol_full_name": "Manish R Patel" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Dexamethasone | Dyspnea | Double-Blind Method | Haloperidol | Delirium | Biomarkers | Lorazepam", "npi_num": "1467760371", "hcp_pin_alias": "136005", "session_name": "Predictive biomarkers of dyspnea response to dexamethasone in cancer patients: A secondary analysis of the Alleviating Breathlessness in Cancer Patients with Dyspnea (ABCD) trial,Haloperidol and Lorazepam for Agitated Delirium in Patients with Advanced Cancer: A Multicenter, Double-Blind, Randomized Clinical Trial (RCT)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "136005", "first_name": "David", "middle_name": "", "last_name": "Hui", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Predictive biomarkers of dyspnea response to dexamethasone in cancer patients: A secondary analysis of the Alleviating Breathlessness in Cancer Patients with Dyspnea (ABCD) trial", "rest_events_session_count": 3, "rest_events_session": "Haloperidol and Lorazepam for Agitated Delirium in Patients with Advanced Cancer: A Multicenter, Double-Blind, Randomized Clinical Trial (RCT)", "events_topic": "Dexamethasone | Dyspnea ", "rest_events_topic_count": 5, "rest_events_topic": " Double-Blind Method | Haloperidol | Delirium | Biomarkers | Lorazepam", "kol_name": "David Hui", "kol_full_name": "David Hui" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Immunoconjugates | Puxitatug Samrotecan | Solid Tumors", "npi_num": "1306932074", "hcp_pin_alias": "133736", "session_name": "Initial results from a first-in-human study of the B7-H4–directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "133736", "first_name": "Funda", "middle_name": "", "last_name": "Meric-bernstam", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Initial results from a first-in-human study of the B7-H4–directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunoconjugates | Puxitatug Samrotecan ", "rest_events_topic_count": 1, "rest_events_topic": " Solid Tumors", "kol_name": "Funda Meric-bernstam", "kol_full_name": "Funda Meric-bernstam" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Drug Development | Tumor-Agnostic Therapy", "npi_num": "1174726384", "hcp_pin_alias": "132200", "session_name": "Tumour-agnostic, biomarker-driven drug development: How and how often?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "132200", "first_name": "Vivek", "middle_name": "", "last_name": "Subbiah", "org_name": "Verdi Oncology Tennessee Pc", "Country": "United States", "Region": "Tennessee", "City": "Nashville", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Tumour-agnostic", "rest_events_session_count": 1, "rest_events_session": " biomarker-driven drug development: How and how often?", "events_topic": "Drug Development | Tumor-Agnostic Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Vivek Subbiah", "kol_full_name": "Vivek Subbiah" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Solid Tumors | Chemotherapy, Adjuvant | Placebos | Pembrolizumab | Melanoma", "npi_num": "1093989196", "hcp_pin_alias": "131441", "session_name": "Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: data from phase 1 dose escalation,Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-Up, rechallenge, and crossover in KEYNOTE-716", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "131441", "first_name": "Jason", "middle_name": "J", "last_name": "Luke", "org_name": "UPMC Hillman Cancer Center", "Country": "United States", "Region": "Pennsylvania", "City": "Pittsburgh", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: data from phase 1 dose escalation", "rest_events_session_count": 3, "rest_events_session": "Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-Up, rechallenge, and crossover in KEYNOTE-716", "events_topic": "Solid Tumors | Chemotherapy, Adjuvant ", "rest_events_topic_count": 3, "rest_events_topic": " Placebos | Pembrolizumab | Melanoma", "kol_name": "Jason J Luke", "kol_full_name": "Jason J Luke" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Oligometastases", "npi_num": "1285722892", "hcp_pin_alias": "130535", "session_name": "The role of the radiation oncologist in treating oligometastases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "130535", "first_name": "Daniel", "middle_name": "Tandel", "last_name": "Chang", "org_name": "University of Michigan Health", "Country": "United States", "Region": "Michigan", "City": "Ann Arbor", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of the radiation oncologist in treating oligometastases", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oligometastases", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Daniel Tandel Chang", "kol_full_name": "Daniel Tandel Chang" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Trastuzumab Deruxtecan | Quality Of Life | Gastroesophageal Junction Adenocarcinoma | Pembrolizumab | Triple Negative Breast Neoplasms | Trastuzumab | Drug Therapy | Survivorship | Esophageal Neoplasms | Adenocarcinoma", "npi_num": "1831330034", "hcp_pin_alias": "130513", "session_name": "Personalisation of surgical and systemic approaches in 2024: Optimising cure and quality of life in gastroesophageal cancer,Personalised systemic approaches to improve survivorship and cure,Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03),Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "130513", "first_name": "Yelena", "middle_name": "Y.", "last_name": "Janjigian", "org_name": "Memorial Sloan Kettering Cancer Center", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Personalisation of surgical and systemic approaches in 2024: Optimising cure and quality of life in gastroesophageal cancer", "rest_events_session_count": 6, "rest_events_session": "Personalised systemic approaches to improve survivorship and cure,Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03),Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma", "events_topic": "Trastuzumab Deruxtecan | Quality Of Life ", "rest_events_topic_count": 8, "rest_events_topic": " Gastroesophageal Junction Adenocarcinoma | Pembrolizumab | Triple Negative Breast Neoplasms | Trastuzumab | Drug Therapy | Survivorship | Esophageal Neoplasms | Adenocarcinoma", "kol_name": "Yelena Y. Janjigian", "kol_full_name": "Yelena Y. Janjigian" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Lung Neoplasms | Immunotherapy", "npi_num": "1366703308", "hcp_pin_alias": "129653", "session_name": "Immunotherapy and beyond for lung cancer prevention", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "129653", "first_name": "Jianjun", "middle_name": "", "last_name": "Zhang", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Immunotherapy and beyond for lung cancer prevention", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Neoplasms | Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Jianjun Zhang", "kol_full_name": "Jianjun Zhang" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Carcinoma, Renal Cell", "npi_num": "1558457028", "hcp_pin_alias": "89611", "session_name": "NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase 1/2 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "89611", "first_name": "Eric", "middle_name": "", "last_name": "Jonasch", "org_name": "University of Texas MD Anderson Cancer Center", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NKT2152", "rest_events_session_count": 2, "rest_events_session": " a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase 1/2 study", "events_topic": "Carcinoma, Renal Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Eric Jonasch", "kol_full_name": "Eric Jonasch" }, { "proj_kol_id": true, "eid": "128202", "event_topics": "Molecular Targets", "npi_num": "1194735944", "hcp_pin_alias": "77094", "session_name": "Emerging molecular targets", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "77094", "first_name": "Anja", "middle_name": "C", "last_name": "Roden", "org_name": "Mayo Clinic, Rochester", "Country": "United States", "Region": "Minnesota", "City": "Rochester", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Emerging molecular targets", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Molecular Targets", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "Anja C Roden", "kol_full_name": "Anja C Roden" }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Circulating Tumor DNA | Clinical Trial | Multiple Co-Occurring Cancer | KRAS Protein, Human | Solid Tumors | Developmental Therapeutics", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454267", "session_name": "Next generation of combinations in early clinical trials,Developmental therapeutics,Multiple co-occurring cancers,Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors,Incorporating ctDNA into RECIST v1.1: Steps ahead", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elena Garralda", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "5", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Next generation of combinations in early clinical trials", "rest_events_session_count": 4, "rest_events_session": "Developmental therapeutics,Multiple co-occurring cancers,Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors,Incorporating ctDNA into RECIST v1.1: Steps ahead", "events_topic": "Circulating Tumor DNA | Clinical Trial ", "rest_events_topic_count": 4, "rest_events_topic": " Multiple Co-Occurring Cancer | KRAS Protein, Human | Solid Tumors | Developmental Therapeutics", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elena Garralda ", "kol_full_name": "Elena Garralda " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung | Anaplastic Lymphoma Kinase | Pneumonia | Chemoradiotherapy | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454293", "session_name": "Treatment experience matters: integration of subcutaneous immunotherapy in the clinic,Targeting NSCLC: new developments in ALK+ and KRAS G12C NSCLC,Understanding resistance in immunotherapy,Combinations with IO,Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with Stage III unresectable NSCLC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jarushka Naidoo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "5", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment experience matters: integration of subcutaneous immunotherapy in the clinic", "rest_events_session_count": 4, "rest_events_session": "Targeting NSCLC: new developments in ALK+ and KRAS G12C NSCLC,Understanding resistance in immunotherapy,Combinations with IO,Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with Stage III unresectable NSCLC", "events_topic": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung ", "rest_events_topic_count": 4, "rest_events_topic": " Anaplastic Lymphoma Kinase | Pneumonia | Chemoradiotherapy | Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jarushka Naidoo ", "kol_full_name": "Jarushka Naidoo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Care | Subcutaneous Therapy | Nursing Research | Oncology Nursing | Cancer Care Facilities", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454496", "session_name": "Cancer care during exceptional circumstances,MASCC-EONS collaborative session: Nursing researchers’ role in supportive care implementation,Integration of subcutaneous therapies in cancer care,European Cancer Nursing Index, 2022 update: The state of cancer nursing in Europe,Mastering the art: Nursing excellence in subcutaneous therapies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Matthew N. Fowler", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Birmingham", "num_sess": "5", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer care during exceptional circumstances", "rest_events_session_count": 5, "rest_events_session": "MASCC-EONS collaborative session: Nursing researchers’ role in supportive care implementation,Integration of subcutaneous therapies in cancer care,European Cancer Nursing Index, 2022 update: The state of cancer nursing in Europe,Mastering the art: Nursing excellence in subcutaneous therapies", "events_topic": "Cancer Care | Subcutaneous Therapy ", "rest_events_topic_count": 3, "rest_events_topic": " Nursing Research | Oncology Nursing | Cancer Care Facilities", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Matthew N. Fowler ", "kol_full_name": "Matthew N. Fowler " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Breast Neoplasms | Cyclin-Dependent Kinases | Aromatase Inhibitors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454403", "session_name": "Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition,New treatment algorithm in the treatment of metastatic breast cancer in 2024,The current context and use of ADC in metastatic breast cancer,Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cristina Saura Manich", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Hormone-receptor (+)", "rest_events_session_count": 4, "rest_events_session": " HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition,New treatment algorithm in the treatment of metastatic breast cancer in 2024,The current context and use of ADC in metastatic breast cancer,Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy", "events_topic": "Immunoconjugates | Breast Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Cyclin-Dependent Kinases | Aromatase Inhibitors", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cristina Saura Manich ", "kol_full_name": "Cristina Saura Manich " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sexuality | Tailored Treatment | Child Health | Health Promotion | Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454648", "session_name": "ESMO-EONS collaborative session: Cancer and sexuality,SIOPE-EONS collaborative session,Health promotion, prevention and screening,Nurse as a transition leader: From paediatric to adults", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eugenia Trigoso Arjona", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO-EONS collaborative session: Cancer and sexuality", "rest_events_session_count": 4, "rest_events_session": "SIOPE-EONS collaborative session,Health promotion, prevention and screening,Nurse as a transition leader: From paediatric to adults", "events_topic": "Sexuality | Tailored Treatment ", "rest_events_topic_count": 3, "rest_events_topic": " Child Health | Health Promotion | Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eugenia Trigoso Arjona ", "kol_full_name": "Eugenia Trigoso Arjona " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Supportive Care | Carcinoma, Renal Cell | Oncology Nursing | Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454316", "session_name": "N.U.R.T.U.R.E. - Time to invest in cancer nurses,Pilot evaluation of RCC4Nurses to enhance nursing education and practice in survivorship care of people with advanced renal cell carcinoma in Europe,The role of cancer nurse scientists in advancing supportive care implementation,Early signs and symptoms? Who is the silent one?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Grigorios Kotronoulas", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "Scotland", "City": "Glasgow", "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "N.U.R.T.U.R.E. - Time to invest in cancer nurses", "rest_events_session_count": 3, "rest_events_session": "Pilot evaluation of RCC4Nurses to enhance nursing education and practice in survivorship care of people with advanced renal cell carcinoma in Europe,The role of cancer nurse scientists in advancing supportive care implementation,Early signs and symptoms? Who is the silent one?", "events_topic": "Supportive Care | Carcinoma, Renal Cell ", "rest_events_topic_count": 2, "rest_events_topic": " Oncology Nursing | Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Grigorios Kotronoulas ", "kol_full_name": "Grigorios Kotronoulas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Survivorship | Palliative Care | Rehabilitation | Pediatric Cancer Care | Oncology Nursing | Advance Care Planning", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454650", "session_name": "Rehabilitation and survivorship care,Advance care planning and palliative care,Cancer nursing and precision health,Journeying Through the Landscape of Home-Based Pediatric Cancer Care: Needs and Expectations from the Insights of Children and Parents", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hazal Özdemir Koyu", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Ankara", "City": "Ankara", "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Rehabilitation and survivorship care", "rest_events_session_count": 3, "rest_events_session": "Advance care planning and palliative care,Cancer nursing and precision health,Journeying Through the Landscape of Home-Based Pediatric Cancer Care: Needs and Expectations from the Insights of Children and Parents", "events_topic": "Survivorship | Palliative Care ", "rest_events_topic_count": 4, "rest_events_topic": " Rehabilitation | Pediatric Cancer Care | Oncology Nursing | Advance Care Planning", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hazal Özdemir Koyu ", "kol_full_name": "Hazal Özdemir Koyu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Digital Technology | Neoplasms | Palliative Care | Clinical Trial | Physician-Patient Relations", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454361", "session_name": "Understanding the cancer journey,Supportive and palliative care,Integrating digital technologies into clinical trials,Doctor / patient relationships (acted out): The right and wrong way of communicating", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ines V. Vaz Luis", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Understanding the cancer journey", "rest_events_session_count": 3, "rest_events_session": "Supportive and palliative care,Integrating digital technologies into clinical trials,Doctor / patient relationships (acted out): The right and wrong way of communicating", "events_topic": "Digital Technology | Neoplasms ", "rest_events_topic_count": 3, "rest_events_topic": " Palliative Care | Clinical Trial | Physician-Patient Relations", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ines V. Vaz Luis ", "kol_full_name": "Ines V. Vaz Luis " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Care Facilities | Palliative Care | Fertility | Fertility Preservation | Microbiota", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454281", "session_name": "ESMO in collaboration with the MASCC: Shedding light on the hidden microbiota,Supportive and palliative care,Oncofertility: What every HCP involved in cancer care should know,Fertility preservation and beyond in female patients with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Matteo Lambertini", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Liguria", "City": "Genova", "num_sess": "4", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO in collaboration with the MASCC: Shedding light on the hidden microbiota", "rest_events_session_count": 3, "rest_events_session": "Supportive and palliative care,Oncofertility: What every HCP involved in cancer care should know,Fertility preservation and beyond in female patients with cancer", "events_topic": "Cancer Care Facilities | Palliative Care ", "rest_events_topic_count": 3, "rest_events_topic": " Fertility | Fertility Preservation | Microbiota", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Matteo Lambertini ", "kol_full_name": "Matteo Lambertini " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Delphi Technique | Oncology Nursing | Telemedicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454348", "session_name": "eHealth and digital innovations,Consensus Research Priorities for Cancer Nursing in Europe: A Delphi Study,Keynote lecture: Shaping the future of cancer nursing: The case for disruption in the pursuit of meaningful and equitable innovation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Amanda Drury", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "eHealth and digital innovations", "rest_events_session_count": 2, "rest_events_session": "Consensus Research Priorities for Cancer Nursing in Europe: A Delphi Study,Keynote lecture: Shaping the future of cancer nursing: The case for disruption in the pursuit of meaningful and equitable innovation", "events_topic": "Delphi Technique | Oncology Nursing ", "rest_events_topic_count": 1, "rest_events_topic": " Telemedicine", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Amanda Drury ", "kol_full_name": "Amanda Drury " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patritumab Deruxtecan | Breast Neoplasms | Triple Negative Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454302", "session_name": "New treatment algorithm in the treatment of metastatic breast cancer in 2024,Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC),HER2 positive breast cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Barbara Pistilli", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New treatment algorithm in the treatment of metastatic breast cancer in 2024", "rest_events_session_count": 3, "rest_events_session": "Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC),HER2 positive breast cancer", "events_topic": "Patritumab Deruxtecan | Breast Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Triple Negative Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Barbara Pistilli ", "kol_full_name": "Barbara Pistilli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung | Anaplastic Lymphoma Kinase | Alectinib | Lung Neoplasms | Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454754", "session_name": "Targeting NSCLC: new developments in ALK+ and KRAS G12C NSCLC,Patient Matters: Innovation in Lung Cancer,ALINA: exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ben J. Solomon", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "Victoria", "City": "Melbourne", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Targeting NSCLC: new developments in ALK+ and KRAS G12C NSCLC", "rest_events_session_count": 2, "rest_events_session": "Patient Matters: Innovation in Lung Cancer,ALINA: exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)", "events_topic": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung ", "rest_events_topic_count": 4, "rest_events_topic": " Anaplastic Lymphoma Kinase | Alectinib | Lung Neoplasms | Drug Therapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ben J. Solomon ", "kol_full_name": "Ben J. Solomon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genital Neoplasms, Female | Nursing Research | Endometrial Neoplasms | Telemedicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454861", "session_name": "eHealth and digital innovations,MASCC-EONS collaborative session: Nursing researchers’ role in supportive care implementation,Improving the experience of care for women with gynaecological cancers: Lessons from cervical and endometrial cancer policy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Carlos Fernandes Cargaleiro", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "eHealth and digital innovations", "rest_events_session_count": 2, "rest_events_session": "MASCC-EONS collaborative session: Nursing researchers’ role in supportive care implementation,Improving the experience of care for women with gynaecological cancers: Lessons from cervical and endometrial cancer policy", "events_topic": "Genital Neoplasms, Female | Nursing Research ", "rest_events_topic_count": 2, "rest_events_topic": " Endometrial Neoplasms | Telemedicine", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Carlos Fernandes Cargaleiro ", "kol_full_name": "Carlos Fernandes Cargaleiro " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Corticosteroids | Gastrointestinal Microbiome | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454538", "session_name": "Improving the management of toxicities from immunotherapy,Treatment beyond corticosteroids,The gut microbiota & immune related adverse events", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christina H. Ruhlmann", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Fyn", "City": "Odense", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Improving the management of toxicities from immunotherapy", "rest_events_session_count": 2, "rest_events_session": "Treatment beyond corticosteroids,The gut microbiota & immune related adverse events", "events_topic": "Corticosteroids | Gastrointestinal Microbiome ", "rest_events_topic_count": 1, "rest_events_topic": " Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christina H. Ruhlmann ", "kol_full_name": "Christina H. Ruhlmann " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasm Metastasis | Translational Research, Biomedical | Biomarkers | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454520", "session_name": "Breast cancer, metastatic,Evolving biomarkers in metastatic disease: Liquid, solid or both?,Integrating translational research into clinical trials: Understanding models and their readouts", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christos Sotiriou", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 4, "rest_events_session": " metastatic,Evolving biomarkers in metastatic disease: Liquid, solid or both?,Integrating translational research into clinical trials: Understanding models and their readouts", "events_topic": "Neoplasm Metastasis | Translational Research, Biomedical ", "rest_events_topic_count": 2, "rest_events_topic": " Biomarkers | Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christos Sotiriou ", "kol_full_name": "Christos Sotiriou " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Pharmacology, Clinical | Antibodies, Bispecific", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454562", "session_name": "Current advances in clinical pharmacology within oncology, and its relevance for daily practice,Bispecifics,Pharmacology and dose-selection of ADCs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Emiliano Calvo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Current advances in clinical pharmacology within oncology", "rest_events_session_count": 3, "rest_events_session": " and its relevance for daily practice,Bispecifics,Pharmacology and dose-selection of ADCs", "events_topic": "Immunoconjugates | Pharmacology, Clinical ", "rest_events_topic_count": 1, "rest_events_topic": " Antibodies, Bispecific", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Emiliano Calvo ", "kol_full_name": "Emiliano Calvo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Treatment Decision | Receptors, Estrogen | Frailty | Geriatric Assessment", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454617", "session_name": "Case study and principles of GA (Geriatric Assessment),Frailty assessments and its impact on treatment decisions: What YOs need to know?,Optimal treatment for elderly ER+ BC patients", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Etienne G. Brain", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Saint Cloud", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Case study and principles of GA (Geriatric Assessment)", "rest_events_session_count": 2, "rest_events_session": "Frailty assessments and its impact on treatment decisions: What YOs need to know?,Optimal treatment for elderly ER+ BC patients", "events_topic": "Treatment Decision | Receptors, Estrogen ", "rest_events_topic_count": 2, "rest_events_topic": " Frailty | Geriatric Assessment", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Etienne G. Brain ", "kol_full_name": "Etienne G. Brain " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Disease Progression", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454701", "session_name": "Which patients should we treat beyond progression and when should we stop?,Investigational immunotherapy,How do we manage patient progression?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fiona Thistlethwaite", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Manchester", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Which patients should we treat beyond progression and when should we stop?", "rest_events_session_count": 2, "rest_events_session": "Investigational immunotherapy,How do we manage patient progression?", "events_topic": "Immunotherapy | Disease Progression", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fiona Thistlethwaite ", "kol_full_name": "Fiona Thistlethwaite " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sexuality | Tailored Treatment | Neoplasms | Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454225", "session_name": "SIOPE-EONS collaborative session,ESMO-EONS collaborative session: Cancer and sexuality,EONS: Cancer nurses", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Johan De Munter", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Oost-Vlaanderen", "City": "Gent", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "SIOPE-EONS collaborative session", "rest_events_session_count": 2, "rest_events_session": "ESMO-EONS collaborative session: Cancer and sexuality,EONS: Cancer nurses", "events_topic": "Sexuality | Tailored Treatment ", "rest_events_topic_count": 2, "rest_events_topic": " Neoplasms | Oncology Nursing", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Johan De Munter ", "kol_full_name": "Johan De Munter " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Cancer Prevention | Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454344", "session_name": "Cancer nursing and precision health,Subcutaneous administration of immunotherapy in different care settings,PrEvCan (Cancer Prevention across Europe): Key learning experiences and impact", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lena Sharp", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Stockholm", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer nursing and precision health", "rest_events_session_count": 2, "rest_events_session": "Subcutaneous administration of immunotherapy in different care settings,PrEvCan (Cancer Prevention across Europe): Key learning experiences and impact", "events_topic": "Immunotherapy | Cancer Prevention ", "rest_events_topic_count": 1, "rest_events_topic": " Oncology Nursing", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lena Sharp ", "kol_full_name": "Lena Sharp " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Of Unknown Primary | Genital Neoplasms, Female", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454372", "session_name": "Dissecting Cancer of Unknown Primary: Case presentation and expert insights,Gynaecological cancers,Optimal workflows for diagnosis and management of CUP patients", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Linda Mileshkin", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "Victoria", "City": "Melbourne", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Dissecting Cancer of Unknown Primary: Case presentation and expert insights", "rest_events_session_count": 2, "rest_events_session": "Gynaecological cancers,Optimal workflows for diagnosis and management of CUP patients", "events_topic": "Cancer Of Unknown Primary | Genital Neoplasms, Female", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Linda Mileshkin ", "kol_full_name": "Linda Mileshkin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Early Detection Of Cancer | Cancer Prevention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454232", "session_name": "The dark age of single cancer screening is over,The vital role of medical oncologists in primary, secondary, and tertiary cancer prevention,Integrated Cancer Prevention Center: One Stop Shop", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nadir Arber", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "Tel Aviv", "City": "Tel Aviv", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The dark age of single cancer screening is over", "rest_events_session_count": 4, "rest_events_session": "The vital role of medical oncologists in primary, secondary, and tertiary cancer prevention,Integrated Cancer Prevention Center: One Stop Shop", "events_topic": "Early Detection Of Cancer | Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nadir Arber ", "kol_full_name": "Nadir Arber " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Early Detection Of Cancer | Cancer Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454360", "session_name": "Understanding the cancer journey,Challenges in access to new oncology medicines,The impact of a cancer diagnosis, advocacy and empowerment through the cancer journey", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Natacha Bolanos Fernandez", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Understanding the cancer journey", "rest_events_session_count": 3, "rest_events_session": "Challenges in access to new oncology medicines,The impact of a cancer diagnosis, advocacy and empowerment through the cancer journey", "events_topic": "Neoplasms | Early Detection Of Cancer ", "rest_events_topic_count": 1, "rest_events_topic": " Cancer Medicine", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Natacha Bolanos Fernandez ", "kol_full_name": "Natacha Bolanos Fernandez " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Complex Drug Products | Clinical Trial | Developmental Therapeutics", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454266", "session_name": "Developmental therapeutics,New endpoints in early clinical trials,PK of complex drugs: Strategies to find recommended dosages", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Neeltje Steeghs", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Developmental therapeutics", "rest_events_session_count": 2, "rest_events_session": "New endpoints in early clinical trials,PK of complex drugs: Strategies to find recommended dosages", "events_topic": "Complex Drug Products | Clinical Trial ", "rest_events_topic_count": 1, "rest_events_topic": " Developmental Therapeutics", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Neeltje Steeghs ", "kol_full_name": "Neeltje Steeghs " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Care Facilities | Quality Improvement | Oncology Nursing | Psychological Well-Being", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454482", "session_name": "Quality improvement in cancer care,N.U.R.T.U.R.E. - Time to invest in cancer nurses,A scoping review of interventions to enhance Cancer Nurses' Psychological Well-being, Occupational Health and Resilience", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nikolina Dodlek", "middle_name": null, "last_name": null, "org_name": "", "Country": "Cyprus", "Region": "Limassol", "City": "Limassol", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Quality improvement in cancer care", "rest_events_session_count": 3, "rest_events_session": "N.U.R.T.U.R.E. - Time to invest in cancer nurses,A scoping review of interventions to enhance Cancer Nurses' Psychological Well-being, Occupational Health and Resilience", "events_topic": "Cancer Care Facilities | Quality Improvement ", "rest_events_topic_count": 2, "rest_events_topic": " Oncology Nursing | Psychological Well-Being", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nikolina Dodlek ", "kol_full_name": "Nikolina Dodlek " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nasopharyngeal Carcinoma | Tailored Treatment | Chemotherapy, Adjuvant | Biochemical Failure", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454423", "session_name": "Recent breakthroughs in the treatment of endemic NPC,Biochemical failure post-local therapy: An opportunity for tailored treatment?,Biomarker driven adjuvant therapy in locally advanced NPC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Pierre Blanchard", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Recent breakthroughs in the treatment of endemic NPC", "rest_events_session_count": 2, "rest_events_session": "Biochemical failure post-local therapy: An opportunity for tailored treatment?,Biomarker driven adjuvant therapy in locally advanced NPC", "events_topic": "Nasopharyngeal Carcinoma | Tailored Treatment ", "rest_events_topic_count": 2, "rest_events_topic": " Chemotherapy, Adjuvant | Biochemical Failure", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Pierre Blanchard ", "kol_full_name": "Pierre Blanchard " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Tumor | Molecular Residual Disease | Ribociclib | Neoplasm, Residual | Breast Neoplasms | Aromatase", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454429", "session_name": "MRD or molecular tumour board case report,Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE,MRD learning from breast cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sherene Loi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "Victoria", "City": "Melbourne", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "MRD or molecular tumour board case report", "rest_events_session_count": 2, "rest_events_session": "Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE,MRD learning from breast cancer", "events_topic": "Molecular Tumor | Molecular Residual Disease ", "rest_events_topic_count": 4, "rest_events_topic": " Ribociclib | Neoplasm, Residual | Breast Neoplasms | Aromatase", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sherene Loi ", "kol_full_name": "Sherene Loi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms | Cardiotoxicity | Neoplasms | Artificial Intelligence | Adolescent And Young Adult Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454529", "session_name": "The future of cancer via patient expertise in research & innovation projects,Adolescent and Young Adult Cancer: Important messages from patient’s perspectives,Can artificial intelligence improve early detection of cardiotoxicity after breast cancer treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Tanja Spanic", "middle_name": null, "last_name": null, "org_name": "", "Country": "Slovenia", "Region": "Ljubljana", "City": "Ljubljana", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The future of cancer via patient expertise in research & innovation projects", "rest_events_session_count": 2, "rest_events_session": "Adolescent and Young Adult Cancer: Important messages from patient’s perspectives,Can artificial intelligence improve early detection of cardiotoxicity after breast cancer treatment", "events_topic": "Breast Neoplasms | Cardiotoxicity ", "rest_events_topic_count": 3, "rest_events_topic": " Neoplasms | Artificial Intelligence | Adolescent And Young Adult Cancer", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Tanja Spanic ", "kol_full_name": "Tanja Spanic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Palliative Care | Skin Neoplasms | Cancer Care Facilities | Advance Care Planning", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454649", "session_name": "Cancer care during exceptional circumstances,Advance care planning and palliative care,It's skin cancer: A rollercoaster of a journey for young people and their significant other", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Wendy Mcinally", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "Scotland", "City": "Edinburgh", "num_sess": "3", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer care during exceptional circumstances", "rest_events_session_count": 2, "rest_events_session": "Advance care planning and palliative care,It's skin cancer: A rollercoaster of a journey for young people and their significant other", "events_topic": "Palliative Care | Skin Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Cancer Care Facilities | Advance Care Planning", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Wendy Mcinally ", "kol_full_name": "Wendy Mcinally " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "PRMT5 Protein, Human | Solid Tumors | Immune-Cell Engagers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454276", "session_name": "Immune-cell engagers,Phase 1 dose escalation and initial dose expansion results of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Adrian G. Sacher", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Immune-cell engagers", "rest_events_session_count": 3, "rest_events_session": "Phase 1 dose escalation and initial dose expansion results of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors", "events_topic": "PRMT5 Protein, Human | Solid Tumors ", "rest_events_topic_count": 1, "rest_events_topic": " Immune-Cell Engagers", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Adrian G. Sacher ", "kol_full_name": "Adrian G. Sacher " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454532", "session_name": "Immunotherapy: New indications, hopes and perspectives,Access to immunotherapies in Poland and in Spain based on EMA and ESMO guidance", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Agata I. Polinska", "middle_name": null, "last_name": null, "org_name": "", "Country": "Poland", "Region": "Mazowieckie", "City": "Warsaw", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Immunotherapy: New indications", "rest_events_session_count": 2, "rest_events_session": " hopes and perspectives,Access to immunotherapies in Poland and in Spain based on EMA and ESMO guidance", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Agata I. Polinska ", "kol_full_name": "Agata I. Polinska " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Mesothelioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454447", "session_name": "Mesothelioma and the role of multidisciplinary team,Systemic therapy for mesothelioma: A growing landscape", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alessandra Curioni-Fontecedro", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Fribourg", "City": "Fribourg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Mesothelioma and the role of multidisciplinary team", "rest_events_session_count": 1, "rest_events_session": "Systemic therapy for mesothelioma: A growing landscape", "events_topic": "Mesothelioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alessandra Curioni-Fontecedro ", "kol_full_name": "Alessandra Curioni-Fontecedro " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tumor Burden | Sentinel Lymph Node | Patient Care | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454246", "session_name": "Primary analysis of the EORTC 1208 Minitub Trial: Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden,Which patients need surgery?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alexander C. Van Akkooi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "New South Wales", "City": "Sydney", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Primary analysis of the EORTC 1208 Minitub Trial: Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden", "rest_events_session_count": 1, "rest_events_session": "Which patients need surgery?", "events_topic": "Tumor Burden | Sentinel Lymph Node ", "rest_events_topic_count": 2, "rest_events_topic": " Patient Care | Melanoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alexander C. Van Akkooi ", "kol_full_name": "Alexander C. Van Akkooi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Survivors | Novel Therapies", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454352", "session_name": "Complexity of perioperative decisions in the era of novel therapies,Who should be responsible for cancer survivorship - General practitioners", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alice Indini", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Complexity of perioperative decisions in the era of novel therapies", "rest_events_session_count": 1, "rest_events_session": "Who should be responsible for cancer survivorship - General practitioners", "events_topic": "Cancer Survivors | Novel Therapies", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alice Indini ", "kol_full_name": "Alice Indini " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454785", "session_name": "Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?,NSCLC, metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alona Zer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?", "rest_events_session_count": 2, "rest_events_session": "NSCLC, metastatic", "events_topic": "Immunoconjugates | Carcinoma, Non-Small-Cell Lung ", "rest_events_topic_count": 1, "rest_events_topic": " Lung Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alona Zer ", "kol_full_name": "Alona Zer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Of Unknown Primary", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454373", "session_name": "Dissecting Cancer of Unknown Primary: Case presentation and expert insights,Optimising trial design and therapeutic strategies targeting driver molecular aberrations in CUP", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alwin Krämer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Dissecting Cancer of Unknown Primary: Case presentation and expert insights", "rest_events_session_count": 1, "rest_events_session": "Optimising trial design and therapeutic strategies targeting driver molecular aberrations in CUP", "events_topic": "Cancer Of Unknown Primary", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alwin Krämer ", "kol_full_name": "Alwin Krämer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Central Nervous System Neoplasms | Brain Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454790", "session_name": "Cancer neuroscience in brain tumours and beyond,CNS tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Amélie Darlix", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Languedoc-Roussillon", "City": "Montpellier", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer neuroscience in brain tumours and beyond", "rest_events_session_count": 1, "rest_events_session": "CNS tumours", "events_topic": "Central Nervous System Neoplasms | Brain Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Amélie Darlix ", "kol_full_name": "Amélie Darlix " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Non-coding DNA | Translational Research, Biomedical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454809", "session_name": "Deciphering the dark matter of the non-coding genome,Basic science & Translational research", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ana Vivancos", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Deciphering the dark matter of the non-coding genome", "rest_events_session_count": 1, "rest_events_session": "Basic science & Translational research", "events_topic": "Non-coding DNA | Translational Research, Biomedical", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ana Vivancos ", "kol_full_name": "Ana Vivancos " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial | Developmental Therapeutics", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454792", "session_name": "New endpoints in early clinical trials,Developmental therapeutics", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anastasios Stathis", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Ticino", "City": "Bellinzona", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New endpoints in early clinical trials", "rest_events_session_count": 1, "rest_events_session": "Developmental therapeutics", "events_topic": "Clinical Trial | Developmental Therapeutics", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anastasios Stathis ", "kol_full_name": "Anastasios Stathis " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Universal Health Insurance | Cancer Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454359", "session_name": "Where does the world stand on achieving Universal Health Coverage by 2030?,A global perspective on access to oncology medicine: Where we do stand?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "André Ilbawi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Geneve", "City": "Geneva", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Where does the world stand on achieving Universal Health Coverage by 2030?", "rest_events_session_count": 1, "rest_events_session": "A global perspective on access to oncology medicine: Where we do stand?", "events_topic": "Universal Health Insurance | Cancer Medicine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
André Ilbawi ", "kol_full_name": "André Ilbawi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Penile Neoplasms | Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454628", "session_name": "Focus on rare GU cancers: A common challenge,Updates in penile cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Andrea Necchi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Focus on rare GU cancers: A common challenge", "rest_events_session_count": 1, "rest_events_session": "Updates in penile cancer", "events_topic": "Penile Neoplasms | Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Andrea Necchi ", "kol_full_name": "Andrea Necchi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Stress Disorder", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454318", "session_name": "The guiding hand in patient care: Managing Antibody-Drug Conjugate (ADC) related adverse events,Coping strategies burnout and stress", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Andreas Charalambous", "middle_name": null, "last_name": null, "org_name": "", "Country": "Cyprus", "Region": "Limassol", "City": "Limassol", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The guiding hand in patient care: Managing Antibody-Drug Conjugate (ADC) related adverse events", "rest_events_session_count": 1, "rest_events_session": "Coping strategies burnout and stress", "events_topic": "Immunoconjugates | Stress Disorder", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Andreas Charalambous ", "kol_full_name": "Andreas Charalambous " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Solid Tumours | Medical Oncology | Cell- And Tissue-Based Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454312", "session_name": "Cell therapy in solid tumours,Developing a career in medical oncology: From the ESMO Medical Student Course to a successful career", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Angelika M. Starzer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Wien", "City": "Vienna", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cell therapy in solid tumours", "rest_events_session_count": 1, "rest_events_session": "Developing a career in medical oncology: From the ESMO Medical Student Course to a successful career", "events_topic": "Solid Tumours | Medical Oncology ", "rest_events_topic_count": 1, "rest_events_topic": " Cell- And Tissue-Based Therapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Angelika M. Starzer ", "kol_full_name": "Angelika M. Starzer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Public Health Surveillance | Case Reports", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5467550", "session_name": "Experiences from the clinic: a dynamic case study discussion,The importance of surveillance and diagnosis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anna Saborowski", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Niedersachsen", "City": "Hannover", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Experiences from the clinic: a dynamic case study discussion", "rest_events_session_count": 1, "rest_events_session": "The importance of surveillance and diagnosis", "events_topic": "Public Health Surveillance | Case Reports", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anna Saborowski ", "kol_full_name": "Anna Saborowski " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454530", "session_name": "Immunotherapy: New indications, hopes and perspectives,Patients’ involvement in immunotherapy trials design", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anne-Marie Baird", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Immunotherapy: New indications", "rest_events_session_count": 2, "rest_events_session": " hopes and perspectives,Patients’ involvement in immunotherapy trials design", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anne-Marie Baird ", "kol_full_name": "Anne-Marie Baird " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Lung Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454630", "session_name": "Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?,Toxicity of ADCs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anne-Marie C. Dingemans", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Rotterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?", "rest_events_session_count": 1, "rest_events_session": "Toxicity of ADCs", "events_topic": "Immunoconjugates | Lung Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anne-Marie C. Dingemans ", "kol_full_name": "Anne-Marie C. Dingemans " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors | Circulating Tumor DNA", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454425", "session_name": "Precision medicine in NEN: Where we are,The value of circulating tumour DNA in neuroendocrine neoplasms", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Annemiek Walenkamp", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Groningen", "City": "Groningen", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Precision medicine in NEN: Where we are", "rest_events_session_count": 1, "rest_events_session": "The value of circulating tumour DNA in neuroendocrine neoplasms", "events_topic": "Neuroendocrine Tumors | Circulating Tumor DNA", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Annemiek Walenkamp ", "kol_full_name": "Annemiek Walenkamp " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms | Carcinoma, Lobular", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454419", "session_name": "Treatment of lobular breast cancer (ILC): From pitfalls to opportunities,Local treatment for ILC: Do’s and don’ts", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ava Kwong", "middle_name": null, "last_name": null, "org_name": "", "Country": "Hong Kong (SAR)", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment of lobular breast cancer (ILC): From pitfalls to opportunities", "rest_events_session_count": 1, "rest_events_session": "Local treatment for ILC: Do’s and don’ts", "events_topic": "Breast Neoplasms | Carcinoma, Lobular", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ava Kwong ", "kol_full_name": "Ava Kwong " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Skin Neoplasms | Glioma | Nivolumab | Ipilimumab | Melanoma | Dendritic Cells", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454255", "session_name": "Melanoma and other skin tumours,A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bart Neyns", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Melanoma and other skin tumours", "rest_events_session_count": 1, "rest_events_session": "A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)", "events_topic": "Skin Neoplasms | Glioma ", "rest_events_topic_count": 4, "rest_events_topic": " Nivolumab | Ipilimumab | Melanoma | Dendritic Cells", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bart Neyns ", "kol_full_name": "Bart Neyns " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Technology Assessment, Biomedical | Decision Making | Clinical Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454356", "session_name": "Can pragmatic clinical trials and optimisation of treatments support development, access and value?,RCT and RWD for HTA decision making", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Beate Wieseler", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Nordrhein-Westfalen", "City": "Koeln", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Can pragmatic clinical trials and optimisation of treatments support development", "rest_events_session_count": 2, "rest_events_session": " access and value?,RCT and RWD for HTA decision making", "events_topic": "Technology Assessment, Biomedical | Decision Making ", "rest_events_topic_count": 1, "rest_events_topic": " Clinical Trial", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Beate Wieseler ", "kol_full_name": "Beate Wieseler " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Transitional Cell | Biomarkers | Carcinoma, Renal Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454463", "session_name": "Addressing uncertainties in the management of urothelial and renal cell carcinomas,Circulating vs tissue-based biomarkers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bernadett E. Szabados", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Addressing uncertainties in the management of urothelial and renal cell carcinomas", "rest_events_session_count": 1, "rest_events_session": "Circulating vs tissue-based biomarkers", "events_topic": "Carcinoma, Transitional Cell | Biomarkers ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Renal Cell", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bernadett E. Szabados ", "kol_full_name": "Bernadett E. Szabados " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Microbiota | Treatment Outcome | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454399", "session_name": "Exploiting the microbiome to improve treatment outcomes,How the microbiome affects immunotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bertrand Routy", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Quebec", "City": "Montreal", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Exploiting the microbiome to improve treatment outcomes", "rest_events_session_count": 1, "rest_events_session": "How the microbiome affects immunotherapy", "events_topic": "Microbiota | Treatment Outcome ", "rest_events_topic_count": 1, "rest_events_topic": " Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bertrand Routy ", "kol_full_name": "Bertrand Routy " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Disease-Free Survival | Clinical Research", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454224", "session_name": "Progression-free survival: Should it be used as a primary end point for registration of anticancer treatments and what is the role of the ESMO-MCBS?,Clinics and research in LMIC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bishal Gyawali", "middle_name": null, "last_name": null, "org_name": "", "Country": "Nepal", "Region": "Bagmati", "City": "Kathmandu", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Progression-free survival: Should it be used as a primary end point for registration of anticancer treatments and what is the role of the ESMO-MCBS?", "rest_events_session_count": 1, "rest_events_session": "Clinics and research in LMIC", "events_topic": "Disease-Free Survival | Clinical Research", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bishal Gyawali ", "kol_full_name": "Bishal Gyawali " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nasopharyngeal Carcinoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454421", "session_name": "Recent breakthroughs in the treatment of endemic NPC,Changing the treatment paradigm in the treatment of recurrent/metastatic NPC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Brigette B. Ma", "middle_name": null, "last_name": null, "org_name": "", "Country": "Hong Kong (SAR)", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Recent breakthroughs in the treatment of endemic NPC", "rest_events_session_count": 1, "rest_events_session": "Changing the treatment paradigm in the treatment of recurrent/metastatic NPC", "events_topic": "Nasopharyngeal Carcinoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Brigette B. Ma ", "kol_full_name": "Brigette B. Ma " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Phosphatidylinositol 3-Kinase | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454842", "session_name": "PI3Ki: An evolving drug class with an exciting future,How can we PI3K the right treatment for every patient with HR+ breast cancer?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Carlos H. Barrios", "middle_name": null, "last_name": null, "org_name": "", "Country": "Brazil", "Region": "Rio Grande do Sul", "City": "Porto Alegre", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "PI3Ki: An evolving drug class with an exciting future", "rest_events_session_count": 1, "rest_events_session": "How can we PI3K the right treatment for every patient with HR+ breast cancer?", "events_topic": "Phosphatidylinositol 3-Kinase | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Carlos H. Barrios ", "kol_full_name": "Carlos H. Barrios " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Skin Neoplasms | Melanoma | Cutaneous Squamous Cell Carcinoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454607", "session_name": "Non-cutaneous melanoma and non-melanoma skin cancers: There is much more we can do,Cutaneous squamous cell carcinoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Caroline Robert", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Non-cutaneous melanoma and non-melanoma skin cancers: There is much more we can do", "rest_events_session_count": 1, "rest_events_session": "Cutaneous squamous cell carcinoma", "events_topic": "Skin Neoplasms | Melanoma ", "rest_events_topic_count": 1, "rest_events_topic": " Cutaneous Squamous Cell Carcinoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Caroline Robert ", "kol_full_name": "Caroline Robert " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma | Hodgkin Disease", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454684", "session_name": "Treatment of difficult lymphomas,Relapsed refractory Hodgkin’s lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cédric Rossi", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Bourgogne", "City": "Dijon", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment of difficult lymphomas", "rest_events_session_count": 1, "rest_events_session": "Relapsed refractory Hodgkin’s lymphoma", "events_topic": "Lymphoma | Hodgkin Disease", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cédric Rossi ", "kol_full_name": "Cédric Rossi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sarcoma | Gastrointestinal Stromal Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454392", "session_name": "Sarcoma,New developments in the treatment of GIST", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cesar Serrano", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sarcoma", "rest_events_session_count": 1, "rest_events_session": "New developments in the treatment of GIST", "events_topic": "Sarcoma | Gastrointestinal Stromal Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cesar Serrano ", "kol_full_name": "Cesar Serrano " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Head And Neck Neoplasms | Caregiver Burden", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454643", "session_name": "Designing and evaluation of a novel, theory-driven eLearning resource to equip professionals to support adults at end of life who have significant caregiving responsibilities for children < 18 years,Experiences and Needs of Carers of Patients with Head and Neck Cancer: A Systematic Review", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cherith J. Semple", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "Northern Ireland", "City": "Belfast", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Designing and evaluation of a novel", "rest_events_session_count": 2, "rest_events_session": " theory-driven eLearning resource to equip professionals to support adults at end of life who have significant caregiving responsibilities for children < 18 years,Experiences and Needs of Carers of Patients with Head and Neck Cancer: A Systematic Review", "events_topic": "Head And Neck Neoplasms | Caregiver Burden", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cherith J. Semple ", "kol_full_name": "Cherith J. Semple " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454830", "session_name": "Controversies in the management and follow up of small localised neuroendocrine tumours,NETs and endocrine tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Chris Verslype", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Leuven", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Controversies in the management and follow up of small localised neuroendocrine tumours", "rest_events_session_count": 1, "rest_events_session": "NETs and endocrine tumours", "events_topic": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Chris Verslype ", "kol_full_name": "Chris Verslype " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Melanoma | Neoadjuvant Therapy | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454245", "session_name": "Why neoadjuvant immunotherapy is the future for melanoma,Personalised immunotherapy approach and future", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christian U. Blank", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Why neoadjuvant immunotherapy is the future for melanoma", "rest_events_session_count": 1, "rest_events_session": "Personalised immunotherapy approach and future", "events_topic": "Melanoma | Neoadjuvant Therapy ", "rest_events_topic_count": 1, "rest_events_topic": " Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christian U. Blank ", "kol_full_name": "Christian U. Blank " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Care Facilities | Fertility | Fertility Preservation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454282", "session_name": "Oncofertility: What every HCP involved in cancer care should know,Fertility preservation and beyond in male patients with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christine Wyns", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Woluwe-Saint-Lambert", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Oncofertility: What every HCP involved in cancer care should know", "rest_events_session_count": 1, "rest_events_session": "Fertility preservation and beyond in male patients with cancer", "events_topic": "Cancer Care Facilities | Fertility ", "rest_events_topic_count": 1, "rest_events_topic": " Fertility Preservation", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christine Wyns ", "kol_full_name": "Christine Wyns " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Whole Genome Sequencing | High-Throughput Nucleotide Sequencing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454367", "session_name": "Molecular profiling from panel NGS to WGS: Do YOs need special training?,How to read commercial NGS test: Tips and tricks for practicing oncologists", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christoph Benedikt Westphalen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Bayern", "City": "Munich", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Molecular profiling from panel NGS to WGS: Do YOs need special training?", "rest_events_session_count": 1, "rest_events_session": "How to read commercial NGS test: Tips and tricks for practicing oncologists", "events_topic": "Whole Genome Sequencing | High-Throughput Nucleotide Sequencing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christoph Benedikt Westphalen ", "kol_full_name": "Christoph Benedikt Westphalen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient Care Management | Qualitative Research", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454664", "session_name": "Oncologists’ voices in time of crisis: Findings from the ESMO Resilience Task Force survey series on how members can be helped and supported – a qualitative analysis,Tips and techniques for people management at work", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Claire Hardy", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Lancaster", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Oncologists’ voices in time of crisis: Findings from the ESMO Resilience Task Force survey series on how members can be helped and supported – a qualitative analysis", "rest_events_session_count": 1, "rest_events_session": "Tips and techniques for people management at work", "events_topic": "Patient Care Management | Qualitative Research", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Claire Hardy ", "kol_full_name": "Claire Hardy " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Non-Coding Mutations | Non-coding DNA", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454579", "session_name": "Deciphering the dark matter of the non-coding genome,Mouse models to study functional effects of non-coding mutations", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daniel Schramek", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Deciphering the dark matter of the non-coding genome", "rest_events_session_count": 1, "rest_events_session": "Mouse models to study functional effects of non-coding mutations", "events_topic": "Non-Coding Mutations | Non-coding DNA", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daniel Schramek ", "kol_full_name": "Daniel Schramek " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Multiple Co-Occurring Cancer | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454604", "session_name": "Multiple co-occurring cancers,Metastatic colorectal cancer: Case presentation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Deniz Can Guven", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Ankara", "City": "Ankara", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Multiple co-occurring cancers", "rest_events_session_count": 1, "rest_events_session": "Metastatic colorectal cancer: Case presentation", "events_topic": "Multiple Co-Occurring Cancer | Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Deniz Can Guven ", "kol_full_name": "Deniz Can Guven " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tailored Treatment | Minimal Intervention | Biochemical Failure", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454397", "session_name": "Biochemical failure post-local therapy: An opportunity for tailored treatment?,Surveillance/minimal intervention for good risk disease", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Derya Tilki", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Hamburg", "City": "Hamburg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Biochemical failure post-local therapy: An opportunity for tailored treatment?", "rest_events_session_count": 1, "rest_events_session": "Surveillance/minimal intervention for good risk disease", "events_topic": "Tailored Treatment | Minimal Intervention ", "rest_events_topic_count": 1, "rest_events_topic": " Biochemical Failure", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Derya Tilki ", "kol_full_name": "Derya Tilki " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Brain Neoplasms | Central Nervous System Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454852", "session_name": "Common clinical problems in neuro-oncology,CNS tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dieta Brandsma", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Common clinical problems in neuro-oncology", "rest_events_session_count": 1, "rest_events_session": "CNS tumours", "events_topic": "Brain Neoplasms | Central Nervous System Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dieta Brandsma ", "kol_full_name": "Dieta Brandsma " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Prostatic Neoplasms, Castration-Resistant | Biomarkers | Cytotoxicity", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454297", "session_name": "Biomarkers for mCRPC: To test or not to test,Are cytotoxics still the next option?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elena Castro", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Biomarkers for mCRPC: To test or not to test", "rest_events_session_count": 1, "rest_events_session": "Are cytotoxics still the next option?", "events_topic": "Prostatic Neoplasms, Castration-Resistant | Biomarkers ", "rest_events_topic_count": 1, "rest_events_topic": " Cytotoxicity", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elena Castro ", "kol_full_name": "Elena Castro " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thrombosis | Multiple Co-Occurring Cancer | Pulmonary Embolism", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454844", "session_name": "Cancer-associated thrombosis: Management of pulmonary embolism,Multiple co-occurring cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elene Mariamidze", "middle_name": null, "last_name": null, "org_name": "", "Country": "Georgia", "Region": "T'bilisi", "City": "Tbilisi", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer-associated thrombosis: Management of pulmonary embolism", "rest_events_session_count": 1, "rest_events_session": "Multiple co-occurring cancers", "events_topic": "Thrombosis | Multiple Co-Occurring Cancer ", "rest_events_topic_count": 1, "rest_events_topic": " Pulmonary Embolism", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elene Mariamidze ", "kol_full_name": "Elene Mariamidze " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cyclin-Dependent Kinases | Triple Negative Breast Neoplasms | Breast Neoplasms | Signal Transduction", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454402", "session_name": "Breast cancer, early stage,Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elgene Lim", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "New South Wales", "City": "Sydney", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 2, "rest_events_session": " early stage,Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer", "events_topic": "Cyclin-Dependent Kinases | Triple Negative Breast Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Breast Neoplasms | Signal Transduction", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elgene Lim ", "kol_full_name": "Elgene Lim " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Prevention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454670", "session_name": "ESMO-IARC – Medical oncology and cancer prevention: The odd couple?,The value of IARC’s cancer prevention resources in daily clinical practice, and how ESMO is supporting them", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elisabete Weiderpass", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Rhone-Alpes", "City": "Lyon", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO-IARC – Medical oncology and cancer prevention: The odd couple?", "rest_events_session_count": 2, "rest_events_session": "The value of IARC’s cancer prevention resources in daily clinical practice, and how ESMO is supporting them", "events_topic": "Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elisabete Weiderpass ", "kol_full_name": "Elisabete Weiderpass " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oligometastatic Disease | Leiomyosarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454264", "session_name": "Use of ablative therapies in patients with oligometastatic disease,Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elizabeth A. Connolly", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "New South Wales", "City": "Sydney", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Use of ablative therapies in patients with oligometastatic disease", "rest_events_session_count": 1, "rest_events_session": "Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort", "events_topic": "Oligometastatic Disease | Leiomyosarcoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elizabeth A. Connolly ", "kol_full_name": "Elizabeth A. Connolly " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors | Appendiceal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454720", "session_name": "Controversies in the management and follow up of small localised neuroendocrine tumours,Appendiceal NEN: When to recommend radical surgery?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Els Nieveen Van Dijkum", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Controversies in the management and follow up of small localised neuroendocrine tumours", "rest_events_session_count": 1, "rest_events_session": "Appendiceal NEN: When to recommend radical surgery?", "events_topic": "Neuroendocrine Tumors | Appendiceal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Els Nieveen Van Dijkum ", "kol_full_name": "Els Nieveen Van Dijkum " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Surgical Procedures, Operative | Colonic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454704", "session_name": "Neoadjuvant treatment for colon cancer: Building upon the existing data,The role of surgery", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva Angenete", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Vastra Gotaland", "City": "Gothenburg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neoadjuvant treatment for colon cancer: Building upon the existing data", "rest_events_session_count": 1, "rest_events_session": "The role of surgery", "events_topic": "Neoadjuvant Therapy | Surgical Procedures, Operative ", "rest_events_topic_count": 1, "rest_events_topic": " Colonic Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva Angenete ", "kol_full_name": "Eva Angenete " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Receptors, Chimeric Antigen | Lymphoma, Follicular | Immunotherapy, Adoptive", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454370", "session_name": "CAR T cells and bispecifics,Follicular lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva K. Kimby", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Stockholm", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CAR T cells and bispecifics", "rest_events_session_count": 1, "rest_events_session": "Follicular lymphoma", "events_topic": "Receptors, Chimeric Antigen | Lymphoma, Follicular ", "rest_events_topic_count": 1, "rest_events_topic": " Immunotherapy, Adoptive", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva K. Kimby ", "kol_full_name": "Eva K. Kimby " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Tumor | Neoplasm, Residual | Translational Research, Biomedical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454837", "session_name": "MRD or molecular tumour board case report,Basic science & Translational research", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Federica Di Nicolantonio", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Emilia-Romagna", "City": "Scandiano", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "MRD or molecular tumour board case report", "rest_events_session_count": 1, "rest_events_session": "Basic science & Translational research", "events_topic": "Molecular Tumor | Neoplasm, Residual ", "rest_events_topic_count": 1, "rest_events_topic": " Translational Research, Biomedical", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Federica Di Nicolantonio ", "kol_full_name": "Federica Di Nicolantonio " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Triple Negative Breast Neoplasms | Brain Neoplasms | Breast Neoplasms | Immunoconjugates", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454634", "session_name": "Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer,ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fei Ma", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Beijing", "City": "Beijing", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Results from a Phase Ia/Ib Study of ESG401", "rest_events_session_count": 5, "rest_events_session": " a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer,ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases", "events_topic": "Triple Negative Breast Neoplasms | Brain Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Breast Neoplasms | Immunoconjugates", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fei Ma ", "kol_full_name": "Fei Ma " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Lung Neoplasms | Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454803", "session_name": "Cancer patients and advocacy,Management of adverse events in lung cancer antibody-drug conjugate (ADC) treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fernanda Conceição", "middle_name": null, "last_name": null, "org_name": "", "Country": "Portugal", "Region": "Lisboa", "City": "Lisbon", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer patients and advocacy", "rest_events_session_count": 1, "rest_events_session": "Management of adverse events in lung cancer antibody-drug conjugate (ADC) treatment", "events_topic": "Immunoconjugates | Lung Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fernanda Conceição ", "kol_full_name": "Fernanda Conceição " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiation | Clinical Trial | Tumor Microenvironment", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454581", "session_name": "Next generation of combinations in early clinical trials,How to exploit radiation-induced tumour microenvironment vulnerabilities?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fernanda Herrera", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Next generation of combinations in early clinical trials", "rest_events_session_count": 1, "rest_events_session": "How to exploit radiation-induced tumour microenvironment vulnerabilities?", "events_topic": "Radiation | Clinical Trial ", "rest_events_topic_count": 1, "rest_events_topic": " Tumor Microenvironment", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fernanda Herrera ", "kol_full_name": "Fernanda Herrera " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genital Neoplasms, Female | Patient Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454441", "session_name": "Gynaecological cancer: How can technology help the fight?,Digitalising the patient journey", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Florence Joly Lobbedez", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Basse-Normandie", "City": "Caen", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gynaecological cancer: How can technology help the fight?", "rest_events_session_count": 1, "rest_events_session": "Digitalising the patient journey", "events_topic": "Genital Neoplasms, Female | Patient Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Florence Joly Lobbedez ", "kol_full_name": "Florence Joly Lobbedez " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Palliative Care | Microbiota", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454818", "session_name": "ESMO in collaboration with the MASCC: Shedding light on the hidden microbiota,Supportive and palliative care", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Florian Scotté", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO in collaboration with the MASCC: Shedding light on the hidden microbiota", "rest_events_session_count": 1, "rest_events_session": "Supportive and palliative care", "events_topic": "Palliative Care | Microbiota", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Florian Scotté ", "kol_full_name": "Florian Scotté " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Brain Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454678", "session_name": "Cancer neuroscience in brain tumours and beyond,Brain tumour cancer neuroscience", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Frank Winkler", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer neuroscience in brain tumours and beyond", "rest_events_session_count": 1, "rest_events_session": "Brain tumour cancer neuroscience", "events_topic": "Brain Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Frank Winkler ", "kol_full_name": "Frank Winkler " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biomarkers | Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454227", "session_name": "POWG 1: Biomarkers in everyday clinical practice,Early, integrated palliative care in older adults with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gabor Liposits", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Vestsjalland", "City": "Herning", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "POWG 1: Biomarkers in everyday clinical practice", "rest_events_session_count": 2, "rest_events_session": "Early, integrated palliative care in older adults with cancer", "events_topic": "Biomarkers | Palliative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gabor Liposits ", "kol_full_name": "Gabor Liposits " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Meningioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454564", "session_name": "Management and diagnostics of meningioma,Treatment changes of meningioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gelareh Zadeh", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management and diagnostics of meningioma", "rest_events_session_count": 1, "rest_events_session": "Treatment changes of meningioma", "events_topic": "Meningioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gelareh Zadeh ", "kol_full_name": "Gelareh Zadeh " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pembrolizumab | Nivolumab | Neoadjuvant Therapy | Placebos | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454545", "session_name": "KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma,Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Georgina V. Long", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "New South Wales", "City": "Sydney", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma", "rest_events_session_count": 1, "rest_events_session": "Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K", "events_topic": "Pembrolizumab | Nivolumab ", "rest_events_topic_count": 3, "rest_events_topic": " Neoadjuvant Therapy | Placebos | Melanoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Georgina V. Long ", "kol_full_name": "Georgina V. Long " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Androgen Receptor Pathway Inhibitor | Androgen Receptor Pathway Inhibition", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454298", "session_name": "Therapeutic options beyond AR pathway inhibitors: What do we choose next?,Novel therapeutic approaches for ARPI-resistant disease", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gerhardt Attard", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Therapeutic options beyond AR pathway inhibitors: What do we choose next?", "rest_events_session_count": 1, "rest_events_session": "Novel therapeutic approaches for ARPI-resistant disease", "events_topic": "Androgen Receptor Pathway Inhibitor | Androgen Receptor Pathway Inhibition", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gerhardt Attard ", "kol_full_name": "Gerhardt Attard " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Treatment Outcome | Microbiota | Translational Research, Biomedical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454848", "session_name": "Exploiting the microbiome to improve treatment outcomes,Basic science & Translational research", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Göran Jönsson", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Skane Lan", "City": "Lund", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Exploiting the microbiome to improve treatment outcomes", "rest_events_session_count": 1, "rest_events_session": "Basic science & Translational research", "events_topic": "Treatment Outcome | Microbiota ", "rest_events_topic_count": 1, "rest_events_topic": " Translational Research, Biomedical", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Göran Jönsson ", "kol_full_name": "Göran Jönsson " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Venous Thromboembolism", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454394", "session_name": "Management of venous thromboembolism: Discussion,Prevention strategies of venous thromboembolism", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Grigorios Gerotziafas", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of venous thromboembolism: Discussion", "rest_events_session_count": 1, "rest_events_session": "Prevention strategies of venous thromboembolism", "events_topic": "Venous Thromboembolism", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Grigorios Gerotziafas ", "kol_full_name": "Grigorios Gerotziafas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Promotion | Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454652", "session_name": "Health promotion, prevention and screening,Experience from cancer nursing during earthquake: The impact on cancer care", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gulcan Bagcivan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Istanbul", "City": "Istanbul", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Health promotion", "rest_events_session_count": 2, "rest_events_session": " prevention and screening,Experience from cancer nursing during earthquake: The impact on cancer care", "events_topic": "Health Promotion | Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gulcan Bagcivan ", "kol_full_name": "Gulcan Bagcivan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "ErbB Receptors | Oncology Nursing | Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454333", "session_name": "Safeguarding Skin Health in NSCLC with EGFR-targeted agents,Where is cancer nursing in precision health?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Helena Ullgren", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Solna", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Safeguarding Skin Health in NSCLC with EGFR-targeted agents", "rest_events_session_count": 1, "rest_events_session": "Where is cancer nursing in precision health?", "events_topic": "ErbB Receptors | Oncology Nursing ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Non-Small-Cell Lung", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Helena Ullgren ", "kol_full_name": "Helena Ullgren " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pregnancy | Ovarian Neoplasms | Safety Management | Fertility", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454287", "session_name": "Fertility and pregnancy in patients with gynaecological cancer,How to manage safety", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ilaria Colombo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Ticino", "City": "Bellinzona", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Fertility and pregnancy in patients with gynaecological cancer", "rest_events_session_count": 1, "rest_events_session": "How to manage safety", "events_topic": "Pregnancy | Ovarian Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Safety Management | Fertility", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ilaria Colombo ", "kol_full_name": "Ilaria Colombo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Head And Neck Neoplasms | Patient Selection", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454698", "session_name": "Personalised immunotherapy strategies for head and neck cancers,How to select patients? Models to predict response", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ingeborg Tinhofer-Keilholz", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Berlin", "City": "Berlin", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Personalised immunotherapy strategies for head and neck cancers", "rest_events_session_count": 1, "rest_events_session": "How to select patients? Models to predict response", "events_topic": "Immunotherapy | Head And Neck Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Patient Selection", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ingeborg Tinhofer-Keilholz ", "kol_full_name": "Ingeborg Tinhofer-Keilholz " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454749", "session_name": "Promises and pitfalls in earlier stage NSCLC,To resect or not to resect, and how? Advancing surgical management in early stage NSCLC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Isabelle Schmitt-Opitz", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Zurich", "City": "Zurich", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Promises and pitfalls in earlier stage NSCLC", "rest_events_session_count": 2, "rest_events_session": "To resect or not to resect, and how? Advancing surgical management in early stage NSCLC", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Isabelle Schmitt-Opitz ", "kol_full_name": "Isabelle Schmitt-Opitz " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Chemoradiotherapy | Drug Therapy | Uterine Cervical Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454727", "session_name": "How can we best manage locally-advanced and persistent cervical cancers?,The role of chemotherapy in concurrent chemoradiation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jack J. Chan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How can we best manage locally-advanced and persistent cervical cancers?", "rest_events_session_count": 1, "rest_events_session": "The role of chemotherapy in concurrent chemoradiation", "events_topic": "Chemoradiotherapy | Drug Therapy ", "rest_events_topic_count": 1, "rest_events_topic": " Uterine Cervical Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jack J. Chan ", "kol_full_name": "Jack J. Chan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial | Machine Learning | Artificial Intelligence | Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454625", "session_name": "AI and machine learning to identify early phase clinical trial biomarkers,Applications of artificial intelligence in precision oncology", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jakob N. Kather", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Sachsen", "City": "Dresden", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "AI and machine learning to identify early phase clinical trial biomarkers", "rest_events_session_count": 1, "rest_events_session": "Applications of artificial intelligence in precision oncology", "events_topic": "Clinical Trial | Machine Learning ", "rest_events_topic_count": 2, "rest_events_topic": " Artificial Intelligence | Biomarkers", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jakob N. Kather ", "kol_full_name": "Jakob N. Kather " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Streptozocin | Everolimus | Neuroendocrine Tumors | Fluorouracil", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454426", "session_name": "Multivariable Analysis of Streptozotocin plus 5-Fluorouracil and Everolimus Sequences in Advanced Pancreatic Neuroendocrine Tumor patients: The SEQTOR Trial (GETNE-1206),Precision systemic therapy in NEN", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jaume Capdevila Castillon", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Multivariable Analysis of Streptozotocin plus 5-Fluorouracil and Everolimus Sequences in Advanced Pancreatic Neuroendocrine Tumor patients: The SEQTOR Trial (GETNE-1206)", "rest_events_session_count": 1, "rest_events_session": "Precision systemic therapy in NEN", "events_topic": "Streptozocin | Everolimus ", "rest_events_topic_count": 2, "rest_events_topic": " Neuroendocrine Tumors | Fluorouracil", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jaume Capdevila Castillon ", "kol_full_name": "Jaume Capdevila Castillon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454795", "session_name": "Supportive and palliative care,9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jayne E. Wood", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Supportive and palliative care", "rest_events_session_count": 1, "rest_events_session": "9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care", "events_topic": "Palliative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jayne E. Wood ", "kol_full_name": "Jayne E. Wood " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cell Death | Chemoradiotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454696", "session_name": "New therapeutic approaches in concomitant chemoradiotherapy,Targeting cell death pathways", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jean Bourhis", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New therapeutic approaches in concomitant chemoradiotherapy", "rest_events_session_count": 1, "rest_events_session": "Targeting cell death pathways", "events_topic": "Cell Death | Chemoradiotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jean Bourhis ", "kol_full_name": "Jean Bourhis " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms | Breast Neoplasms | Cancer Vaccines | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454271", "session_name": "New indications for immunotherapies and the difference they deliver: Lung, breast, and other cancers. Does it work for all?,Personalised anti-tumour vaccines", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jean-Pascal Machiels", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Woluwe-Saint-Lambert", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New indications for immunotherapies and the difference they deliver: Lung", "rest_events_session_count": 3, "rest_events_session": " breast, and other cancers. Does it work for all?,Personalised anti-tumour vaccines", "events_topic": "Lung Neoplasms | Breast Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Cancer Vaccines | Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jean-Pascal Machiels ", "kol_full_name": "Jean-Pascal Machiels " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms | Carcinoma, Lobular", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454420", "session_name": "Treatment of lobular breast cancer (ILC): From pitfalls to opportunities,Systemic treatment for ILCs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jens Huober", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Sankt Gallen", "City": "Sankt Gallen", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment of lobular breast cancer (ILC): From pitfalls to opportunities", "rest_events_session_count": 1, "rest_events_session": "Systemic treatment for ILCs", "events_topic": "Breast Neoplasms | Carcinoma, Lobular", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jens Huober ", "kol_full_name": "Jens Huober " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454800", "session_name": "New developments in the treatment of sarcomas in 2024,Sarcoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Joanna Szkandera", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Steiermark", "City": "Graz", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New developments in the treatment of sarcomas in 2024", "rest_events_session_count": 1, "rest_events_session": "Sarcoma", "events_topic": "Sarcoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joanna Szkandera ", "kol_full_name": "Joanna Szkandera " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genomics | Molecular Tumor Board | Precision Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454428", "session_name": "Integrating precision medicine / ESCAT in your choice of treatment,Navigating the molecular tumour board and genomic reports", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Joaquin Mateo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Integrating precision medicine / ESCAT in your choice of treatment", "rest_events_session_count": 1, "rest_events_session": "Navigating the molecular tumour board and genomic reports", "events_topic": "Genomics | Molecular Tumor Board ", "rest_events_topic_count": 1, "rest_events_topic": " Precision Medicine", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joaquin Mateo ", "kol_full_name": "Joaquin Mateo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Solid Tumours | MRNA Vaccines | Immunotherapy, Adoptive | Receptors, Chimeric Antigen | BNT211-01 | Solid Tumors | Cell- And Tissue-Based Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454584", "session_name": "Cell therapy in solid tumours,Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, Phase 1 study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "John B. Haanen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cell therapy in solid tumours", "rest_events_session_count": 4, "rest_events_session": "Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, Phase 1 study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors", "events_topic": "Solid Tumours | MRNA Vaccines ", "rest_events_topic_count": 5, "rest_events_topic": " Immunotherapy, Adoptive | Receptors, Chimeric Antigen | BNT211-01 | Solid Tumors | Cell- And Tissue-Based Therapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
John B. Haanen ", "kol_full_name": "John B. Haanen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thymic Epithelial Tumours | Thymus Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454462", "session_name": "Updates on the treatment of thymic epithelial tumours,Systemic treatment for thymic tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jordi Remon Masip", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Updates on the treatment of thymic epithelial tumours", "rest_events_session_count": 1, "rest_events_session": "Systemic treatment for thymic tumours", "events_topic": "Thymic Epithelial Tumours | Thymus Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jordi Remon Masip ", "kol_full_name": "Jordi Remon Masip " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oligoprogressive Disease | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454860", "session_name": "Management of oligoprogressive disease,Breast cancer, metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Karen A. Gelmon", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "British Columbia", "City": "Vancouver", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of oligoprogressive disease", "rest_events_session_count": 2, "rest_events_session": "Breast cancer, metastatic", "events_topic": "Oligoprogressive Disease | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Karen A. Gelmon ", "kol_full_name": "Karen A. Gelmon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Skin Neoplasms | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454833", "session_name": "Melanoma and other skin tumours,Survivors of advanced melanoma: Management and support", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Karijn Suijkerbuijk", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Utrecht", "City": "Utrecht", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Melanoma and other skin tumours", "rest_events_session_count": 1, "rest_events_session": "Survivors of advanced melanoma: Management and support", "events_topic": "Skin Neoplasms | Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Karijn Suijkerbuijk ", "kol_full_name": "Karijn Suijkerbuijk " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Survivorship | Rehabilitation | Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454641", "session_name": "Rehabilitation and survivorship care,Cancer is a family affair", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Karin B. Dieperink", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Fyn", "City": "Odense", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Rehabilitation and survivorship care", "rest_events_session_count": 1, "rest_events_session": "Cancer is a family affair", "events_topic": "Survivorship | Rehabilitation ", "rest_events_topic_count": 1, "rest_events_topic": " Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Karin B. Dieperink ", "kol_full_name": "Karin B. Dieperink " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Soft Tissue Sarcoma | Sarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454391", "session_name": "Definition and clinical implication of response in localised sarcomas,New developments in the treatment of soft tissue sarcomas", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kjetil Boye", "middle_name": null, "last_name": null, "org_name": "", "Country": "Norway", "Region": "Oslo", "City": "Oslo", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Definition and clinical implication of response in localised sarcomas", "rest_events_session_count": 1, "rest_events_session": "New developments in the treatment of soft tissue sarcomas", "events_topic": "Soft Tissue Sarcoma | Sarcoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kjetil Boye ", "kol_full_name": "Kjetil Boye " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Psychological Well-Being", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454351", "session_name": "Optimising well-being and tackling burnout in oncology,Should we try immunotherapy for all patients with advanced cancer? - No", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kok Haw Jonathan Lim", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Optimising well-being and tackling burnout in oncology", "rest_events_session_count": 1, "rest_events_session": "Should we try immunotherapy for all patients with advanced cancer? - No", "events_topic": "Immunotherapy | Psychological Well-Being", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kok Haw Jonathan Lim ", "kol_full_name": "Kok Haw Jonathan Lim " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Toripalimab | Anlotinib | Temozolomide | Glioblastoma | Glioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454587", "session_name": "A Clinical Study of the Safety and Efficacy of Toripalimab in Combination with Anilotinib for the Treatment of Recurrent Glioblastoma (GBM),A Clinical Study of the Safety and Efficacy of Anlotinib Hydrochloride Combined with Temozolomide dose density scheme for the Treatment of Recurrent High Grade Glioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Liang Wang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Clinical Study of the Safety and Efficacy of Toripalimab in Combination with Anilotinib for the Treatment of Recurrent Glioblastoma (GBM)", "rest_events_session_count": 1, "rest_events_session": "A Clinical Study of the Safety and Efficacy of Anlotinib Hydrochloride Combined with Temozolomide dose density scheme for the Treatment of Recurrent High Grade Glioma", "events_topic": "Toripalimab | Anlotinib ", "rest_events_topic_count": 3, "rest_events_topic": " Temozolomide | Glioblastoma | Glioma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Liang Wang ", "kol_full_name": "Liang Wang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thoracic Neoplasms | Radionecrosis | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454771", "session_name": "Next generation immunotherapies in thoracic malignancies,Radionecrosis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lizza E. Hendriks", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Limburg", "City": "Maastricht", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Next generation immunotherapies in thoracic malignancies", "rest_events_session_count": 1, "rest_events_session": "Radionecrosis", "events_topic": "Thoracic Neoplasms | Radionecrosis ", "rest_events_topic_count": 1, "rest_events_topic": " Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lizza E. Hendriks ", "kol_full_name": "Lizza E. Hendriks " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Hepatocellular | Neoadjuvant Therapy | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454761", "session_name": "Management of adjuvant/neoadjuvant HCC in 2024,How to select first-line and what to do after progression to immunotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lorenza Rimassa", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of adjuvant/neoadjuvant HCC in 2024", "rest_events_session_count": 1, "rest_events_session": "How to select first-line and what to do after progression to immunotherapy", "events_topic": "Carcinoma, Hepatocellular | Neoadjuvant Therapy ", "rest_events_topic_count": 1, "rest_events_topic": " Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lorenza Rimassa ", "kol_full_name": "Lorenza Rimassa " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oligoprogressive Disease | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454301", "session_name": "Management of oligoprogressive disease,Hormone-receptor positive breast cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lucia Del Mastro", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Liguria", "City": "Genova", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of oligoprogressive disease", "rest_events_session_count": 1, "rest_events_session": "Hormone-receptor positive breast cancer", "events_topic": "Oligoprogressive Disease | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lucia Del Mastro ", "kol_full_name": "Lucia Del Mastro " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Case Reports | Carcinoma, Hepatocellular", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5467549", "session_name": "Experiences from the clinic: a dynamic case study discussion,Current therapeutic approaches in HCC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Manon Allaire", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Experiences from the clinic: a dynamic case study discussion", "rest_events_session_count": 1, "rest_events_session": "Current therapeutic approaches in HCC", "events_topic": "Case Reports | Carcinoma, Hepatocellular", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Manon Allaire ", "kol_full_name": "Manon Allaire " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Anus Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454702", "session_name": "Multidisciplinary team working in the management of anal cancer: Current perspectives,Anal cancer: Biological classifications and current thinking", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Antonietta Gambacorta", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lazio", "City": "Rome", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Multidisciplinary team working in the management of anal cancer: Current perspectives", "rest_events_session_count": 1, "rest_events_session": "Anal cancer: Biological classifications and current thinking", "events_topic": "Anus Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Antonietta Gambacorta ", "kol_full_name": "Maria Antonietta Gambacorta " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma | Hematologic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454783", "session_name": "Treatment of difficult lymphomas,Haematological malignancies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Gomes Da Silva", "middle_name": null, "last_name": null, "org_name": "", "Country": "Portugal", "Region": "Lisboa", "City": "Lisbon", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment of difficult lymphomas", "rest_events_session_count": 1, "rest_events_session": "Haematological malignancies", "events_topic": "Lymphoma | Hematologic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Gomes Da Silva ", "kol_full_name": "Maria Gomes Da Silva " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pregnancy | Ovarian Neoplasms | Fertility | Carcinoma, Ovarian Epithelial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454602", "session_name": "Fertility and pregnancy in patients with gynaecological cancer,Epithelial ovarian cancer: Case presentation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Kfoury", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Provence-Alpes-Cote d'Azur", "City": "Marseille", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Fertility and pregnancy in patients with gynaecological cancer", "rest_events_session_count": 1, "rest_events_session": "Epithelial ovarian cancer: Case presentation", "events_topic": "Pregnancy | Ovarian Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Fertility | Carcinoma, Ovarian Epithelial", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Kfoury ", "kol_full_name": "Maria Kfoury " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Proto-Oncogene Proteins B-raf | Raf1 Protein, Human | Tovorafenib | Melanoma | Solid Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454375", "session_name": "Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification,Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Vieito", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification", "rest_events_session_count": 2, "rest_events_session": "Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors", "events_topic": "Proto-Oncogene Proteins B-raf | Raf1 Protein, Human ", "rest_events_topic_count": 3, "rest_events_topic": " Tovorafenib | Melanoma | Solid Tumors", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Vieito ", "kol_full_name": "Maria Vieito " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Enterocolitis | Immunotherapy | Gastrointestinal Diseases", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454676", "session_name": "Improving the management of toxicities from immunotherapy,Gastrointestinal disorders: Enterocolitis and beyond", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Mario Mandalà", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Umbria", "City": "Perugia", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Improving the management of toxicities from immunotherapy", "rest_events_session_count": 1, "rest_events_session": "Gastrointestinal disorders: Enterocolitis and beyond", "events_topic": "Enterocolitis | Immunotherapy ", "rest_events_topic_count": 1, "rest_events_topic": " Gastrointestinal Diseases", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Mario Mandalà ", "kol_full_name": "Mario Mandalà " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Triple Negative Breast Neoplasms | Polymerase Chain Reaction | Chemo-Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454307", "session_name": "The rapidly changing treatment landscape of early triple negative breast cancer,Treatments for eTNBC patients with non-pCR after chemo-immunotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marleen Kok", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The rapidly changing treatment landscape of early triple negative breast cancer", "rest_events_session_count": 1, "rest_events_session": "Treatments for eTNBC patients with non-pCR after chemo-immunotherapy", "events_topic": "Triple Negative Breast Neoplasms | Polymerase Chain Reaction ", "rest_events_topic_count": 1, "rest_events_topic": " Chemo-Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marleen Kok ", "kol_full_name": "Marleen Kok " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Profiling | Brain Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454387", "session_name": "Common clinical problems in neuro-oncology,Comprehensive molecular profiling of AYA patients: An EORTC-SPECTA proof of concept study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Martin Mccabe", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Manchester", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Common clinical problems in neuro-oncology", "rest_events_session_count": 1, "rest_events_session": "Comprehensive molecular profiling of AYA patients: An EORTC-SPECTA proof of concept study", "events_topic": "Molecular Profiling | Brain Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Martin Mccabe ", "kol_full_name": "Martin Mccabe " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Patient Readmission", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454500", "session_name": "Cancer patients and advocacy,A targeted discharge pathway to reduce hospital readmissions and dying in hospital in cancer patients at the end of life", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Merel Van Klinken", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer patients and advocacy", "rest_events_session_count": 1, "rest_events_session": "A targeted discharge pathway to reduce hospital readmissions and dying in hospital in cancer patients at the end of life", "events_topic": "Neoplasms | Patient Readmission", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Merel Van Klinken ", "kol_full_name": "Merel Van Klinken " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunomodulation | Clinical Trial, Phase I | Antigens", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454716", "session_name": "The evolving diagnostic landscape of early phase trials,Challenges of HLA, neoantigen, and immune biomarker testing for early phase immunomodulatory therapy trials", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Michal Bassani-Sternberg", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The evolving diagnostic landscape of early phase trials", "rest_events_session_count": 3, "rest_events_session": "Challenges of HLA, neoantigen, and immune biomarker testing for early phase immunomodulatory therapy trials", "events_topic": "Immunomodulation | Clinical Trial, Phase I ", "rest_events_topic_count": 1, "rest_events_topic": " Antigens", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Michal Bassani-Sternberg ", "kol_full_name": "Michal Bassani-Sternberg " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Real World Data | Real World Evidence", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454695", "session_name": "How Real World Data (RWD) are transforming oncology,Future directions in the development and use of Real World Evidence", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Miriam Koopman", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Utrecht", "City": "Utrecht", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How Real World Data (RWD) are transforming oncology", "rest_events_session_count": 1, "rest_events_session": "Future directions in the development and use of Real World Evidence", "events_topic": "Real World Data | Real World Evidence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Miriam Koopman ", "kol_full_name": "Miriam Koopman " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immune Checkpoint Inhibitors | Thoracic Neoplasms | Programmed Cell Death Ligand 1 | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454466", "session_name": "Next generation immunotherapies in thoracic malignancies,Targeting T cells beyond PD-1/PD-L1 axis: Other checkpoints inhibitors and costimulatory receptors agonists", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nathalie Chaput-Gras", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Next generation immunotherapies in thoracic malignancies", "rest_events_session_count": 1, "rest_events_session": "Targeting T cells beyond PD-1/PD-L1 axis: Other checkpoints inhibitors and costimulatory receptors agonists", "events_topic": "Immune Checkpoint Inhibitors | Thoracic Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Programmed Cell Death Ligand 1 | Immunotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nathalie Chaput-Gras ", "kol_full_name": "Nathalie Chaput-Gras " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Liquid Biopsy | Colorectal Neoplasms | Translational Research, Biomedical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454430", "session_name": "Basic science & Translational research,Liquid biopsies across the disease spectrum; learning from colorectal cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Naureen Starling", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Basic science & Translational research", "rest_events_session_count": 1, "rest_events_session": "Liquid biopsies across the disease spectrum; learning from colorectal cancer", "events_topic": "Liquid Biopsy | Colorectal Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Translational Research, Biomedical", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Naureen Starling ", "kol_full_name": "Naureen Starling " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Prostatic Neoplasms | Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454813", "session_name": "GU tumours, prostate,What’s on the horizon for metastatic prostate cancer patients?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Niven Mehra", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Gelderland", "City": "Nijmegen", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GU tumours", "rest_events_session_count": 2, "rest_events_session": " prostate,What’s on the horizon for metastatic prostate cancer patients?", "events_topic": "Prostatic Neoplasms | Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Niven Mehra ", "kol_full_name": "Niven Mehra " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Ipilimumab | Genital Neoplasms, Female | Nivolumab | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454597", "session_name": "Nivolumab and Ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study,Nivolumab and Ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Oliver Klein", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nivolumab and Ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study", "rest_events_session_count": 1, "rest_events_session": "Nivolumab and Ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial", "events_topic": "Ipilimumab | Genital Neoplasms, Female ", "rest_events_topic_count": 2, "rest_events_topic": " Nivolumab | Colorectal Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Oliver Klein ", "kol_full_name": "Oliver Klein " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms | Carcinoma, Non-Small-Cell Lung | Early Detection Of Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454300", "session_name": "Lung cancer interception: New approaches to lung cancer screening and prevention,Should we be screening in never smokers for NSCLC?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Pan-Chyr Yang", "middle_name": null, "last_name": null, "org_name": "", "Country": "Taiwan", "Region": "T'ai-pei", "City": "Taipei", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Lung cancer interception: New approaches to lung cancer screening and prevention", "rest_events_session_count": 1, "rest_events_session": "Should we be screening in never smokers for NSCLC?", "events_topic": "Lung Neoplasms | Carcinoma, Non-Small-Cell Lung ", "rest_events_topic_count": 1, "rest_events_topic": " Early Detection Of Cancer", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Pan-Chyr Yang ", "kol_full_name": "Pan-Chyr Yang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Translational Research, Biomedical | Basic Science", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454786", "session_name": "Basic science & Translational research,Basic science & TR", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Philippe L. Bedard", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Basic science & Translational research", "rest_events_session_count": 1, "rest_events_session": "Basic science & TR", "events_topic": "Translational Research, Biomedical | Basic Science", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Philippe L. Bedard ", "kol_full_name": "Philippe L. Bedard " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Case Reports | Carcinoma, Hepatocellular", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5467548", "session_name": "Experiences from the clinic: a dynamic case study discussion,Current therapeutic approaches in HCC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Pierce Chow", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Experiences from the clinic: a dynamic case study discussion", "rest_events_session_count": 1, "rest_events_session": "Current therapeutic approaches in HCC", "events_topic": "Case Reports | Carcinoma, Hepatocellular", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Pierce Chow ", "kol_full_name": "Pierce Chow " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Geriatricians | Personalized Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454681", "session_name": "ESMO-SIOG: Working together in the era of personalized care for older adults with cancer,Geriatrician perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rabia Boulahssass", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Provence-Alpes-Cote d'Azur", "City": "Nice", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO-SIOG: Working together in the era of personalized care for older adults with cancer", "rest_events_session_count": 1, "rest_events_session": "Geriatrician perspective", "events_topic": "Geriatricians | Personalized Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rabia Boulahssass ", "kol_full_name": "Rabia Boulahssass " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Syndrome | Diagnosis, Differential | Malignant Carcinoid Syndrome", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454723", "session_name": "Differential diagnosis and management of clinical syndromes,Carcinoid syndrome", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rachel Riechelmann", "middle_name": null, "last_name": null, "org_name": "", "Country": "Brazil", "Region": null, "City": null, "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Differential diagnosis and management of clinical syndromes", "rest_events_session_count": 1, "rest_events_session": "Carcinoid syndrome", "events_topic": "Clinical Syndrome | Diagnosis, Differential ", "rest_events_topic_count": 1, "rest_events_topic": " Malignant Carcinoid Syndrome", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rachel Riechelmann ", "kol_full_name": "Rachel Riechelmann " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung | Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454700", "session_name": "Treating KRAS-mutated NSCLC,Do we have clinical or radiological biomarkers to guide us?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Roberto Ferrara", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treating KRAS-mutated NSCLC", "rest_events_session_count": 1, "rest_events_session": "Do we have clinical or radiological biomarkers to guide us?", "events_topic": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung ", "rest_events_topic_count": 1, "rest_events_topic": " Biomarkers", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Roberto Ferrara ", "kol_full_name": "Roberto Ferrara " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "IDH1 Protein, Human | Olutasidenib | Chondrosarcoma | Soft Tissue Sarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454259", "session_name": "Landmark trials in soft tissue sarcomas (incl. LPS/LMS),Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Robin L. Jones", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Landmark trials in soft tissue sarcomas (incl. LPS/LMS)", "rest_events_session_count": 3, "rest_events_session": "Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma", "events_topic": "IDH1 Protein, Human | Olutasidenib ", "rest_events_topic_count": 2, "rest_events_topic": " Chondrosarcoma | Soft Tissue Sarcoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Robin L. Jones ", "kol_full_name": "Robin L. Jones " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endocrine Gland Neoplasms | Clinical Syndrome | Neuroendocrine Tumors | Diagnosis, Differential", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454845", "session_name": "Differential diagnosis and management of clinical syndromes,NETs and endocrine tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rocio Garcia-Carbonero", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Differential diagnosis and management of clinical syndromes", "rest_events_session_count": 1, "rest_events_session": "NETs and endocrine tumours", "events_topic": "Endocrine Gland Neoplasms | Clinical Syndrome ", "rest_events_topic_count": 2, "rest_events_topic": " Neuroendocrine Tumors | Diagnosis, Differential", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rocio Garcia-Carbonero ", "kol_full_name": "Rocio Garcia-Carbonero " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pregnancy | Ovarian Neoplasms | Venous Thromboembolism | Fertility", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454601", "session_name": "Fertility and pregnancy in patients with gynaecological cancer,Management of venous thromboembolism: Case presentation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rodrigo Sanchez Bayona", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Fertility and pregnancy in patients with gynaecological cancer", "rest_events_session_count": 1, "rest_events_session": "Management of venous thromboembolism: Case presentation", "events_topic": "Pregnancy | Ovarian Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Venous Thromboembolism | Fertility", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rodrigo Sanchez Bayona ", "kol_full_name": "Rodrigo Sanchez Bayona " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Drug Monitoring | Pharmacology, Clinical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454559", "session_name": "Current advances in clinical pharmacology within oncology, and its relevance for daily practice,Implementation in clinical practice of therapeutic drug monitoring (TDM) of kinase inhibitors anno 2024", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ron H. Mathijssen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Rotterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Current advances in clinical pharmacology within oncology", "rest_events_session_count": 2, "rest_events_session": " and its relevance for daily practice,Implementation in clinical practice of therapeutic drug monitoring (TDM) of kinase inhibitors anno 2024", "events_topic": "Drug Monitoring | Pharmacology, Clinical", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ron H. Mathijssen ", "kol_full_name": "Ron H. Mathijssen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Targeted Therapy | Esophageal Neoplasms | Molecular Characterization | Pancreatic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454470", "session_name": "Molecular characterisation and novel targeted therapies in gastroesophageal and pancreatic cancer,New developments in molecular characterisation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rupert Langer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Oberosterreich", "City": "Linz", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Molecular characterisation and novel targeted therapies in gastroesophageal and pancreatic cancer", "rest_events_session_count": 1, "rest_events_session": "New developments in molecular characterisation", "events_topic": "Molecular Targeted Therapy | Esophageal Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Molecular Characterization | Pancreatic Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rupert Langer ", "kol_full_name": "Rupert Langer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antineoplastic Agents | Clinical Trial | Drug Development", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454518", "session_name": "ESMO-CDDF – Regulatory challenges in clinical cancer drug development,New approaches to trial design to minimise costs and maximise benefit: The oncologists perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ruth Plummer", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Newcastle Upon Tyne", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO-CDDF – Regulatory challenges in clinical cancer drug development", "rest_events_session_count": 1, "rest_events_session": "New approaches to trial design to minimise costs and maximise benefit: The oncologists perspective", "events_topic": "Antineoplastic Agents | Clinical Trial ", "rest_events_topic_count": 1, "rest_events_topic": " Drug Development", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ruth Plummer ", "kol_full_name": "Ruth Plummer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antigens, Neoplasm", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454439", "session_name": "Are we targeting the right antigens?,Should we target shared or unique antigens?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Samra Turajlic", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Are we targeting the right antigens?", "rest_events_session_count": 1, "rest_events_session": "Should we target shared or unique antigens?", "events_topic": "Antigens, Neoplasm", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Samra Turajlic ", "kol_full_name": "Samra Turajlic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sarcoma | Osteosarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454393", "session_name": "New developments in the treatment of sarcomas in 2024,New developments in the treatment of bone sarcomas", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sandra Strauss", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New developments in the treatment of sarcomas in 2024", "rest_events_session_count": 1, "rest_events_session": "New developments in the treatment of bone sarcomas", "events_topic": "Sarcoma | Osteosarcoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sandra Strauss ", "kol_full_name": "Sandra Strauss " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing | Subcutaneous Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454494", "session_name": "What is your last wish? A volunteer project led by an oncology nurse,Current trends in subcutaneous therapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sara M. Gomes", "middle_name": null, "last_name": null, "org_name": "", "Country": "Portugal", "Region": "Coimbra", "City": "Coimbra", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What is your last wish? A volunteer project led by an oncology nurse", "rest_events_session_count": 1, "rest_events_session": "Current trends in subcutaneous therapy", "events_topic": "Oncology Nursing | Subcutaneous Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sara M. Gomes ", "kol_full_name": "Sara M. Gomes " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Targeted Therapy | Esophageal Neoplasms | Pancreatic Neoplasms | Gastrointestinal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454782", "session_name": "Molecular characterisation and novel targeted therapies in gastroesophageal and pancreatic cancer,Gastrointestinal tumours, upper digestive", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sarah Derks", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Molecular characterisation and novel targeted therapies in gastroesophageal and pancreatic cancer", "rest_events_session_count": 2, "rest_events_session": "Gastrointestinal tumours, upper digestive", "events_topic": "Molecular Targeted Therapy | Esophageal Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Pancreatic Neoplasms | Gastrointestinal Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sarah Derks ", "kol_full_name": "Sarah Derks " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antigens, Neoplasm | Neoantigens", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454274", "session_name": "Beyond coding neoantigens: What else is there for T cells to see?,Noncoding regions as a source of targetable tumour-specific antigens", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sebastian Amigorena", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Beyond coding neoantigens: What else is there for T cells to see?", "rest_events_session_count": 1, "rest_events_session": "Noncoding regions as a source of targetable tumour-specific antigens", "events_topic": "Antigens, Neoplasm | Neoantigens", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sebastian Amigorena ", "kol_full_name": "Sebastian Amigorena " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Head And Neck Neoplasms | Public Health", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454796", "session_name": "Head and neck cancer,ESMO-MCBS: A practical tool with public health implications", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sjoukje Oosting", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Groningen", "City": "Groningen", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Head and neck cancer", "rest_events_session_count": 1, "rest_events_session": "ESMO-MCBS: A practical tool with public health implications", "events_topic": "Head And Neck Neoplasms | Public Health", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sjoukje Oosting ", "kol_full_name": "Sjoukje Oosting " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Proteolysis | Molecular Glues", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454742", "session_name": "Protein degradation as a novel approach for cancer therapy,Degraders and molecular glues: Where are we in the clinic now?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sophie Postel-Vinay", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Protein degradation as a novel approach for cancer therapy", "rest_events_session_count": 1, "rest_events_session": "Degraders and molecular glues: Where are we in the clinic now?", "events_topic": "Neoplasms | Proteolysis ", "rest_events_topic_count": 1, "rest_events_topic": " Molecular Glues", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sophie Postel-Vinay ", "kol_full_name": "Sophie Postel-Vinay " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454294", "session_name": "Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?,Could optimal systemic therapy be adequate without locoregional therapy?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Srikala S. Sridhar", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?", "rest_events_session_count": 1, "rest_events_session": "Could optimal systemic therapy be adequate without locoregional therapy?", "events_topic": "Neoadjuvant Therapy | Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Srikala S. Sridhar ", "kol_full_name": "Srikala S. Sridhar " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Hematologic Neoplasms | Lymphoma, Follicular", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454382", "session_name": "Treatment of elderly patients with haematological malignancies,Follicular lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Stefano Luminari", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Emilia-Romagna", "City": "Modena", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment of elderly patients with haematological malignancies", "rest_events_session_count": 1, "rest_events_session": "Follicular lymphoma", "events_topic": "Hematologic Neoplasms | Lymphoma, Follicular", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Stefano Luminari ", "kol_full_name": "Stefano Luminari " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cyclin-Dependent Kinases | Receptors, Estrogen | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454615", "session_name": "Incorporating novel treatment insights for ER+ early BC patients,CDK4/6 inhibitors for early breast cancer: State-of-the-art", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Stephen R. Johnston", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Incorporating novel treatment insights for ER+ early BC patients", "rest_events_session_count": 1, "rest_events_session": "CDK4/6 inhibitors for early breast cancer: State-of-the-art", "events_topic": "Cyclin-Dependent Kinases | Receptors, Estrogen ", "rest_events_topic_count": 1, "rest_events_topic": " Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Stephen R. Johnston ", "kol_full_name": "Stephen R. Johnston " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Policy | Real World Data", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454789", "session_name": "How Real World Data (RWD) are transforming oncology,Policy and preventive strategies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Suzette Delaloge", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How Real World Data (RWD) are transforming oncology", "rest_events_session_count": 1, "rest_events_session": "Policy and preventive strategies", "events_topic": "Health Policy | Real World Data", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Suzette Delaloge ", "kol_full_name": "Suzette Delaloge " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antineoplastic Agents | Drug Development | Developmental Therapeutics", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454806", "session_name": "ESMO-CDDF – Regulatory challenges in clinical cancer drug development,Developmental therapeutics", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Teresa M. Amaral", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Tubingen", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO-CDDF – Regulatory challenges in clinical cancer drug development", "rest_events_session_count": 1, "rest_events_session": "Developmental therapeutics", "events_topic": "Antineoplastic Agents | Drug Development ", "rest_events_topic_count": 1, "rest_events_topic": " Developmental Therapeutics", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Teresa M. Amaral ", "kol_full_name": "Teresa M. Amaral " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Enfortumab Vedotin | Non-Muscle Invasive Bladder Neoplasms | Pembrolizumab | Carcinoma, Renal Cell | NECTIN4 Protein, Human", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454600", "session_name": "EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC),Renal-cell carcinoma: Discussion", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Thomas B. Powles", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC)", "rest_events_session_count": 1, "rest_events_session": "Renal-cell carcinoma: Discussion", "events_topic": "Enfortumab Vedotin | Non-Muscle Invasive Bladder Neoplasms ", "rest_events_topic_count": 3, "rest_events_topic": " Pembrolizumab | Carcinoma, Renal Cell | NECTIN4 Protein, Human", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Thomas B. Powles ", "kol_full_name": "Thomas B. Powles " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Care Facilities | Quality Improvement", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454330", "session_name": "Quality improvement in cancer care,How to plan and implement quality improvement projects", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Virpi Sulosaari", "middle_name": null, "last_name": null, "org_name": "", "Country": "Finland", "Region": "Lansi-Suomen Laani", "City": "Turku", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Quality improvement in cancer care", "rest_events_session_count": 1, "rest_events_session": "How to plan and implement quality improvement projects", "events_topic": "Cancer Care Facilities | Quality Improvement", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Virpi Sulosaari ", "kol_full_name": "Virpi Sulosaari " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Receptors, Vascular Endothelial Growth Factor | Proto-Oncogene Proteins B-raf | Glioblastoma | Pharmacokinetics | Macrophage Colony-Stimulating Factor | Brain Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454586", "session_name": "A Phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumors: interim result,SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Wenbin Li", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Beijing", "City": "Beijing", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Phase I study for safety", "rest_events_session_count": 6, "rest_events_session": " tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumors: interim result,SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma", "events_topic": "Receptors, Vascular Endothelial Growth Factor | Proto-Oncogene Proteins B-raf ", "rest_events_topic_count": 4, "rest_events_topic": " Glioblastoma | Pharmacokinetics | Macrophage Colony-Stimulating Factor | Brain Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Wenbin Li ", "kol_full_name": "Wenbin Li " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoantigens | Antigens, Bacterial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454273", "session_name": "Beyond coding neoantigens: What else is there for T cells to see?,Bacterial derived antigens", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yardena Samuels", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "HaMerkaz (Central)", "City": "Rehovot", "num_sess": "2", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Beyond coding neoantigens: What else is there for T cells to see?", "rest_events_session_count": 1, "rest_events_session": "Bacterial derived antigens", "events_topic": "Neoantigens | Antigens, Bacterial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yardena Samuels ", "kol_full_name": "Yardena Samuels " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antineoplastic Agents", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454672", "session_name": "Specifics of CHMP assessment of cancer drugs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Aaron E. Sosa Mejia", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Kobenhavn", "City": "Copenhagen ", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Specifics of CHMP assessment of cancer drugs", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Antineoplastic Agents", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Aaron E. Sosa Mejia ", "kol_full_name": "Aaron E. Sosa Mejia " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Uterine Cervical Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454339", "session_name": "Patient perspective – a personal experience of living with cervical cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Abagail Gardiner", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Patient perspective – a personal experience of living with cervical cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Uterine Cervical Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Abagail Gardiner ", "kol_full_name": "Abagail Gardiner " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454808", "session_name": "NSCLC metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Adrianus Johannes De Langen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NSCLC metastatic", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Adrianus Johannes De Langen ", "kol_full_name": "Adrianus Johannes De Langen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454846", "session_name": "Sarcoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Aisha Miah", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sarcoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Sarcoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Aisha Miah ", "kol_full_name": "Aisha Miah " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454492", "session_name": "Cancer nursing interventions: The importance of the role of nursing in successful scalp cooling", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Aisling Burke", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer nursing interventions: The importance of the role of nursing in successful scalp cooling", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Aisling Burke ", "kol_full_name": "Aisling Burke " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454834", "session_name": "Investigational immunotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Akseli Hemminki", "middle_name": null, "last_name": null, "org_name": "", "Country": "Finland", "Region": "Etela-Suomen Laani", "City": "Helsinki", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Investigational immunotherapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Akseli Hemminki ", "kol_full_name": "Akseli Hemminki " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Perioperative Care | Systemic Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454817", "session_name": "POWG 2: Optimal perioperative systemic treatment in different tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alberto J. Cunquero Tomas", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "POWG 2: Optimal perioperative systemic treatment in different tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Perioperative Care | Systemic Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alberto J. Cunquero Tomas ", "kol_full_name": "Alberto J. Cunquero Tomas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Osteopontin | Multikinase Inhibitor | Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454690", "session_name": "Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): underlying molecular mechanisms.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alberto Lens-Pardo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): underlying molecular mechanisms.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Osteopontin | Multikinase Inhibitor ", "rest_events_topic_count": 1, "rest_events_topic": " Neuroendocrine Tumors", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alberto Lens-Pardo ", "kol_full_name": "Alberto Lens-Pardo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antigens, Neoplasm", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454812", "session_name": "Are we targeting the right antigens?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alena Gros", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Are we targeting the right antigens?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Antigens, Neoplasm", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alena Gros ", "kol_full_name": "Alena Gros " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Rectal Neoplasms | DNA Mismatch Repair", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454433", "session_name": "Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alessio Amatu", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoadjuvant Therapy | Rectal Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " DNA Mismatch Repair", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alessio Amatu ", "kol_full_name": "Alessio Amatu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cabozantinib", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454250", "session_name": "Interim analysis of CABONEN – a multicenter phase II trial investigating Cabozantinib in patients with advanced, low proliferative NEN G3", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alexander Otto Koenig", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Niedersachsen", "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Interim analysis of CABONEN – a multicenter phase II trial investigating Cabozantinib in patients with advanced", "rest_events_session_count": 1, "rest_events_session": " low proliferative NEN G3", "events_topic": "Cabozantinib", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alexander Otto Koenig ", "kol_full_name": "Alexander Otto Koenig " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454703", "session_name": "The role of radiotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alexandra Gilbert", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Leeds", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of radiotherapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alexandra Gilbert ", "kol_full_name": "Alexandra Gilbert " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung | Cohort Studies", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454524", "session_name": "Environmental Pollutants and Molecular Alterations in Non-Small Cell Lung Cancer: Insights from the KBP-2020 Cohort Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Alexis B. Cortot", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Nord-Pas-de-Calais", "City": "Lille", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Environmental Pollutants and Molecular Alterations in Non-Small Cell Lung Cancer: Insights from the KBP-2020 Cohort Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung | Cohort Studies", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Alexis B. Cortot ", "kol_full_name": "Alexis B. Cortot " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genetic Therapy | Solid Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454289", "session_name": "Novel gene therapy in advanced solid malignancies: a phase I/II clinical trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Amanda Hahn", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Uppsala Lan", "City": "Uppsala", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Novel gene therapy in advanced solid malignancies: a phase I/II clinical trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Genetic Therapy | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Amanda Hahn ", "kol_full_name": "Amanda Hahn " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Leptomeningeal Disease", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454732", "session_name": "Leptomeningeal disease", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Amanda M. Fitzpatrick", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Leptomeningeal disease", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Leptomeningeal Disease", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Amanda M. Fitzpatrick ", "kol_full_name": "Amanda M. Fitzpatrick " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Social Media Intervention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454234", "session_name": "Social media intervention", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Amil Druzic", "middle_name": null, "last_name": null, "org_name": "", "Country": "Bosnia and Herzegovina", "Region": "Federation of Bosnia and Herzegovina", "City": "Sarajevo", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Social media intervention", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Social Media Intervention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Amil Druzic ", "kol_full_name": "Amil Druzic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Programmed Cell Death 1 Receptor | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454822", "session_name": "Systemic treatment of anti PD-1 resistance in advanced melanoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ana Maria Arance", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Systemic treatment of anti PD-1 resistance in advanced melanoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Programmed Cell Death 1 Receptor | Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ana Maria Arance ", "kol_full_name": "Ana Maria Arance " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Early Detection Of Cancer | Immunoconjugates | Prophylaxis", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454315", "session_name": "Role of cancer nurse in prophylaxis, early detection, and management of ADC related adverse events", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ana Rodriguez-Ortega", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Role of cancer nurse in prophylaxis", "rest_events_session_count": 2, "rest_events_session": " early detection, and management of ADC related adverse events", "events_topic": "Early Detection Of Cancer | Immunoconjugates ", "rest_events_topic_count": 1, "rest_events_topic": " Prophylaxis", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ana Rodriguez-Ortega ", "kol_full_name": "Ana Rodriguez-Ortega " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454865", "session_name": "The future of cancer via patient expertise in research & innovation projects", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "André Deschamps", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Antwerpen", "City": "Antwerp", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The future of cancer via patient expertise in research & innovation projects", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
André Deschamps ", "kol_full_name": "André Deschamps " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radionuclide Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454427", "session_name": "Precision radionuclide therapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Andreas Kjaer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Kobenhavn", "City": "Copenhagen ", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Precision radionuclide therapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radionuclide Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Andreas Kjaer ", "kol_full_name": "Andreas Kjaer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Central Nervous System Lymphoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454685", "session_name": "Primary CNS lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Andres J. Ferreri", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Primary CNS lymphoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Central Nervous System Lymphoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Andres J. Ferreri ", "kol_full_name": "Andres J. Ferreri " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms | Early Detection Of Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454708", "session_name": "AI-Derived Diagnostic Criteria for Early Lung Cancer Screening using Primary Care Health Records", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Andrew D. Houston", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "AI-Derived Diagnostic Criteria for Early Lung Cancer Screening using Primary Care Health Records", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Neoplasms | Early Detection Of Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Andrew D. Houston ", "kol_full_name": "Andrew D. Houston " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Poly(ADP-ribose) Polymerases", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454469", "session_name": "Team science to find and target an “Achilles Heel” through PARP inhibition", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Andrew N. Tutt", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Team science to find and target an “Achilles Heel” through PARP inhibition", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Poly(ADP-ribose) Polymerases", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Andrew N. Tutt ", "kol_full_name": "Andrew N. Tutt " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nivolumab | Cystectomy | Chemoradiotherapy | Non-Muscle Invasive Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454763", "session_name": "Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: a phase II, randomized study by the Hellenic GU Cancer Group.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Andromachi Kougioumtzopoulou", "middle_name": null, "last_name": null, "org_name": "", "Country": "Greece", "Region": "Attiki", "City": "Athens", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC)", "rest_events_session_count": 2, "rest_events_session": " not undergoing cystectomy: a phase II, randomized study by the Hellenic GU Cancer Group.", "events_topic": "Nivolumab | Cystectomy ", "rest_events_topic_count": 2, "rest_events_topic": " Chemoradiotherapy | Non-Muscle Invasive Bladder Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Andromachi Kougioumtzopoulou ", "kol_full_name": "Andromachi Kougioumtzopoulou " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thoracic Neoplasms | Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454326", "session_name": "Integration of Specialized Mobile Palliative Unit Care into Management of Patients with Thoracic Malignancies – A Single Center Experience", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anela Muratovic", "middle_name": null, "last_name": null, "org_name": "", "Country": "Slovenia", "Region": "Nova Gorica", "City": "Gorizia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Integration of Specialized Mobile Palliative Unit Care into Management of Patients with Thoracic Malignancies – A Single Center Experience", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Thoracic Neoplasms | Palliative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anela Muratovic ", "kol_full_name": "Anela Muratovic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Translational Research, Biomedical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454831", "session_name": "Basic science & Translational research", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Angela George", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Sutton", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Basic science & Translational research", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Translational Research, Biomedical", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Angela George ", "kol_full_name": "Angela George " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Testicular Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454627", "session_name": "Controversies in testis cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Angelika Terbuch", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Steiermark", "City": "Graz", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Controversies in testis cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Testicular Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Angelika Terbuch ", "kol_full_name": "Angelika Terbuch " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454319", "session_name": "NURTURE and prevention in cancer nursing", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Angelos Kassianos", "middle_name": null, "last_name": null, "org_name": "", "Country": "Greece", "Region": "Attiki", "City": "Athens", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NURTURE and prevention in cancer nursing", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Angelos Kassianos ", "kol_full_name": "Angelos Kassianos " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Artificial Intelligence", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454458", "session_name": "AI: Isn't a solution to all?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anita Grigoriadis", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "AI: Isn't a solution to all?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Artificial Intelligence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anita Grigoriadis ", "kol_full_name": "Anita Grigoriadis " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Technology Assessment Bodies", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454357", "session_name": "Challenges for national HTA bodies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anja Schiel", "middle_name": null, "last_name": null, "org_name": "", "Country": "Norway", "Region": "Oslo", "City": "Oslo", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Challenges for national HTA bodies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Health Technology Assessment Bodies", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anja Schiel ", "kol_full_name": "Anja Schiel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immune Checkpoint Inhibitors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454543", "session_name": "Predisposition, clinical characteristics and management of immune checkpoint inhibitor-induced nephritis: a series of 190 cases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anna C. Olsson-Brown", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Brighton", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Predisposition", "rest_events_session_count": 1, "rest_events_session": " clinical characteristics and management of immune checkpoint inhibitor-induced nephritis: a series of 190 cases", "events_topic": "Immune Checkpoint Inhibitors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anna C. Olsson-Brown ", "kol_full_name": "Anna C. Olsson-Brown " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454856", "session_name": "9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anna Reyners", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Groningen", "City": "Groningen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Palliative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anna Reyners ", "kol_full_name": "Anna Reyners " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neurologic Manifestations | Cognitive Remediation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454731", "session_name": "Neuro-cognitive remediation in case of permanent neurological deficits", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anne Rogiers", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brabant Wallon", "City": "Jodoigne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neuro-cognitive remediation in case of permanent neurological deficits", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neurologic Manifestations | Cognitive Remediation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anne Rogiers ", "kol_full_name": "Anne Rogiers " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454815", "session_name": "Achieving successful scalp cooling – the importance of nursing in chemotherapy side effect management", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Annie Young", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Coventry", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Achieving successful scalp cooling – the importance of nursing in chemotherapy side effect management", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Drug Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Annie Young ", "kol_full_name": "Annie Young " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Diseases, Interstitial | Trastuzumab Deruxtecan | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454636", "session_name": "Trastuzumab Deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Anthony Canellas", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Trastuzumab Deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Diseases, Interstitial | Trastuzumab Deruxtecan ", "rest_events_topic_count": 1, "rest_events_topic": " Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Anthony Canellas ", "kol_full_name": "Anthony Canellas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Policy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454515", "session_name": "Policy and advocacy at the European and member state level: A collaborative approach", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Antonella Cardone", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Policy and advocacy at the European and member state level: A collaborative approach", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Health Policy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Antonella Cardone ", "kol_full_name": "Antonella Cardone " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Inflammation | Fatigue | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454542", "session_name": "Systemic inflammation, unhealthy behaviors, and cancer-related fatigue (CRF) among survivors of breast cancer (BC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Antonio Di Meglio", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Systemic inflammation", "rest_events_session_count": 2, "rest_events_session": " unhealthy behaviors, and cancer-related fatigue (CRF) among survivors of breast cancer (BC)", "events_topic": "Inflammation | Fatigue ", "rest_events_topic_count": 1, "rest_events_topic": " Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Antonio Di Meglio ", "kol_full_name": "Antonio Di Meglio " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Amivantamab | Zipalertinib | ErbB Receptors | Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454405", "session_name": "Safety and Antitumor Activity of Zipalertinib in NSCLC Patients (pts) with EGFR Exon 20 Insertion (ex20ins) Mutations Who Received Prior Amivantamab", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Antonio Passaro", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Safety and Antitumor Activity of Zipalertinib in NSCLC Patients (pts) with EGFR Exon 20 Insertion (ex20ins) Mutations Who Received Prior Amivantamab", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Amivantamab | Zipalertinib ", "rest_events_topic_count": 2, "rest_events_topic": " ErbB Receptors | Carcinoma, Non-Small-Cell Lung", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Antonio Passaro ", "kol_full_name": "Antonio Passaro " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Real World Evidence", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454694", "session_name": "How to overcome biases to build Real World Evidence", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Antonis Valachis", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Orebro Lan", "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How to overcome biases to build Real World Evidence", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Real World Evidence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Antonis Valachis ", "kol_full_name": "Antonis Valachis " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454869", "session_name": "GU tumours, non-prostate", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Aristotelis Bamias", "middle_name": null, "last_name": null, "org_name": "", "Country": "Greece", "Region": "Attiki", "City": "Athens", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GU tumours", "rest_events_session_count": 1, "rest_events_session": " non-prostate", "events_topic": "Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Aristotelis Bamias ", "kol_full_name": "Aristotelis Bamias " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cohort Studies", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454692", "session_name": "Predicting major outcomes from large cohorts: How is it actionable?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ash Kieran Clift", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Oxford", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Predicting major outcomes from large cohorts: How is it actionable?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cohort Studies", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ash Kieran Clift ", "kol_full_name": "Ash Kieran Clift " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pheochromocytoma | Paraganglioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454725", "session_name": "Functioning paraganglioma and pheochromocytoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ashley Grossman", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Oxford", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Functioning paraganglioma and pheochromocytoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pheochromocytoma | Paraganglioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ashley Grossman ", "kol_full_name": "Ashley Grossman " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Solid Tumours | Immune Checkpoint Inhibitors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454521", "session_name": "Cost and value of EMA-registered checkpoint inhibitors for solid tumours in the Netherlands", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Atse H. Huisman", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Utrecht", "City": "Zeist", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cost and value of EMA-registered checkpoint inhibitors for solid tumours in the Netherlands", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Solid Tumours | Immune Checkpoint Inhibitors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Atse H. Huisman ", "kol_full_name": "Atse H. Huisman " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "In Vitro Techniques", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454673", "session_name": "Current status and implications of the In Vitro Diagnostics regulation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Audrey Wolf", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Current status and implications of the In Vitro Diagnostics regulation", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "In Vitro Techniques", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Audrey Wolf ", "kol_full_name": "Audrey Wolf " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urologists", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454683", "session_name": "Urologist perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Axel S. Merseburger", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Schleswig-Holstein", "City": "Lubeck", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Urologist perspective", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Urologists", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Axel S. Merseburger ", "kol_full_name": "Axel S. Merseburger " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Technology-Based Intervention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454657", "session_name": "Innovative Paths: A Qualitative Exploration of Nurses' Views on Technology-Based Interventions in Pediatric Oncology Care", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ayse Ay", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Ankara", "City": "Ankara", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Innovative Paths: A Qualitative Exploration of Nurses' Views on Technology-Based Interventions in Pediatric Oncology Care", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Technology-Based Intervention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ayse Ay ", "kol_full_name": "Ayse Ay " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Hematopoietic Stem Cell Transplantation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454663", "session_name": "Review of Nursing Interventions for the Management of Psychosocial Problems in Adults After Hematopoietic Stem Cell Transplantation: A Systematic Review", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Aysenur Cetin Uceriz", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Istanbul", "City": "Istanbul", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Review of Nursing Interventions for the Management of Psychosocial Problems in Adults After Hematopoietic Stem Cell Transplantation: A Systematic Review", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Hematopoietic Stem Cell Transplantation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Aysenur Cetin Uceriz ", "kol_full_name": "Aysenur Cetin Uceriz " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454493", "session_name": "The patient perspective: The power of scalp cooling", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Begoña Parrado", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Huddersfield", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The patient perspective: The power of scalp cooling", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Patient Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Begoña Parrado ", "kol_full_name": "Begoña Parrado " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Standard Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454465", "session_name": "Building on standard therapies: Novel agents and promising combinations", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Begona Perez Valderrama", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Andalucia", "City": "Sevilla ", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Building on standard therapies: Novel agents and promising combinations", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Standard Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Begona Perez Valderrama ", "kol_full_name": "Begona Perez Valderrama " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Perioperative Care | Systemic Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454866", "session_name": "POWG 2: Optimal perioperative systemic treatment in different tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Benedetta Pellegrino", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Emilia-Romagna", "City": "Parma", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "POWG 2: Optimal perioperative systemic treatment in different tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Perioperative Care | Systemic Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Benedetta Pellegrino ", "kol_full_name": "Benedetta Pellegrino " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immune Checkpoint Inhibitors | DNA Mismatch Repair | Microsatellite Repeats | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454523", "session_name": "Value of Immune Checkpoint Blockade (ICB) in Microsatellite Stable/Mismatch Repair Proficient (MSS/pMMR) Metastatic Colorectal Cancer (mCRC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Benjamin P. Geisler", "middle_name": null, "last_name": null, "org_name": "", "Country": "Norway", "Region": "Oslo", "City": "Oslo", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Value of Immune Checkpoint Blockade (ICB) in Microsatellite Stable/Mismatch Repair Proficient (MSS/pMMR) Metastatic Colorectal Cancer (mCRC)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immune Checkpoint Inhibitors | DNA Mismatch Repair ", "rest_events_topic_count": 2, "rest_events_topic": " Microsatellite Repeats | Colorectal Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Benjamin P. Geisler ", "kol_full_name": "Benjamin P. Geisler " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Soft Tissue Sarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454719", "session_name": "Multisarc: A randomized precision medicine study in advanced soft-tissue sarcomas.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Benjamin Verret", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Multisarc: A randomized precision medicine study in advanced soft-tissue sarcomas.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Soft Tissue Sarcoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Benjamin Verret ", "kol_full_name": "Benjamin Verret " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immune Checkpoint Inhibitors | Neoadjuvant Therapy | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454485", "session_name": "Toxicities in Breast Cancer Patients Undergoing Neoadjuvant Immune Checkpoint Inhibitor Therapy: Insights from a Nurse Practitioner Perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Benjamin Walbaum", "middle_name": null, "last_name": null, "org_name": "", "Country": "Chile", "Region": "Region Metropolitana", "City": "Santiago", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Toxicities in Breast Cancer Patients Undergoing Neoadjuvant Immune Checkpoint Inhibitor Therapy: Insights from a Nurse Practitioner Perspective", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immune Checkpoint Inhibitors | Neoadjuvant Therapy ", "rest_events_topic_count": 1, "rest_events_topic": " Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Benjamin Walbaum ", "kol_full_name": "Benjamin Walbaum " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Prevention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454364", "session_name": "Partnering with ESMO on game-changing tools to improve cancer prevention and control worldwide", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bente Mikkelsen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Geneve", "City": "Geneva", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Partnering with ESMO on game-changing tools to improve cancer prevention and control worldwide", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bente Mikkelsen ", "kol_full_name": "Bente Mikkelsen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urinary Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454640", "session_name": "Nursing management of late and long-term effects of bladder cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bente Thoft Jensen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Arhus", "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nursing management of late and long-term effects of bladder cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Urinary Bladder Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bente Thoft Jensen ", "kol_full_name": "Bente Thoft Jensen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sarcoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454832", "session_name": "Sarcoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bernd Kasper", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Mannheim", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sarcoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Sarcoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bernd Kasper ", "kol_full_name": "Bernd Kasper " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Real World Evidence", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454526", "session_name": "Real world experience & patients' participation in multidisciplinary consortiums", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bettina Ryll", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Uppsala Lan", "City": "Uppsala", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Real world experience & patients' participation in multidisciplinary consortiums", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Real World Evidence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bettina Ryll ", "kol_full_name": "Bettina Ryll " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Hepatocellular | Locoregional Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454760", "session_name": "How are locoregional therapies evolving in HCC?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Bruno Sangro", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Navarra", "City": "Pamplona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How are locoregional therapies evolving in HCC?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Hepatocellular | Locoregional Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Bruno Sangro ", "kol_full_name": "Bruno Sangro " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454228", "session_name": "Socioeconomic disparities in delivery of specialized palliative care at the end of life", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Camilla Zimmermann", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Socioeconomic disparities in delivery of specialized palliative care at the end of life", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Palliative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Camilla Zimmermann ", "kol_full_name": "Camilla Zimmermann " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454824", "session_name": "GU tumours, non-prostate", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Camillo Guglielmo Porta", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Puglia", "City": "Bari", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GU tumours", "rest_events_session_count": 1, "rest_events_session": " non-prostate", "events_topic": "Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Camillo Guglielmo Porta ", "kol_full_name": "Camillo Guglielmo Porta " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Renal Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454599", "session_name": "Renal-cell carcinoma: Case presentation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Carlo Messina", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Sicilia", "City": "Palermo", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Renal-cell carcinoma: Case presentation", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Renal Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Carlo Messina ", "kol_full_name": "Carlo Messina " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454689", "session_name": "Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models. Unveiling novel neuroendocrine subtypes and their clinical implications.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Carlos Carretero-Puche", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models. Unveiling novel neuroendocrine subtypes and their clinical implications.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Carlos Carretero-Puche ", "kol_full_name": "Carlos Carretero-Puche " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454839", "session_name": "Breast cancer, metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Carmen Criscitiello", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 1, "rest_events_session": " metastatic", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Carmen Criscitiello ", "kol_full_name": "Carmen Criscitiello " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiotherapy | Cytotoxicity | Antineoplastic Agents", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454688", "session_name": "The mechanisms of action and principles of synergistic cancer cytotoxicity of electric fields with antineoplastic agents and irradiation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Carsten Hagemann", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Bayern", "City": "WURZBURG", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The mechanisms of action and principles of synergistic cancer cytotoxicity of electric fields with antineoplastic agents and irradiation", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiotherapy | Cytotoxicity ", "rest_events_topic_count": 1, "rest_events_topic": " Antineoplastic Agents", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Carsten Hagemann ", "kol_full_name": "Carsten Hagemann " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endometrial Neoplasms | Cross-Sectional Studies", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454516", "session_name": "Quality of Endometrial Cancer Care from the Patients’ perspective – A Cross-Sectional Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cecilia Olsson", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Varmlands Lan", "City": "Karlstad", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Quality of Endometrial Cancer Care from the Patients’ perspective – A Cross-Sectional Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Endometrial Neoplasms | Cross-Sectional Studies", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cecilia Olsson ", "kol_full_name": "Cecilia Olsson " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Prostatic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454769", "session_name": "Phenotypic and genomic characterization of de novo metastatic prostate cancer: an ancillary study of the PEACE-1 phase 3 trial.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cedric Pobel", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phenotypic and genomic characterization of de novo metastatic prostate cancer: an ancillary study of the PEACE-1 phase 3 trial.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Prostatic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cedric Pobel ", "kol_full_name": "Cedric Pobel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454334", "session_name": "Genomic data management in precision oncology nursing", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Celia Díez De Los Ríos De La Serna", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "Scotland", "City": "Glasgow", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Genomic data management in precision oncology nursing", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Celia Díez De Los Ríos De La Serna ", "kol_full_name": "Celia Díez De Los Ríos De La Serna " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cell-Free Nucleic Acids", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454707", "session_name": "Cell-free DNA indicates potential preclinical detectability of cancer signals up to 30 months prior to diagnosis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Celine M. Vachon", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Minnesota", "City": "Rochester", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cell-free DNA indicates potential preclinical detectability of cancer signals up to 30 months prior to diagnosis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cell-Free Nucleic Acids", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Celine M. Vachon ", "kol_full_name": "Celine M. Vachon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nasopharyngeal Carcinoma | Chemoradiotherapy | Induction Chemotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454566", "session_name": "Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Chaosu Hu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre", "rest_events_session_count": 4, "rest_events_session": " open-label, non-inferiority, randomised, phase 3 trial", "events_topic": "Nasopharyngeal Carcinoma | Chemoradiotherapy ", "rest_events_topic_count": 1, "rest_events_topic": " Induction Chemotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Chaosu Hu ", "kol_full_name": "Chaosu Hu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Treatment Sequelae", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454729", "session_name": "Managing long-term treatment sequelae", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Charlée Nardin", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Franche-Comte", "City": "Besancon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Managing long-term treatment sequelae", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Treatment Sequelae", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Charlée Nardin ", "kol_full_name": "Charlée Nardin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Early Detection Of Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454231", "session_name": "Pan-cancer screening tests: Blood and beyond", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Charles Swanton", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pan-cancer screening tests: Blood and beyond", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Early Detection Of Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Charles Swanton ", "kol_full_name": "Charles Swanton " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms | Solid Tumors | Immunoconjugates", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454635", "session_name": "IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): results from a phase I study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Charlotte Lemech", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "New South Wales", "City": "Sydney", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): results from a phase I study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms | Solid Tumors ", "rest_events_topic_count": 1, "rest_events_topic": " Immunoconjugates", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Charlotte Lemech ", "kol_full_name": "Charlotte Lemech " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454556", "session_name": "Molecular Biology Study of Primary Immuno-privileged Lymphomas", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Chen Zhang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Beijing", "City": "Beijing", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Molecular Biology Study of Primary Immuno-privileged Lymphomas", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lymphoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Chen Zhang ", "kol_full_name": "Chen Zhang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454249", "session_name": "CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Chia Jui Yen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Taiwan", "Region": "Kao-hsiung", "City": "Tainan", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CVM-005: Phase IIa study of CVM-1118", "rest_events_session_count": 2, "rest_events_session": " a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy", "events_topic": "Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Chia Jui Yen ", "kol_full_name": "Chia Jui Yen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Pembrolizumab | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454622", "session_name": "IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christelle De La Fouchardiere", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Provence-Alpes-Cote d'Azur", "City": "Marseille", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoadjuvant Therapy | Pembrolizumab ", "rest_events_topic_count": 1, "rest_events_topic": " Colorectal Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christelle De La Fouchardiere ", "kol_full_name": "Christelle De La Fouchardiere " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Papillomavirus Vaccines | Carcinoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454738", "session_name": "HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christian H. Ottensmeier", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Liverpool", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Papillomavirus Vaccines | Carcinoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christian H. Ottensmeier ", "kol_full_name": "Christian H. Ottensmeier " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genetic Risk Score | Immune Checkpoint Inhibitors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454766", "session_name": "Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christian W. Thorball", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Genetic Risk Score | Immune Checkpoint Inhibitors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christian W. Thorball ", "kol_full_name": "Christian W. Thorball " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454424", "session_name": "The molecular landscape of neuroendocrine neoplasms", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christina Thirlwell", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Bristol", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The molecular landscape of neuroendocrine neoplasms", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christina Thirlwell ", "kol_full_name": "Christina Thirlwell " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454693", "session_name": "How much do real world patients really differ from clinical trials?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christina Yap", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Sutton", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How much do real world patients really differ from clinical trials?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Trial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christina Yap ", "kol_full_name": "Christina Yap " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Personalised Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454495", "session_name": "Personalizing care delivery options for people with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christine A. Ghione Mastry", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Islas Baleares", "City": "Valldemosa", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Personalizing care delivery options for people with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Personalised Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christine A. Ghione Mastry ", "kol_full_name": "Christine A. Ghione Mastry " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Policy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454828", "session_name": "Policy and preventive strategies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christine Chomienne", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Policy and preventive strategies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Health Policy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christine Chomienne ", "kol_full_name": "Christine Chomienne " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Early Detection Of Cancer | Hematologic Tests", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454706", "session_name": "Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christopher Douville", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Maryland", "City": "Baltimore", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Organ-specific performance of a multi-analyte", "rest_events_session_count": 1, "rest_events_session": " multi-cancer early detection (MCED) blood test in a prospectively-collected cohort", "events_topic": "Early Detection Of Cancer | Hematologic Tests", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christopher Douville ", "kol_full_name": "Christopher Douville " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tyrosine Kinase Inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454555", "session_name": "Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christopher Hackenbruch", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Tubingen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Tyrosine Kinase Inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christopher Hackenbruch ", "kol_full_name": "Christopher Hackenbruch " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454877", "session_name": "New technology, new ideas: What is on the horizon for colorectal cancer?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christopher J. Williams", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Leeds", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New technology", "rest_events_session_count": 1, "rest_events_session": " new ideas: What is on the horizon for colorectal cancer?", "events_topic": "Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christopher J. Williams ", "kol_full_name": "Christopher J. Williams " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454880", "session_name": "GU tumours, prostate", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Christopher Sweeney", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "South Australia", "City": "Adelaide", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GU tumours", "rest_events_session_count": 1, "rest_events_session": " prostate", "events_topic": "Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Christopher Sweeney ", "kol_full_name": "Christopher Sweeney " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Venous Thrombosis | Catheters", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454396", "session_name": "Prevention and management of catheter-associated venous thrombosis in adults with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cihan Ay", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Wien", "City": "Vienna", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Prevention and management of catheter-associated venous thrombosis in adults with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Venous Thrombosis | Catheters", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cihan Ay ", "kol_full_name": "Cihan Ay " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Gastrointestinal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454811", "session_name": "GI tumours, lower", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Claire Gallois", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 1, "rest_events_session": " lower", "events_topic": "Gastrointestinal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Claire Gallois ", "kol_full_name": "Claire Gallois " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "G12C Mutations", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454310", "session_name": "Non-G12C mutations: Future perspectives", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Colin Lindsay", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Manchester", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Non-G12C mutations: Future perspectives", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "G12C Mutations", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Colin Lindsay ", "kol_full_name": "Colin Lindsay " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Research", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454491", "session_name": "Clinical research and data on scalp cooling: Retention and regrowth", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Corina Van Den Hurk", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Utrecht", "City": "Utrecht", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Clinical research and data on scalp cooling: Retention and regrowth", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Research", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Corina Van Den Hurk ", "kol_full_name": "Corina Van Den Hurk " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Sexual Health", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454283", "session_name": "Addressing sexual health in female and male patients with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cristiane D. Bergerot", "middle_name": null, "last_name": null, "org_name": "", "Country": "Brazil", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Addressing sexual health in female and male patients with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms | Sexual Health", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cristiane D. Bergerot ", "kol_full_name": "Cristiane D. Bergerot " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Survivors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454659", "session_name": "Optimizing cancer survivorship care plans: Empowering long-term survivors and families beyond treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cristina García-Vivar", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Navarra", "City": "Pamplona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Optimizing cancer survivorship care plans: Empowering long-term survivors and families beyond treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Survivors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cristina García-Vivar ", "kol_full_name": "Cristina García-Vivar " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Fertility Preservation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454484", "session_name": "Nurses’comunication barriers about fertility preservation: an integrative review", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cristina Mazzega Fabbro", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Campania", "City": "Avellino", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nurses’comunication barriers about fertility preservation: an integrative review", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Fertility Preservation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cristina Mazzega Fabbro ", "kol_full_name": "Cristina Mazzega Fabbro " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Multiple Antigens", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454438", "session_name": "Should we target single or multiple antigens?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cristina Puig-Saus", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "California", "City": "Los Angeles", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Should we target single or multiple antigens?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Multiple Antigens", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cristina Puig-Saus ", "kol_full_name": "Cristina Puig-Saus " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cetuximab | Circulating Tumor DNA | Irinotecan | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454434", "session_name": "Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cristina Santos Vivas", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cetuximab | Circulating Tumor DNA ", "rest_events_topic_count": 2, "rest_events_topic": " Irinotecan | Colorectal Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cristina Santos Vivas ", "kol_full_name": "Cristina Santos Vivas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Renal Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454835", "session_name": "Updates in the management of advanced renal cell carcinoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Cristina Suarez Rodriguez", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Updates in the management of advanced renal cell carcinoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Renal Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Cristina Suarez Rodriguez ", "kol_full_name": "Cristina Suarez Rodriguez " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Prostatic Neoplasms | Urinary Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454638", "session_name": "Where do we stand in biomarker for prostate- & bladder cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daan Demaeseneer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Oost-Vlaanderen", "City": "Gent", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Where do we stand in biomarker for prostate- & bladder cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Prostatic Neoplasms | Urinary Bladder Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daan Demaeseneer ", "kol_full_name": "Daan Demaeseneer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Ovarian Neoplasms | Sacituzumab Tirumotecan | Endometrial Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454573", "session_name": "Safety and Efficacy of Sacituzumab Tirumotecan (sac-TMT) in Patients (pts) with Previously Treated Advanced Endometrial Carcinoma (EC) and Ovarian Cancer (OC) from a Phase 2 Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Danbo Wang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Liaoning", "City": "Shenyang", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Safety and Efficacy of Sacituzumab Tirumotecan (sac-TMT) in Patients (pts) with Previously Treated Advanced Endometrial Carcinoma (EC) and Ovarian Cancer (OC) from a Phase 2 Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Ovarian Neoplasms | Sacituzumab Tirumotecan ", "rest_events_topic_count": 1, "rest_events_topic": " Endometrial Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Danbo Wang ", "kol_full_name": "Danbo Wang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454354", "session_name": "Designing, running and funding deescalation clinical trials", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daniel Goldstein", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "HaMerkaz (Central)", "City": "Petach Tikva", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Designing", "rest_events_session_count": 1, "rest_events_session": " running and funding deescalation clinical trials", "events_topic": "Clinical Trial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daniel Goldstein ", "kol_full_name": "Daniel Goldstein " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Uterine Cervical Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454340", "session_name": "What have we learned from 10 years’ progress in the prevention, diagnosis and treatment of cervical cancers and where do policy makers and health systems go next?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daniel Kelly", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "Wales", "City": "Cardiff", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What have we learned from 10 years’ progress in the prevention", "rest_events_session_count": 1, "rest_events_session": " diagnosis and treatment of cervical cancers and where do policy makers and health systems go next?", "events_topic": "Uterine Cervical Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daniel Kelly ", "kol_full_name": "Daniel Kelly " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antineoplastic Agents", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454522", "session_name": "Indication-specific pricing and weighted-average pricing: Estimated price and cost savings for cancer drugs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daniel T. Michaeli", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Indication-specific pricing and weighted-average pricing: Estimated price and cost savings for cancer drugs", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Antineoplastic Agents", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daniel T. Michaeli ", "kol_full_name": "Daniel T. Michaeli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Prostate Specific Membrane Antigen | Positron-Emission Tomography", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454398", "session_name": "PSMA PET as a game changer for decision making?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daniela E. Oprea-Lager", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "PSMA PET as a game changer for decision making?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Prostate Specific Membrane Antigen | Positron-Emission Tomography", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daniela E. Oprea-Lager ", "kol_full_name": "Daniela E. Oprea-Lager " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Translational Research, Biomedical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454853", "session_name": "Basic science & Translational research", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daniela S. Thommen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Basic science & Translational research", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Translational Research, Biomedical", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daniela S. Thommen ", "kol_full_name": "Daniela S. Thommen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454332", "session_name": "Transforming Cancer Care: \u000bThe Impact of Cancer@Home Initiatives: Phase 1", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Daniella Chiappetta", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "Victoria", "City": "Melbourne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Transforming Cancer Care: \u000bThe Impact of Cancer@Home Initiatives: Phase 1", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Daniella Chiappetta ", "kol_full_name": "Daniella Chiappetta " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454479", "session_name": "Managing ADC-related adverse events: How nurses contribute to improving patient outcomes", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Danijela Dohnal-Suvajac", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Niederosterreich", "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Managing ADC-related adverse events: How nurses contribute to improving patient outcomes", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunoconjugates", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Danijela Dohnal-Suvajac ", "kol_full_name": "Danijela Dohnal-Suvajac " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Triple Negative Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454308", "session_name": "How to treat stage I TNBC?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "David Cescon", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How to treat stage I TNBC?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Triple Negative Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
David Cescon ", "kol_full_name": "David Cescon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Adolescent And Young Adult Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454691", "session_name": "Delivering precision oncology to AYA patients with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "David M. Thomas", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "New South Wales", "City": "Sydney", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Delivering precision oncology to AYA patients with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Adolescent And Young Adult Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
David M. Thomas ", "kol_full_name": "David M. Thomas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pembrolizumab | Microsatellite Repeats | Colorectal Neoplasms | Bevacizumab", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454620", "session_name": "Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "David Tougeron", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Poitou-Charentes", "City": "Poitiers", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pembrolizumab | Microsatellite Repeats ", "rest_events_topic_count": 2, "rest_events_topic": " Colorectal Neoplasms | Bevacizumab", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
David Tougeron ", "kol_full_name": "David Tougeron " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Targeted Therapy | Pancreatic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454472", "session_name": "Novel targeted therapies for pancreatic cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Davide Melisi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Veneto", "City": "Verona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Novel targeted therapies for pancreatic cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Molecular Targeted Therapy | Pancreatic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Davide Melisi ", "kol_full_name": "Davide Melisi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Systemic Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454464", "session_name": "How to manage patients with durable response on systemic therapy? Optimal therapy duration and role de-escalation?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Debbie Robbrecht", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Rotterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How to manage patients with durable response on systemic therapy? Optimal therapy duration and role de-escalation?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Systemic Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Debbie Robbrecht ", "kol_full_name": "Debbie Robbrecht " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454862", "session_name": "Can pragmatic clinical trials and optimisation of treatments support development, access and value?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Denis A. Lacombe", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Can pragmatic clinical trials and optimisation of treatments support development", "rest_events_session_count": 1, "rest_events_session": " access and value?", "events_topic": "Clinical Trial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Denis A. Lacombe ", "kol_full_name": "Denis A. Lacombe " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Ovarian Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454575", "session_name": "SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase 1 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dihong Tang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Hunan", "City": "Changsha", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase 1 study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Ovarian Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dihong Tang ", "kol_full_name": "Dihong Tang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454317", "session_name": "Building up resilience in cancer nursing: Strategies and skills", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dimitrios Protogiros", "middle_name": null, "last_name": null, "org_name": "", "Country": "Greece", "Region": "Attiki", "City": "Athens", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Building up resilience in cancer nursing: Strategies and skills", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dimitrios Protogiros ", "kol_full_name": "Dimitrios Protogiros " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Chemoradiotherapy | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454728", "session_name": "The role of immunotherapy plus concurrent chemoradiation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dina Najjari Jamal", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of immunotherapy plus concurrent chemoradiation", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Chemoradiotherapy | Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dina Najjari Jamal ", "kol_full_name": "Dina Najjari Jamal " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "ErbB Receptors | Immunoconjugates | Carcinoma, Transitional Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454279", "session_name": "BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dingwei Ye", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "BL-B01D1", "rest_events_session_count": 2, "rest_events_session": " an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC)", "events_topic": "ErbB Receptors | Immunoconjugates ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Transitional Cell", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dingwei Ye ", "kol_full_name": "Dingwei Ye " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Colorectal Neoplasms | Optimal Sequencing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454305", "session_name": "Optimal sequencing of therapeutic strategies in molecularly-driven CRC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dominik P. Modest", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Berlin", "City": "Berlin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Optimal sequencing of therapeutic strategies in molecularly-driven CRC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Colorectal Neoplasms | Optimal Sequencing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dominik P. Modest ", "kol_full_name": "Dominik P. Modest " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Telemedicine | Biomedical Technology", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454483", "session_name": "Remote patient monitoring using mHealth technology in cancer care and research: patients’ perspectives, willingness, and current use", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dominique Stuijt", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Leiden", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Remote patient monitoring using mHealth technology in cancer care and research: patients’ perspectives", "rest_events_session_count": 2, "rest_events_session": " willingness, and current use", "events_topic": "Telemedicine | Biomedical Technology", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dominique Stuijt ", "kol_full_name": "Dominique Stuijt " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pharmacovigilance | Immunoconjugates", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454314", "session_name": "Pharmacovigilance in management of ADC related AEs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Dorieke Van Balen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pharmacovigilance in management of ADC related AEs", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pharmacovigilance | Immunoconjugates", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Dorieke Van Balen ", "kol_full_name": "Dorieke Van Balen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Neoadjuvant Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454611", "session_name": "Rationale for neoadjuvant treatment of localised cancer: Biological insights", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Drew Pardoll", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Maryland", "City": "Baltimore", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Rationale for neoadjuvant treatment of localised cancer: Biological insights", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms | Neoadjuvant Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Drew Pardoll ", "kol_full_name": "Drew Pardoll " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Diagnostic Imaging", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454265", "session_name": "Innovative imaging techniques to evaluate response", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "E.G. Elisabeth De Vries", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Groningen", "City": "Groningen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Innovative imaging techniques to evaluate response", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Diagnostic Imaging", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
E.G. Elisabeth De Vries ", "kol_full_name": "E.G. Elisabeth De Vries " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Competence", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454329", "session_name": "Assessing oncology nurse practitioner students' clinical competency and capability", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eileen Furlong", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Assessing oncology nurse practitioner students' clinical competency and capability", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Competence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eileen Furlong ", "kol_full_name": "Eileen Furlong " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Malnutrition", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454345", "session_name": "Nurses management of malnutrition risk in cancer patients: the importance of screening tools", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eleonora Favot", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Campania", "City": "Avellino", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nurses management of malnutrition risk in cancer patients: the importance of screening tools", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Malnutrition", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eleonora Favot ", "kol_full_name": "Eleonora Favot " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Toxicity", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454677", "session_name": "What about long-term toxicities?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eleonora Ghisoni", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What about long-term toxicities?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Toxicity", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eleonora Ghisoni ", "kol_full_name": "Eleonora Ghisoni " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "ErbB Receptors | Nursing Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454647", "session_name": "Nursing care of patients with EGFR targeted agents: challenging side-effects", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elin Nildén", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Skane Lan", "City": "Helsingborg", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nursing care of patients with EGFR targeted agents: challenging side-effects", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "ErbB Receptors | Nursing Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elin Nildén ", "kol_full_name": "Elin Nildén " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Quality Of Life", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454507", "session_name": "Quality of life and symptoms in cancer patients more than 80 years of age", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elisabeth Beisland", "middle_name": null, "last_name": null, "org_name": "", "Country": "Norway", "Region": "Hordaland", "City": "Bergen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Quality of life and symptoms in cancer patients more than 80 years of age", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms | Quality Of Life", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elisabeth Beisland ", "kol_full_name": "Elisabeth Beisland " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endocrine Therapy | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454474", "session_name": "Explaining the Relationships between Age, Endocrine Therapy Persistence and Risk of Recurrence in Hormone-Positive Early Breast Cancer: A Nationwide Cohort Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Elise Dumas", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Explaining the Relationships between Age", "rest_events_session_count": 1, "rest_events_session": " Endocrine Therapy Persistence and Risk of Recurrence in Hormone-Positive Early Breast Cancer: A Nationwide Cohort Study", "events_topic": "Endocrine Therapy | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Elise Dumas ", "kol_full_name": "Elise Dumas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Androgen Deprivation Therapy | Docetaxel | Prostatic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454770", "session_name": "Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): an ancillary study of the STAMPEDE docetaxel trials", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Emily Grist", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): an ancillary study of the STAMPEDE docetaxel trials", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Androgen Deprivation Therapy | Docetaxel ", "rest_events_topic_count": 1, "rest_events_topic": " Prostatic Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Emily Grist ", "kol_full_name": "Emily Grist " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tisagenlecleucel | Immunotherapy, Adoptive | Lymphoma, Follicular", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454242", "session_name": "Real-world efficacy and safety of Tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the Early Access Program through the French DESCAR-T registry", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Emmanuel Bachy", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Picardie", "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Real-world efficacy and safety of Tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the Early Access Program through the French DESCAR-T registry", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Tisagenlecleucel | Immunotherapy, Adoptive ", "rest_events_topic_count": 1, "rest_events_topic": " Lymphoma, Follicular", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Emmanuel Bachy ", "kol_full_name": "Emmanuel Bachy " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Precision Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454849", "session_name": "Integrating precision medicine / ESCAT in your choice of treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Emre Kocakavuk", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Nordrhein-Westfalen", "City": "Essen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Integrating precision medicine / ESCAT in your choice of treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Precision Medicine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Emre Kocakavuk ", "kol_full_name": "Emre Kocakavuk " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thymus Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454460", "session_name": "The role of surgery in the treatment of thymic tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Enrico Ruffini", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Piemonte", "City": "Torino", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of surgery in the treatment of thymic tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Thymus Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Enrico Ruffini ", "kol_full_name": "Enrico Ruffini " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Circulating Tumor DNA | Colonic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454414", "session_name": "Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Enzo Medico", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Emilia-Romagna", "City": "Scandiano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Circulating Tumor DNA | Colonic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Enzo Medico ", "kol_full_name": "Enzo Medico " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oxaliplatin | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454431", "session_name": "Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eric Assenat", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Languedoc-Roussillon", "City": "Montpellier", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oxaliplatin | Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eric Assenat ", "kol_full_name": "Eric Assenat " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thoracic Surgery | Mesothelioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454446", "session_name": "Thoracic surgery for mesothelioma: The old and the new", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eric Lim", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Thoracic surgery for mesothelioma: The old and the new", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Thoracic Surgery | Mesothelioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eric Lim ", "kol_full_name": "Eric Lim " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tumor Microenvironment", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454440", "session_name": "Tumour or microenvironment target?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Erik Sahai", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Tumour or microenvironment target?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Tumor Microenvironment", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Erik Sahai ", "kol_full_name": "Erik Sahai " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Azeliragon | Temozolomide | Radiotherapy | Glioblastoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454591", "session_name": "Early Experience with Azeliragon, a RAGE inhibitor, in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib/II CAN-201 NDG Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Estela Pineda", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Early Experience with Azeliragon", "rest_events_session_count": 2, "rest_events_session": " a RAGE inhibitor, in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib/II CAN-201 NDG Trial", "events_topic": "Azeliragon | Temozolomide ", "rest_events_topic_count": 2, "rest_events_topic": " Radiotherapy | Glioblastoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Estela Pineda ", "kol_full_name": "Estela Pineda " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Head And Neck Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454814", "session_name": "Head and neck cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ester Orlandi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Pavia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Head and neck cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ester Orlandi ", "kol_full_name": "Ester Orlandi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Driver Mutation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454578", "session_name": "Identification of non-coding cancer driver mutations", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Esther Rheinbay", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Massachusetts", "City": "Boston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Identification of non-coding cancer driver mutations", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Driver Mutation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Esther Rheinbay ", "kol_full_name": "Esther Rheinbay " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Quality Of Life | Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454487", "session_name": "Health-related quality of life of Brazilian cancer patients with an indication for chemotherapy and associated factors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Etreo Junior Carneiro Da Silva Minarini", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Pais Vasco", "City": "Vitoria", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Health-related quality of life of Brazilian cancer patients with an indication for chemotherapy and associated factors", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Quality Of Life | Drug Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Etreo Junior Carneiro Da Silva Minarini ", "kol_full_name": "Etreo Junior Carneiro Da Silva Minarini " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Feeding | Cohort Studies | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454384", "session_name": "Breastfeeding after breast cancer in young BRCA carriers: results from an international cohort study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva Blondeaux", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Liguria", "City": "Genova", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breastfeeding after breast cancer in young BRCA carriers: results from an international cohort study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Feeding | Cohort Studies ", "rest_events_topic_count": 1, "rest_events_topic": " Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva Blondeaux ", "kol_full_name": "Eva Blondeaux " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Medication Safety", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454506", "session_name": "Medication safety and management of side-effects in across care settings, including home", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva Muñoz-Couselo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Medication safety and management of side-effects in across care settings", "rest_events_session_count": 1, "rest_events_session": " including home", "events_topic": "Medication Safety", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva Muñoz-Couselo ", "kol_full_name": "Eva Muñoz-Couselo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Rectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454322", "session_name": "A Nurse-Led Clinic' Stepped-Care Intervention for rectal cancer survivors with bowel problems", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva Pape", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Oost-Vlaanderen", "City": "Gent", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Nurse-Led Clinic' Stepped-Care Intervention for rectal cancer survivors with bowel problems", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Rectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva Pape ", "kol_full_name": "Eva Pape " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454295", "session_name": "Biomarkers and prediction of clinical complete response", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva Schaake", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Biomarkers and prediction of clinical complete response", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva Schaake ", "kol_full_name": "Eva Schaake " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Biology", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454390", "session_name": "New developments in pathology and molecular biology", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva Wardelmann", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Nordrhein-Westfalen", "City": "Munster", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "New developments in pathology and molecular biology", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Molecular Biology", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva Wardelmann ", "kol_full_name": "Eva Wardelmann " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454863", "session_name": "Challenges in access to new oncology medicines", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eva-Maria Strömsholm", "middle_name": null, "last_name": null, "org_name": "", "Country": "Finland", "Region": "Lansi-Suomen Laani", "City": "Vaasa", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Challenges in access to new oncology medicines", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Medicine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eva-Maria Strömsholm ", "kol_full_name": "Eva-Maria Strömsholm " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cardiovascular Diseases | Myocarditis", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454675", "session_name": "Cardiovascular toxicities: Focus on myocarditis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Evandro De Azambuja", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cardiovascular toxicities: Focus on myocarditis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cardiovascular Diseases | Myocarditis", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Evandro De Azambuja ", "kol_full_name": "Evandro De Azambuja " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Small Cell Lung Carcinoma | Nivolumab | Etoposide | Carboplatin", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454291", "session_name": "BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase 2 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ewa Kalinka", "middle_name": null, "last_name": null, "org_name": "", "Country": "Poland", "Region": "Lodzkie", "City": "Lodz", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase 2 study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Small Cell Lung Carcinoma | Nivolumab ", "rest_events_topic_count": 2, "rest_events_topic": " Etoposide | Carboplatin", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ewa Kalinka ", "kol_full_name": "Ewa Kalinka " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Technology-Based Intervention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454651", "session_name": "Effectiveness of Technology-Based Intervention in Symptom Management in Pediatric Oncology Patients: A Systematic Review and Meta-analysis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Eysan Hanzade Savaş", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Istanbul", "City": "Istanbul", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Effectiveness of Technology-Based Intervention in Symptom Management in Pediatric Oncology Patients: A Systematic Review and Meta-analysis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Technology-Based Intervention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Eysan Hanzade Savaş ", "kol_full_name": "Eysan Hanzade Savaş " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Macrophages | Glioblastoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454588", "session_name": "Macrophage derived immunotherapy in Glioblastoma: Phase 1 TEM-GBM-001 results (NCT03866109)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fabio Ciceri", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Macrophage derived immunotherapy in Glioblastoma: Phase 1 TEM-GBM-001 results (NCT03866109)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy | Macrophages ", "rest_events_topic_count": 1, "rest_events_topic": " Glioblastoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fabio Ciceri ", "kol_full_name": "Fabio Ciceri " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient‐Derived Organoids", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454549", "session_name": "The promise of patient-derived organoids (PDOs) in functional precision oncology", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fanny Jaulin", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The promise of patient-derived organoids (PDOs) in functional precision oncology", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Patient‐Derived Organoids", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fanny Jaulin ", "kol_full_name": "Fanny Jaulin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Prevention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454669", "session_name": "Personalised cancer prevention programme (Interception): A cost analysis to inform public policy decision-making", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Farah Erdogan", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Personalised cancer prevention programme (Interception): A cost analysis to inform public policy decision-making", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Farah Erdogan ", "kol_full_name": "Farah Erdogan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454851", "session_name": "Breast cancer, early stage", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fatima Cardoso", "middle_name": null, "last_name": null, "org_name": "", "Country": "Portugal", "Region": "Lisboa", "City": "Lisbon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 1, "rest_events_session": " early stage", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fatima Cardoso ", "kol_full_name": "Fatima Cardoso " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Feeding | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454383", "session_name": "Breastfeeding after breast cancer: Results from the POSITIVE trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fedro A. Peccatori", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breastfeeding after breast cancer: Results from the POSITIVE trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Feeding | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fedro A. Peccatori ", "kol_full_name": "Fedro A. Peccatori " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Meningioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454563", "session_name": "Molecular characteristics in meningioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Felix Sahm", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Molecular characteristics in meningioma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Meningioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Felix Sahm ", "kol_full_name": "Felix Sahm " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms | Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454840", "session_name": "Detecting targets early: biomarkers and testing in lung cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Fernando Lopez-Rios", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Detecting targets early: biomarkers and testing in lung cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Neoplasms | Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Fernando Lopez-Rios ", "kol_full_name": "Fernando Lopez-Rios " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454353", "session_name": "The Cancer Medicine Forum of the EMA", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Francesco Pignatti", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The Cancer Medicine Forum of the EMA", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Medicine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Francesco Pignatti ", "kol_full_name": "Francesco Pignatti " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Receptors, Chimeric Antigen | Immunotherapy, Adoptive", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454592", "session_name": "Moving CAR-T beyond haemato-oncology", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Franco Locatelli", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lazio", "City": "Rome", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Moving CAR-T beyond haemato-oncology", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Receptors, Chimeric Antigen | Immunotherapy, Adoptive", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Franco Locatelli ", "kol_full_name": "Franco Locatelli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pembrolizumab | Triple Negative Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454477", "session_name": "PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Francois Cherifi", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Basse-Normandie", "City": "Caen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer", "rest_events_session_count": 1, "rest_events_session": " reAl worlD frEnch cohort", "events_topic": "Pembrolizumab | Triple Negative Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Francois Cherifi ", "kol_full_name": "Francois Cherifi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biomarkers | Mesothelioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454445", "session_name": "Advances in pathology and biomarker discovery in mesothelioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Françoise Galateau-Sallé", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Rhone-Alpes", "City": "Lyon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Advances in pathology and biomarker discovery in mesothelioma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biomarkers | Mesothelioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Françoise Galateau-Sallé ", "kol_full_name": "Françoise Galateau-Sallé " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Glioblastoma | Vasculogenesis", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454585", "session_name": "Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Frank A. Giordano", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Mannheim", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Glioblastoma | Vasculogenesis", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Frank A. Giordano ", "kol_full_name": "Frank A. Giordano " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cyclin-Dependent Kinases | Glioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454258", "session_name": "The prognostic impact of CDKN2A/B heterozygous deletions in IDH-mutant glioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Franziska M. Ippen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The prognostic impact of CDKN2A/B heterozygous deletions in IDH-mutant glioma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cyclin-Dependent Kinases | Glioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Franziska M. Ippen ", "kol_full_name": "Franziska M. Ippen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma, B-Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454381", "session_name": "Diffuse large B cell lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Frederic Peyrade", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Provence-Alpes-Cote d'Azur", "City": "Nice", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Diffuse large B cell lymphoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lymphoma, B-Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Frederic Peyrade ", "kol_full_name": "Frederic Peyrade " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454598", "session_name": "Overcoming the resistance to IO: What can we do?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Frederik Marmé", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Mannheim", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Overcoming the resistance to IO: What can we do?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Frederik Marmé ", "kol_full_name": "Frederik Marmé " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tumor Microenvironment | Biopsy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454456", "session_name": "Tissue biopsy: Capturing tumour microenvironment and beyond", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Frederique Penault-Llorca", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Auvergne", "City": "Clermont-Ferrand", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Tissue biopsy: Capturing tumour microenvironment and beyond", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Tumor Microenvironment | Biopsy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Frederique Penault-Llorca ", "kol_full_name": "Frederique Penault-Llorca " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454631", "session_name": "Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA Program (BIG 14-01) subanalysis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gabriele Zoppoli", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Liguria", "City": "Genova", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA Program (BIG 14-01) subanalysis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gabriele Zoppoli ", "kol_full_name": "Gabriele Zoppoli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pembrolizumab | Solid Tumors | Combined Modality Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454737", "session_name": "A First-In-Human Phase I/Ib study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Advanced Solid Tumors – STAMINA-01", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ganessan Kichenadasse", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "South Australia", "City": "Adelaide", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A First-In-Human Phase I/Ib study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Advanced Solid Tumors – STAMINA-01", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pembrolizumab | Solid Tumors ", "rest_events_topic_count": 1, "rest_events_topic": " Combined Modality Therapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ganessan Kichenadasse ", "kol_full_name": "Ganessan Kichenadasse " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Socio-Psychological Impact", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454235", "session_name": "Socio psychological impact and implementation issues", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gareth D. Evans", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Manchester", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Socio psychological impact and implementation issues", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Socio-Psychological Impact", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gareth D. Evans ", "kol_full_name": "Gareth D. Evans " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Diagnostic Imaging", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454457", "session_name": "Novel imaging approaches: Towards a better estimation of response", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gary Cook", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Novel imaging approaches: Towards a better estimation of response", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Diagnostic Imaging", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gary Cook ", "kol_full_name": "Gary Cook " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Induction Chemotherapy | Chemoradiotherapy | Uterine Cervical Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454595", "session_name": "Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: quality of life outcomes of the GCIG INTERLACE trial.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gemma Eminowicz", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: quality of life outcomes of the GCIG INTERLACE trial.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Induction Chemotherapy | Chemoradiotherapy ", "rest_events_topic_count": 1, "rest_events_topic": " Uterine Cervical Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gemma Eminowicz ", "kol_full_name": "Gemma Eminowicz " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasm, Residual | Head And Neck Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454415", "session_name": "Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay for MRD in Head and Neck cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Geoffrey Liu", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay for MRD in Head and Neck cancers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasm, Residual | Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Geoffrey Liu ", "kol_full_name": "Geoffrey Liu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma, Mantle-Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454686", "session_name": "Mantle cell lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Georg Hess", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Rheinland-Pfalz", "City": "Mainz", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Mantle cell lymphoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lymphoma, Mantle-Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Georg Hess ", "kol_full_name": "Georg Hess " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Immunity | Endogenous Retroelements", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454272", "session_name": "Endogenous retroelements in cancer immunity", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "George Kassiotis", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Endogenous retroelements in cancer immunity", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Immunity | Endogenous Retroelements", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
George Kassiotis ", "kol_full_name": "George Kassiotis " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Targeted Therapy | Breast Neoplasms", "npi_num": "1447789912", "hcp_pin_alias": "FU_HCP_5454632", "session_name": "Metastatic Hormone Receptor-Positive Breast Cancer Outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real World Data Analysis of Genomics and Targeted Therapy Sequencing", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gerneiva Parkinson", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "California", "City": "Stanford", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Metastatic Hormone Receptor-Positive Breast Cancer Outcomes in 628 patients with BRCA1", "rest_events_session_count": 2, "rest_events_session": " BRCA2, or PALB2 pathogenic variants: Real World Data Analysis of Genomics and Targeted Therapy Sequencing", "events_topic": "Molecular Targeted Therapy | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gerneiva Parkinson ", "kol_full_name": "Gerneiva Parkinson " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Vaccines | Glioblastoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454254", "session_name": "First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): first results from the dose escalation phase", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ghazaleh Tabatabai", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Tubingen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): first results from the dose escalation phase", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Vaccines | Glioblastoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ghazaleh Tabatabai ", "kol_full_name": "Ghazaleh Tabatabai " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454788", "session_name": "Breast cancer, metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Giampaolo Bianchini", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 1, "rest_events_session": " metastatic", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Giampaolo Bianchini ", "kol_full_name": "Giampaolo Bianchini " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Personnel", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454486", "session_name": "Healthcare professionals’ wellbeing in post-pandemic oncology settings: a cross-sectional multisite study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gianluca Catania", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Liguria", "City": "Genova", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Healthcare professionals’ wellbeing in post-pandemic oncology settings: a cross-sectional multisite study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Health Personnel", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gianluca Catania ", "kol_full_name": "Gianluca Catania " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "ErbB Receptors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454646", "session_name": "Management of skin toxicity with EGFR targeted agents – a patient’s perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gini Harrison", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Croydon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of skin toxicity with EGFR targeted agents – a patient’s perspective", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "ErbB Receptors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gini Harrison ", "kol_full_name": "Gini Harrison " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Invasive Ductal Carcinoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454418", "session_name": "Pitfalls in diagnosis of ILC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Giuseppe Floris", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Leuven", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pitfalls in diagnosis of ILC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Invasive Ductal Carcinoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Giuseppe Floris ", "kol_full_name": "Giuseppe Floris " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Central Nervous System Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454821", "session_name": "CNS tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Giuseppe Lombardi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Veneto", "City": "Padova", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CNS tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Central Nervous System Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Giuseppe Lombardi ", "kol_full_name": "Giuseppe Lombardi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Self Care | Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454510", "session_name": "Nursing intervention for self-management of symptoms in people undergoing chemotherapy. Feasibility and acceptability test.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gloria Mabel Carrillo González", "middle_name": null, "last_name": null, "org_name": "", "Country": "Colombia", "Region": "Distrito Capital", "City": "Bogota", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nursing intervention for self-management of symptoms in people undergoing chemotherapy. Feasibility and acceptability test.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Self Care | Drug Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gloria Mabel Carrillo González ", "kol_full_name": "Gloria Mabel Carrillo González " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pancreatic Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454724", "session_name": "Functional pancreatic NETs syndromes", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Grigorios A. Kaltsas", "middle_name": null, "last_name": null, "org_name": "", "Country": "Greece", "Region": "Attiki", "City": "Athens", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Functional pancreatic NETs syndromes", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pancreatic Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Grigorios A. Kaltsas ", "kol_full_name": "Grigorios A. Kaltsas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Surgical Approach", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454609", "session_name": "To operate or not operate: Personalised surgical approaches in the curative setting", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Guillaume Piessen", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Nord-Pas-de-Calais", "City": "Lille", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "To operate or not operate: Personalised surgical approaches in the curative setting", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Surgical Approach", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Guillaume Piessen ", "kol_full_name": "Guillaume Piessen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454504", "session_name": "Use, benefits, and barriers of subcutaneous immunotherapy applications", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Guillermo Antonio De Velasco Oria", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Use", "rest_events_session_count": 2, "rest_events_session": " benefits, and barriers of subcutaneous immunotherapy applications", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Guillermo Antonio De Velasco Oria ", "kol_full_name": "Guillermo Antonio De Velasco Oria " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial | Quality Of Life", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454658", "session_name": "Mobile application-based intervention study in improving Treatment Adherence and Quality of Life in Cancer Patients", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gunisetty H. Prakash", "middle_name": null, "last_name": null, "org_name": "", "Country": "India", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Mobile application-based intervention study in improving Treatment Adherence and Quality of Life in Cancer Patients", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Trial | Quality Of Life", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gunisetty H. Prakash ", "kol_full_name": "Gunisetty H. Prakash " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Atezolizumab | Tumor Microenvironment | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454288", "session_name": "A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Gustav J. Ullenhag", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Uppsala Lan", "City": "Uppsala", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Atezolizumab | Tumor Microenvironment ", "rest_events_topic_count": 1, "rest_events_topic": " Melanoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Gustav J. Ullenhag ", "kol_full_name": "Gustav J. Ullenhag " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Succinate Dehydrogenase | Olverembatinib | Gastrointestinal Stromal Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454260", "session_name": "Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Haibo Qiu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Guangdong", "City": "Guangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Succinate Dehydrogenase | Olverembatinib ", "rest_events_topic_count": 1, "rest_events_topic": " Gastrointestinal Stromal Tumors", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Haibo Qiu ", "kol_full_name": "Haibo Qiu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454791", "session_name": "Investigational immunotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Han Chong Toh", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Investigational immunotherapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Han Chong Toh ", "kol_full_name": "Han Chong Toh " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Off-Label Use", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454666", "session_name": "Mapping the scale of off-label use in oncology: an important step in harmonising access", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hans J. Timmer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Leiden", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Mapping the scale of off-label use in oncology: an important step in harmonising access", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Off-Label Use", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hans J. Timmer ", "kol_full_name": "Hans J. Timmer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454499", "session_name": "Providing palliative care in a hospital setting", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Heidi Bergenholtz", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Roskilde", "City": "Roskilde", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Providing palliative care in a hospital setting", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Palliative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Heidi Bergenholtz ", "kol_full_name": "Heidi Bergenholtz " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Leadership", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454665", "session_name": "Leadership roles in oncology: gender is still a barrier. Results from the new ESMO Women for Oncology Committee authorship and monitoring studies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Helena Linardou", "middle_name": null, "last_name": null, "org_name": "", "Country": "Greece", "Region": "Attiki", "City": "Athens", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Leadership roles in oncology: gender is still a barrier. Results from the new ESMO Women for Oncology Committee authorship and monitoring studies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Leadership", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Helena Linardou ", "kol_full_name": "Helena Linardou " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454774", "session_name": "Effects of a high-intensity exercise intervention on recurrence and survival: the OptiTrain breast cancer trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Helene Rundqvist", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Stockholm", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Effects of a high-intensity exercise intervention on recurrence and survival: the OptiTrain breast cancer trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Helene Rundqvist ", "kol_full_name": "Helene Rundqvist " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pain Monitoring", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454489", "session_name": "Pain monitoring and assessment in oncology: a best practice implementation project", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Helga T. Martins", "middle_name": null, "last_name": null, "org_name": "", "Country": "Portugal", "Region": "Faro", "City": "Albufeira", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pain monitoring and assessment in oncology: a best practice implementation project", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pain Monitoring", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Helga T. Martins ", "kol_full_name": "Helga T. Martins " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Social Isolation | Lung Neoplasms | Early Detection Of Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454346", "session_name": "Association of Life Satisfaction, Emotional Support, Social Isolation with Lung Cancer Screening Adherence among US Adults", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hermine Poghosyan", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Connecticut", "City": "New Haven", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Association of Life Satisfaction", "rest_events_session_count": 2, "rest_events_session": " Emotional Support, Social Isolation with Lung Cancer Screening Adherence among US Adults", "events_topic": "Social Isolation | Lung Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Early Detection Of Cancer", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hermine Poghosyan ", "kol_full_name": "Hermine Poghosyan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454546", "session_name": "Survival before and after the Introduction of Adjuvant Treatment in Stage III Melanoma: A Nationwide Registry-Based Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hildur Helgadottir", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Solna", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Survival before and after the Introduction of Adjuvant Treatment in Stage III Melanoma: A Nationwide Registry-Based Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hildur Helgadottir ", "kol_full_name": "Hildur Helgadottir " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "BCG Vaccine | Urinary Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454614", "session_name": "JCOG1019: An Open-label, Non-inferiority, Randomised Phase 3 Study Comparing the Effectiveness of Watchful Waiting (WW) and Intravesical Bacillus Calmette-Guérin (BCG) in Patients (Pts) with High-grade pT1 (HGT1) Bladder Cancer with pT0 on the 2nd Transurethral Resection (TUR) Specimen", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hiroshi Kitamura", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Toyama", "City": "Toyama", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "JCOG1019: An Open-label", "rest_events_session_count": 2, "rest_events_session": " Non-inferiority, Randomised Phase 3 Study Comparing the Effectiveness of Watchful Waiting (WW) and Intravesical Bacillus Calmette-Guérin (BCG) in Patients (Pts) with High-grade pT1 (HGT1) Bladder Cancer with pT0 on the 2nd Transurethral Resection (TUR) Specimen", "events_topic": "BCG Vaccine | Urinary Bladder Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hiroshi Kitamura ", "kol_full_name": "Hiroshi Kitamura " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Head And Neck Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454868", "session_name": "Head and neck cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hisham Mehanna", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Birmingham", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Head and neck cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hisham Mehanna ", "kol_full_name": "Hisham Mehanna " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nausea | Olanzapine | Placebos | Trastuzumab Deruxtecan | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454385", "session_name": "A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hitomi Sakai", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Tokyo", "City": "Tokyo", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A multicentre", "rest_events_session_count": 3, "rest_events_session": " randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)", "events_topic": "Nausea | Olanzapine ", "rest_events_topic_count": 3, "rest_events_topic": " Placebos | Trastuzumab Deruxtecan | Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hitomi Sakai ", "kol_full_name": "Hitomi Sakai " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Solid Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454277", "session_name": "YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase 1 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hongyun Zhao", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Guangdong", "City": "Guangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "YL201", "rest_events_session_count": 2, "rest_events_session": " a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase 1 study", "events_topic": "Immunoconjugates | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hongyun Zhao ", "kol_full_name": "Hongyun Zhao " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Ganglia, Sympathetic | Lymphedema", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454324", "session_name": "The Effects of Lumbar Sympathetic Ganglion Block Therapy on Secondary Lower Limb Lymphedema", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Hua-Qing Huang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Fujian", "City": "Fuzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The Effects of Lumbar Sympathetic Ganglion Block Therapy on Secondary Lower Limb Lymphedema", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Ganglia, Sympathetic | Lymphedema", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Hua-Qing Huang ", "kol_full_name": "Hua-Qing Huang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Trastuzumab Deruxtecan | Salivary Gland Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454567", "session_name": "Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: results from the MYTHOS trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ichiro Kinoshita", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Hokkaido", "City": "Sapporo", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: results from the MYTHOS trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Trastuzumab Deruxtecan | Salivary Gland Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ichiro Kinoshita ", "kol_full_name": "Ichiro Kinoshita " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oligometastatic Disease", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454637", "session_name": "Use of ablative therapies in patients with oligometastatic disease", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Icro Meattini", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Toscana", "City": "Firenze", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Use of ablative therapies in patients with oligometastatic disease", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oligometastatic Disease", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Icro Meattini ", "kol_full_name": "Icro Meattini " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454794", "session_name": "Genitourinary tumours, non-prostate", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ignacio Duran", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Cantabria", "City": "Santander", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Genitourinary tumours", "rest_events_session_count": 1, "rest_events_session": " non-prostate", "events_topic": "Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ignacio Duran ", "kol_full_name": "Ignacio Duran " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "ErbB Receptors | Lung Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454645", "session_name": "Use of EGFR targeted agents in lung cancer, now and future", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ignacio Gil Bazo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Use of EGFR targeted agents in lung cancer", "rest_events_session_count": 1, "rest_events_session": " now and future", "events_topic": "ErbB Receptors | Lung Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ignacio Gil Bazo ", "kol_full_name": "Ignacio Gil Bazo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Disease Progression", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454875", "session_name": "Which patients should we treat beyond progression and when should we stop?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ignacio Melero", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Navarra", "City": "Pamplona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Which patients should we treat beyond progression and when should we stop?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Disease Progression", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ignacio Melero ", "kol_full_name": "Ignacio Melero " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cell- And Tissue-Based Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454593", "session_name": "Cellular therapies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Inge Marie Svane", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Kobenhavn", "City": "Herlev", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cellular therapies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cell- And Tissue-Based Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Inge Marie Svane ", "kol_full_name": "Inge Marie Svane " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Head And Neck Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454780", "session_name": "Head and neck cancer, excluding thyroid", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Irene Braña", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Head and neck cancer", "rest_events_session_count": 1, "rest_events_session": " excluding thyroid", "events_topic": "Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Irene Braña ", "kol_full_name": "Irene Braña " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Anticancer Therapy | Gonadal Toxicity", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454280", "session_name": "Risk of gonadal toxicities with anticancer therapies with a focus on newer treatments", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Isabelle Demeestere", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Risk of gonadal toxicities with anticancer therapies with a focus on newer treatments", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Anticancer Therapy | Gonadal Toxicity", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Isabelle Demeestere ", "kol_full_name": "Isabelle Demeestere " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454850", "session_name": "NETs and endocrine tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ivan Borbath", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Woluwe-Saint-Lambert", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NETs and endocrine tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ivan Borbath ", "kol_full_name": "Ivan Borbath " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Skin Neoplasms | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454810", "session_name": "Melanoma and other skin tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ivan Marquez-Rodas", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Melanoma and other skin tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Skin Neoplasms | Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ivan Marquez-Rodas ", "kol_full_name": "Ivan Marquez-Rodas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Adolescent And Young Adult Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454874", "session_name": "ESMO in collaboration with SIOPE / ESMO AYA: The greatest need for better outcome of Adolescent and Young Adult Cancer (AYA) with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ivana Bozovic Spasojevic", "middle_name": null, "last_name": null, "org_name": "", "Country": "Yugoslavia", "Region": "Srbija (Serbia)", "City": "Belgrade", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO in collaboration with SIOPE / ESMO AYA: The greatest need for better outcome of Adolescent and Young Adult Cancer (AYA) with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Adolescent And Young Adult Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ivana Bozovic Spasojevic ", "kol_full_name": "Ivana Bozovic Spasojevic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "KRAS Protein, Human", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454767", "session_name": "Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors - an individual patient meta-analysis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jakob M. Riedl", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Steiermark", "City": "Graz", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors - an individual patient meta-analysis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "KRAS Protein, Human", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jakob M. Riedl ", "kol_full_name": "Jakob M. Riedl " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urinary Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454296", "session_name": "The role of urologist in bladder preservation strategies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "James Catto", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Sheffield", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of urologist in bladder preservation strategies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Urinary Bladder Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
James Catto ", "kol_full_name": "James Catto " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Safusidenib | IDH1 Protein, Human | Glioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454257", "session_name": "A perioperative study of Safusidenib in Patients with IDH1 mutated glioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "James R. Whittle", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "Victoria", "City": "Melbourne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A perioperative study of Safusidenib in Patients with IDH1 mutated glioma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Safusidenib | IDH1 Protein, Human ", "rest_events_topic_count": 1, "rest_events_topic": " Glioma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
James R. Whittle ", "kol_full_name": "James R. Whittle " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genetically Modified Bacteria | Anti-Tumor Immunity", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454401", "session_name": "Improving anti-tumour immunity with engineered bacteria", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jan Theys", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Limburg", "City": "Maastricht", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Improving anti-tumour immunity with engineered bacteria", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Genetically Modified Bacteria | Anti-Tumor Immunity", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jan Theys ", "kol_full_name": "Jan Theys " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient-Centered Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454525", "session_name": "How patient-centred research and innovation drives improved cancer care", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jan Willem Van De Loo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "West-Vlaanderen", "City": "Izegem", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How patient-centred research and innovation drives improved cancer care", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Patient-Centered Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jan Willem Van De Loo ", "kol_full_name": "Jan Willem Van De Loo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Second-Line Treatment | Third-Line Treatment", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454362", "session_name": "The difficulties of moving from second to third line treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jana Pelouchova", "middle_name": null, "last_name": null, "org_name": "", "Country": "Czech Republic", "Region": "Hlavni Mesto Praha", "City": "Prague", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The difficulties of moving from second to third line treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Second-Line Treatment | Third-Line Treatment", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jana Pelouchova ", "kol_full_name": "Jana Pelouchova " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial | Proteome | Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454717", "session_name": "Expanding proteome interrogation to identify early phase clinical trial biomarkers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Janne Lehtiö", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Stockholm", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Expanding proteome interrogation to identify early phase clinical trial biomarkers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Trial | Proteome ", "rest_events_topic_count": 1, "rest_events_topic": " Biomarkers", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Janne Lehtiö ", "kol_full_name": "Janne Lehtiö " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nivolumab | Sunitinib | Sarcoma, Clear Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454263", "session_name": "IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): results from the clear cell sarcoma (CCS) cohort. a GEIS, ISG, and UCL study.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Javier Martin-Broto", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): results from the clear cell sarcoma (CCS) cohort. a GEIS", "rest_events_session_count": 2, "rest_events_session": " ISG, and UCL study.", "events_topic": "Nivolumab | Sunitinib ", "rest_events_topic_count": 1, "rest_events_topic": " Sarcoma, Clear Cell", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Javier Martin-Broto ", "kol_full_name": "Javier Martin-Broto " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Allogeneic Stem Cell Transplantation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454660", "session_name": "A cent: A model for person-cantered care in allogenic stem cell transplantation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jeanette Winterling", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Huddinge", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A cent: A model for person-cantered care in allogenic stem cell transplantation", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Allogeneic Stem Cell Transplantation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jeanette Winterling ", "kol_full_name": "Jeanette Winterling " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454533", "session_name": "What has been done at the EU level: Cancer Mission and the EU Beating Plan", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jeliazko I. Arabadjiev", "middle_name": null, "last_name": null, "org_name": "", "Country": "Bulgaria", "Region": "Sofiya", "City": "Sofia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What has been done at the EU level: Cancer Mission and the EU Beating Plan", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jeliazko I. Arabadjiev ", "kol_full_name": "Jeliazko I. Arabadjiev " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Prevention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454343", "session_name": "The role of schools in cancer prevention: Strategies for involving school nurses and teachers in promoting healthy habits", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jennie Jackson", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Stockholm", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of schools in cancer prevention: Strategies for involving school nurses and teachers in promoting healthy habits", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jennie Jackson ", "kol_full_name": "Jennie Jackson " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nivolumab | Carcinoma, Transitional Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454764", "session_name": "Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jens Bedke", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Stuttgart", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Nivolumab | Carcinoma, Transitional Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jens Bedke ", "kol_full_name": "Jens Bedke " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pembrolizumab | Setanaxib | Squamous Cell Carcinoma Of Head And Neck", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454453", "session_name": "Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind Phase 2 trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jérome Fayette", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Rhone-Alpes", "City": "Lyon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized", "rest_events_session_count": 1, "rest_events_session": " double-blind Phase 2 trial", "events_topic": "Pembrolizumab | Setanaxib ", "rest_events_topic_count": 1, "rest_events_topic": " Squamous Cell Carcinoma Of Head And Neck", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jérome Fayette ", "kol_full_name": "Jérome Fayette " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Barometer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454233", "session_name": "Lessons from France's Cancer Barometers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jérôme Foucaud", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Boulogne-Billancourt", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Lessons from France's Cancer Barometers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Barometer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jérôme Foucaud ", "kol_full_name": "Jérôme Foucaud " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Skin Neoplasms | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454819", "session_name": "Melanoma and other skin tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jessica C. Hassel", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Melanoma and other skin tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Skin Neoplasms | Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jessica C. Hassel ", "kol_full_name": "Jessica C. Hassel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Quality Of Life", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454610", "session_name": "How does surgery with curative intent impact quality of life?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jessie A. Elliott", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How does surgery with curative intent impact quality of life?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Quality Of Life", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jessie A. Elliott ", "kol_full_name": "Jessie A. Elliott " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454802", "session_name": "Non-metastatic NSCLC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jia Wu", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Non-metastatic NSCLC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jia Wu ", "kol_full_name": "Jia Wu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Orelabrutinib | Obinutuzumab | Prospective Studies | Lymphoma, B-Cell, Marginal Zone", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454557", "session_name": "A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): preliminary analysis on efficacy and safety", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jia-Dai Xu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): preliminary analysis on efficacy and safety", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Orelabrutinib | Obinutuzumab ", "rest_events_topic_count": 2, "rest_events_topic": " Prospective Studies | Lymphoma, B-Cell, Marginal Zone", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jia-Dai Xu ", "kol_full_name": "Jia-Dai Xu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung | Beclometasone | Radiotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454756", "session_name": "The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: a randomized controlled, open-label phase II study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jie Zhang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: a randomized controlled", "rest_events_session_count": 1, "rest_events_session": " open-label phase II study", "events_topic": "Carcinoma, Non-Small-Cell Lung | Beclometasone ", "rest_events_topic_count": 1, "rest_events_topic": " Radiotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jie Zhang ", "kol_full_name": "Jie Zhang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Peritoneal Metastasis", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454619", "session_name": "Peritoneal metastases beyond surgery", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jimmy B. So", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Peritoneal metastases beyond surgery", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Peritoneal Metastasis", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jimmy B. So ", "kol_full_name": "Jimmy B. So " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunoconjugates | Genital Neoplasms, Female", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454577", "session_name": "IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase 1 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jin Shu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Chongqing", "City": "Chongqing", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase 1 study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunoconjugates | Genital Neoplasms, Female", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jin Shu ", "kol_full_name": "Jin Shu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pembrolizumab | Sacituzumab Tirumotecan | Uterine Cervical Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454574", "session_name": "Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jing Wang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Hunan", "City": "Changsha", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pembrolizumab | Sacituzumab Tirumotecan ", "rest_events_topic_count": 1, "rest_events_topic": " Uterine Cervical Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jing Wang ", "kol_full_name": "Jing Wang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Paclitaxel | Triple Negative Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454776", "session_name": "A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jiong Wu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Paclitaxel | Triple Negative Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jiong Wu ", "kol_full_name": "Jiong Wu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Vaccines", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454467", "session_name": "Vaccines", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Joachim G. Aerts", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Rotterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Vaccines", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Vaccines", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joachim G. Aerts ", "kol_full_name": "Joachim G. Aerts " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454336", "session_name": "Three-year evaluation of an immunotherapy late effects screening clinic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Joanne Bird", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Sheffield", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Three-year evaluation of an immunotherapy late effects screening clinic", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joanne Bird ", "kol_full_name": "Joanne Bird " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Brain-Gut Axis | Microbiota", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454537", "session_name": "What is the microbiota-gut-brain-axis?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Joanne Bowen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "South Australia", "City": "Adelaide", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What is the microbiota-gut-brain-axis?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Brain-Gut Axis | Microbiota", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joanne Bowen ", "kol_full_name": "Joanne Bowen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiotherapy | Durvalumab | Squamous Cell Carcinoma Of Head And Neck", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454452", "session_name": "REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Joël Castelli", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Bretagne", "City": "Rennes", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiotherapy | Durvalumab ", "rest_events_topic_count": 1, "rest_events_topic": " Squamous Cell Carcinoma Of Head And Neck", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joël Castelli ", "kol_full_name": "Joël Castelli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Circulating Tumor DNA | Immunotherapy | Cystectomy | Urinary Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454762", "session_name": "Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jorgen Bjerggaard Jensen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Arhus", "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Circulating Tumor DNA | Immunotherapy ", "rest_events_topic_count": 2, "rest_events_topic": " Cystectomy | Urinary Bladder Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jorgen Bjerggaard Jensen ", "kol_full_name": "Jorgen Bjerggaard Jensen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454347", "session_name": "Welcome from Spanish Oncology Nursing Society (Sociedad Española de Enfermería Oncológica, SEEO)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jorgina Serra López", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Welcome from Spanish Oncology Nursing Society (Sociedad Española de Enfermería Oncológica", "rest_events_session_count": 1, "rest_events_session": " SEEO)", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jorgina Serra López ", "kol_full_name": "Jorgina Serra López " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Trametinib | Dabrafenib | Proto-Oncogene Proteins B-raf | Pembrolizumab | Programmed Cell Death 1 Receptor | Molecular Targeted Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454710", "session_name": "Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jorja Braden", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "New South Wales", "City": "Sydney", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Trametinib | Dabrafenib ", "rest_events_topic_count": 4, "rest_events_topic": " Proto-Oncogene Proteins B-raf | Pembrolizumab | Programmed Cell Death 1 Receptor | Molecular Targeted Therapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jorja Braden ", "kol_full_name": "Jorja Braden " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radical Surgery | Gastric Neuroendocrine Carcinoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454721", "session_name": "Gastric NEN: When to recommend radical surgery?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "José Díaz Tasende", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gastric NEN: When to recommend radical surgery?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radical Surgery | Gastric Neuroendocrine Carcinoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
José Díaz Tasende ", "kol_full_name": "José Díaz Tasende " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Prevention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454365", "session_name": "The WHO Pandemic Accord and the review of the International Health Regulations (IHR): The need to include cancer prevention and control", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Jose M. Martin-Moreno", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The WHO Pandemic Accord and the review of the International Health Regulations (IHR): The need to include cancer prevention and control", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Jose M. Martin-Moreno ", "kol_full_name": "Jose M. Martin-Moreno " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Uveal Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454606", "session_name": "Uveal melanoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Josep Maria Piulats Rodriguez", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Uveal melanoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Uveal Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Josep Maria Piulats Rodriguez ", "kol_full_name": "Josep Maria Piulats Rodriguez " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "T-Cell Engagers | T Cell Fitness", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454765", "session_name": "Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Joseph J. Sacco", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "T-Cell Engagers | T Cell Fitness", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Joseph J. Sacco ", "kol_full_name": "Joseph J. Sacco " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Policy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454872", "session_name": "Policy and preventive strategies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Judith Balmaña", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Policy and preventive strategies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Health Policy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Judith Balmaña ", "kol_full_name": "Judith Balmaña " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pathologic Complete Response", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454568", "session_name": "How to define pathologic response?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Judith Bovée", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Leiden", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How to define pathologic response?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pathologic Complete Response", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Judith Bovée ", "kol_full_name": "Judith Bovée " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Merkel Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454608", "session_name": "Novel targets in Merkel cell carcinoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Juergen C. Becker", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Heidelberg", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Novel targets in Merkel cell carcinoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Merkel Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Juergen C. Becker ", "kol_full_name": "Juergen C. Becker " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Randomized Controlled Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454668", "session_name": "Clinical trial design and treatment effects: A meta-analysis of randomized-controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Julia Caroline Michaeli", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Bayern", "City": "Munich", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Clinical trial design and treatment effects: A meta-analysis of randomized-controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Randomized Controlled Trial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Julia Caroline Michaeli ", "kol_full_name": "Julia Caroline Michaeli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Glioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454388", "session_name": "Assessing patient fitness for treatment of gliomas", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Julia Furtner", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Wien", "City": "Vienna", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Assessing patient fitness for treatment of gliomas", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Glioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Julia Furtner ", "kol_full_name": "Julia Furtner " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Prostatic Neoplasms | B7-H3", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454448", "session_name": "B7-H3 as therapeutic target for PC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Juliet Carmichael", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "B7-H3 as therapeutic target for PC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Prostatic Neoplasms | B7-H3", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Juliet Carmichael ", "kol_full_name": "Juliet Carmichael " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy, Adoptive | B-Cell Maturation Antigen | Multiple Myeloma", "npi_num": "1285321547", "hcp_pin_alias": "FU_HCP_5454239", "session_name": "Real-world Comparison of Overall Survival between BCMA - Bispecific and CAR-T Therapies in Multiple Myeloma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Junmin Song", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "New York", "City": "Bronx", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Real-world Comparison of Overall Survival between BCMA - Bispecific and CAR-T Therapies in Multiple Myeloma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy, Adoptive | B-Cell Maturation Antigen ", "rest_events_topic_count": 1, "rest_events_topic": " Multiple Myeloma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Junmin Song ", "kol_full_name": "Junmin Song " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma, Non-Hodgkin | Leukemia, Myeloid, Acute", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454237", "session_name": "First Report of BCL-2 Inhibitor TQB3909 in Pts with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML): Data From a Phase 1 Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Junyuan Qi", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Tianjin", "City": "TIANJIN", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "First Report of BCL-2 Inhibitor TQB3909 in Pts with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML): Data From a Phase 1 Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lymphoma, Non-Hodgkin | Leukemia, Myeloid, Acute", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Junyuan Qi ", "kol_full_name": "Junyuan Qi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma | HIV", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454687", "session_name": "HIV lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kai Hübel", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Nordrhein-Westfalen", "City": "Koeln", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "HIV lymphoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lymphoma | HIV", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kai Hübel ", "kol_full_name": "Kai Hübel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cross-Sectional Studies", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454481", "session_name": "Predictors of Safe handling precautions amongst Cancer Nurses in the UK: A Cross Sectional Survey.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Karen Campbell", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Predictors of Safe handling precautions amongst Cancer Nurses in the UK: A Cross Sectional Survey.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cross-Sectional Studies", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Karen Campbell ", "kol_full_name": "Karen Campbell " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Thrombosis | Pulmonary Embolism", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454807", "session_name": "Cancer-associated thrombosis: Management of pulmonary embolism", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Karin Jordan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Brandenburg", "City": "Potsdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer-associated thrombosis: Management of pulmonary embolism", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Thrombosis | Pulmonary Embolism", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Karin Jordan ", "kol_full_name": "Karin Jordan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454337", "session_name": "“To Get Through to Survive\": Exploring the Symptom Cluster Management Process During Oncological Treatment From the Perspective of Patients With Lung Cancer.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Katarina Karlsson", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Varmlands Lan", "City": "Karlstad", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "“To Get Through to Survive\": Exploring the Symptom Cluster Management Process During Oncological Treatment From the Perspective of Patients With Lung Cancer.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Katarina Karlsson ", "kol_full_name": "Katarina Karlsson " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient Participation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454528", "session_name": "Understanding patient engagement in EU funded projects", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Katharina Beyer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Rotterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Understanding patient engagement in EU funded projects", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Patient Participation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Katharina Beyer ", "kol_full_name": "Katharina Beyer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tailored Treatment", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454743", "session_name": "Sex and gender: First steps towards tailored treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kathrin Heinrich", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Bayern", "City": "Munich", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sex and gender: First steps towards tailored treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Tailored Treatment", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kathrin Heinrich ", "kol_full_name": "Kathrin Heinrich " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454514", "session_name": "EU-CAYAS-NET IDE toolkit: Youth Cancer Europe", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Katie Rizvi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Romania", "Region": "Cluj", "City": "Cluj-Napoca", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "EU-CAYAS-NET IDE toolkit: Youth Cancer Europe", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Katie Rizvi ", "kol_full_name": "Katie Rizvi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454878", "session_name": "Non-metastatic NSCLC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kersti Oselin", "middle_name": null, "last_name": null, "org_name": "", "Country": "Estonia", "Region": "Harjumaa", "City": "Tallinn", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Non-metastatic NSCLC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kersti Oselin ", "kol_full_name": "Kersti Oselin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antineoplastic Agents", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454667", "session_name": "Analysis of concordance between trial and target populations for cancer drugs in the US, EU, and Switzerland (2014-2023)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kerstin N. Vokinger", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Zurich", "City": "Zurich", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Analysis of concordance between trial and target populations for cancer drugs in the US", "rest_events_session_count": 2, "rest_events_session": " EU, and Switzerland (2014-2023)", "events_topic": "Antineoplastic Agents", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kerstin N. Vokinger ", "kol_full_name": "Kerstin N. Vokinger " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Mesothelioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454292", "session_name": "ARTIMES: Automated Response evaluation to Treatment In MESothelioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kevin B. Groot Lipman", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ARTIMES: Automated Response evaluation to Treatment In MESothelioma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Mesothelioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kevin B. Groot Lipman ", "kol_full_name": "Kevin B. Groot Lipman " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immune System | Head And Neck Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454269", "session_name": "Harnessing the immune system as a therapeutic tool in the treatment of head and neck cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kirsten Lauber", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Bayern", "City": "Munich", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Harnessing the immune system as a therapeutic tool in the treatment of head and neck cancers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immune System | Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kirsten Lauber ", "kol_full_name": "Kirsten Lauber " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Solid Tumors | Immune Checkpoint Inhibitors | Prognosis", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454713", "session_name": "Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Kyosuke Seguchi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Chiba", "City": "Komatsu", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Solid Tumors | Immune Checkpoint Inhibitors ", "rest_events_topic_count": 1, "rest_events_topic": " Prognosis", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Kyosuke Seguchi ", "kol_full_name": "Kyosuke Seguchi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors | Malignant Carcinoid Syndrome | Carcinoid Heart Disease", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454253", "session_name": "Carcinoid Heart Disease in Patients with Advanced Small-intestinal Neuroendocrine Tumours and Carcinoid Syndrome: A Retrospective experience of two Centers of Excellence", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Laura Algeri", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Sicilia", "City": "Palermo", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Carcinoid Heart Disease in Patients with Advanced Small-intestinal Neuroendocrine Tumours and Carcinoid Syndrome: A Retrospective experience of two Centers of Excellence", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neuroendocrine Tumors | Malignant Carcinoid Syndrome ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoid Heart Disease", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Laura Algeri ", "kol_full_name": "Laura Algeri " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncologists", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454682", "session_name": "Medical oncologist perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Laura Biganzoli", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Toscana", "City": "Prato", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Medical oncologist perspective", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncologists", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Laura Biganzoli ", "kol_full_name": "Laura Biganzoli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lenvatinib | Radioiodine Therapy | Thyroid Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454248", "session_name": "Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: real-world treatment patterns and clinical outcomes in Europe and Canada", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Laura D. Locati", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Pavia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: real-world treatment patterns and clinical outcomes in Europe and Canada", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lenvatinib | Radioiodine Therapy ", "rest_events_topic_count": 1, "rest_events_topic": " Thyroid Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Laura D. Locati ", "kol_full_name": "Laura D. Locati " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy, Adoptive | Gastrointestinal Microbiome", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454241", "session_name": "Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Laura Marcos-Kovandzic", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy, Adoptive | Gastrointestinal Microbiome", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Laura Marcos-Kovandzic ", "kol_full_name": "Laura Marcos-Kovandzic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454855", "session_name": "Cancer nursing interventions: The importance of the role of nursing in successful scalp cooling", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Laura Marqués Jiménez", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer nursing interventions: The importance of the role of nursing in successful scalp cooling", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Laura Marqués Jiménez ", "kol_full_name": "Laura Marqués Jiménez " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient Outcome Assessment | Prehabilitation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454540", "session_name": "Pre-habilitation interventions to improve outcomes in patients with cancer. What is the evidence?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Laurien Buffart", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Gelderland", "City": "Nijmegen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pre-habilitation interventions to improve outcomes in patients with cancer. What is the evidence?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Patient Outcome Assessment | Prehabilitation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Laurien Buffart ", "kol_full_name": "Laurien Buffart " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urinary Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454535", "session_name": "Bladder cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lazar S. Popovic", "middle_name": null, "last_name": null, "org_name": "", "Country": "Yugoslavia", "Region": "Srbija (Serbia)", "City": "Belgrade", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Bladder cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Urinary Bladder Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lazar S. Popovic ", "kol_full_name": "Lazar S. Popovic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Central Nervous System Neoplasms | Neural Influences", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454679", "session_name": "Neural influences on non-CNS malignancies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Leanne Li", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neural influences on non-CNS malignancies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Central Nervous System Neoplasms | Neural Influences", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Leanne Li ", "kol_full_name": "Leanne Li " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Self Care | Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454512", "session_name": "Empowering patient education to enhance self-care of nutritional side-effects during the chemotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Leena Tuominen", "middle_name": null, "last_name": null, "org_name": "", "Country": "Finland", "Region": "Lansi-Suomen Laani", "City": "Turku", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Empowering patient education to enhance self-care of nutritional side-effects during the chemotherapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Self Care | Drug Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Leena Tuominen ", "kol_full_name": "Leena Tuominen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy, Adoptive | Receptors, Chimeric Antigen | B-cell Acute Lymphoblastic Leukemia | Renal Insufficiency, Chronic | Interleukin-6", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454243", "session_name": "High Efficacy and Safety of Interleukin-6-knockdown CD19-targeted CAR T cells in relapsed/refractory B-ALL patients.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lei Yu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "High Efficacy and Safety of Interleukin-6-knockdown CD19-targeted CAR T cells in relapsed/refractory B-ALL patients.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy, Adoptive | Receptors, Chimeric Antigen ", "rest_events_topic_count": 3, "rest_events_topic": " B-cell Acute Lymphoblastic Leukemia | Renal Insufficiency, Chronic | Interleukin-6", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lei Yu ", "kol_full_name": "Lei Yu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Diagnostic Techniques | Glioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454386", "session_name": "Rational molecular testing for treatment of gliomas", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Leonille Schweizer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Brandenburg", "City": "Frankfurt", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Rational molecular testing for treatment of gliomas", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Molecular Diagnostic Techniques | Glioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Leonille Schweizer ", "kol_full_name": "Leonille Schweizer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Developmental Therapeutics", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454858", "session_name": "Developmental therapeutics", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lillian L. Siu", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Developmental therapeutics", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Developmental Therapeutics", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lillian L. Siu ", "kol_full_name": "Lillian L. Siu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Care Facilities | Healthcare", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454517", "session_name": "Healthcare needs, experiences of cancer care, and attitudes towards cancer among ethnic Chinese immigrants in Scotland", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lin Cheng", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "Scotland", "City": "Glasgow", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Healthcare needs", "rest_events_session_count": 2, "rest_events_session": " experiences of cancer care, and attitudes towards cancer among ethnic Chinese immigrants in Scotland", "events_topic": "Cancer Care Facilities | Healthcare", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lin Cheng ", "kol_full_name": "Lin Cheng " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Rovadicitinib | Baricitinib | Primary Myelofibrosis | Hydroxyurea", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454236", "session_name": "The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ling Pan", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Sichuan", "City": "Chengdu", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Rovadicitinib | Baricitinib ", "rest_events_topic_count": 2, "rest_events_topic": " Primary Myelofibrosis | Hydroxyurea", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ling Pan ", "kol_full_name": "Ling Pan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Inequities", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454358", "session_name": "Inequalities across countries", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Liora Bowers", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Inequalities across countries", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Health Inequities", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Liora Bowers ", "kol_full_name": "Liora Bowers " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Gastrointestinal Microbiome | Neurocognitive Disorders", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454539", "session_name": "The gut microbiota & neurocognitive functioning in patients with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lisa Derosa", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The gut microbiota & neurocognitive functioning in patients with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Gastrointestinal Microbiome | Neurocognitive Disorders", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lisa Derosa ", "kol_full_name": "Lisa Derosa " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Trastuzumab | Anthracyclines | Cardiotoxicity | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454325", "session_name": "Risk stratification for cardiotoxicity and follow-up in breast cancer patients treated with anthracycline and/or trastuzumab: an exploratory analysis of patient records", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lise-Marie Kinnaer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Oost-Vlaanderen", "City": "Gent", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Risk stratification for cardiotoxicity and follow-up in breast cancer patients treated with anthracycline and/or trastuzumab: an exploratory analysis of patient records", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Trastuzumab | Anthracyclines ", "rest_events_topic_count": 2, "rest_events_topic": " Cardiotoxicity | Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lise-Marie Kinnaer ", "kol_full_name": "Lise-Marie Kinnaer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Leukemia, Myelomonocytic, Chronic | Azacitidine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454238", "session_name": "Efficacy and Safety of a Phase 2 Study: Timdarpacept (IMM01) Combined with Azacitidine (AZA) As the First-Line Treatment in Adults with Chronic Myelomonocytic Leukemia (CMML)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Liya Ma", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Zhejiang", "City": "Hangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Efficacy and Safety of a Phase 2 Study: Timdarpacept (IMM01) Combined with Azacitidine (AZA) As the First-Line Treatment in Adults with Chronic Myelomonocytic Leukemia (CMML)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Leukemia, Myelomonocytic, Chronic | Azacitidine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Liya Ma ", "kol_full_name": "Liya Ma " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Akkermansia | Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454712", "session_name": "Akkermansia muciniphila-based multi-omic profiling in advanced non-small cell lung cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lorenzo Belluomini", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Veneto", "City": "Verona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Akkermansia muciniphila-based multi-omic profiling in advanced non-small cell lung cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Akkermansia | Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lorenzo Belluomini ", "kol_full_name": "Lorenzo Belluomini " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Head And Neck Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454503", "session_name": "Existential distress in Head-and-neck male cancer patients. A comprehensive study of demographic factors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lucas Sanz Monge", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Existential distress in Head-and-neck male cancer patients. A comprehensive study of demographic factors", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Head And Neck Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lucas Sanz Monge ", "kol_full_name": "Lucas Sanz Monge " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Deep Sedation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454501", "session_name": "Nurses’ emotional affect when caring for cancer patients undergoing deep sedation: Findings from a meta-synthesis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Lucia Cadorin", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Campania", "City": "Avellino", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nurses’ emotional affect when caring for cancer patients undergoing deep sedation: Findings from a meta-synthesis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms | Deep Sedation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Lucia Cadorin ", "kol_full_name": "Lucia Cadorin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Anticoagulation | Pulmonary Embolism", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454395", "session_name": "Treatment strategies and duration of anticoagulation in cancer-associated pulmonary embolism", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Luis Jara-Palomares", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Andalucia", "City": "Sevilla ", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment strategies and duration of anticoagulation in cancer-associated pulmonary embolism", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Anticoagulation | Pulmonary Embolism", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Luis Jara-Palomares ", "kol_full_name": "Luis Jara-Palomares " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Liver Neoplasms | Sitravatinib | Tislelizumab | Uveal Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454547", "session_name": "Sitravatinib Plus Tislelizumab for Metastatic Uveal Melanoma with Liver Metastasis: The Open-Label, Multicenter, Phase II GEM-2101 Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Luis Paul De Carpio Huerta", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sitravatinib Plus Tislelizumab for Metastatic Uveal Melanoma with Liver Metastasis: The Open-Label", "rest_events_session_count": 2, "rest_events_session": " Multicenter, Phase II GEM-2101 Trial", "events_topic": "Liver Neoplasms | Sitravatinib ", "rest_events_topic_count": 2, "rest_events_topic": " Tislelizumab | Uveal Melanoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Luis Paul De Carpio Huerta ", "kol_full_name": "Luis Paul De Carpio Huerta " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Psychological Burden", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454363", "session_name": "The fear of recurrence: Best practice in coping with the psychological burden", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Luzia Travado", "middle_name": null, "last_name": null, "org_name": "", "Country": "Portugal", "Region": "Lisboa", "City": "Lisbon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The fear of recurrence: Best practice in coping with the psychological burden", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Psychological Burden", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Luzia Travado ", "kol_full_name": "Luzia Travado " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "DNA Damage", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454697", "session_name": "Targeting the DNA damage response", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Magnus Dillon", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Targeting the DNA damage response", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "DNA Damage", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Magnus Dillon ", "kol_full_name": "Magnus Dillon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biologic Signature", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454374", "session_name": "The elusive CUP biologic signature: are we missing a primary or a biology?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Manel Esteller", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The elusive CUP biologic signature: are we missing a primary or a biology?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biologic Signature", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Manel Esteller ", "kol_full_name": "Manel Esteller " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Pathologic Complete Response | Triple Negative Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454475", "session_name": "Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: a registry-based study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Manon De Graaf", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: a registry-based study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoadjuvant Therapy | Pathologic Complete Response ", "rest_events_topic_count": 1, "rest_events_topic": " Triple Negative Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Manon De Graaf ", "kol_full_name": "Manon De Graaf " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454801", "session_name": "GU tumours, non-prostate", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Manuela Schmidinger", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Wien", "City": "Vienna", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GU tumours", "rest_events_session_count": 1, "rest_events_session": " non-prostate", "events_topic": "Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Manuela Schmidinger ", "kol_full_name": "Manuela Schmidinger " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Programmed Cell Death Ligand 1 | Solid Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454278", "session_name": "Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marc Oliva", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Programmed Cell Death Ligand 1 | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marc Oliva ", "kol_full_name": "Marc Oliva " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Self Care | Antineoplastic Agents | Quality Of Life", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454498", "session_name": "Short term effects of self-care behaviours on quality of life for patients on oral anticancer agents", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marco Di Nitto", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Liguria", "City": "Genova", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Short term effects of self-care behaviours on quality of life for patients on oral anticancer agents", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Self Care | Antineoplastic Agents ", "rest_events_topic_count": 1, "rest_events_topic": " Quality Of Life", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marco Di Nitto ", "kol_full_name": "Marco Di Nitto " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Disease Progression | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454624", "session_name": "Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marco M. Germani", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Toscana", "City": "Pisa", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Disease Progression | Colorectal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marco M. Germani ", "kol_full_name": "Marco M. Germani " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Technology Assessment", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454674", "session_name": "Initiatives for a joint EU HTA assessment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marcus Guardian", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Berlin", "City": "Berlin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Initiatives for a joint EU HTA assessment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Health Technology Assessment", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marcus Guardian ", "kol_full_name": "Marcus Guardian " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Intracellular Antigens", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454437", "session_name": "Should we target surface vs intracellular antigens?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marcus O. Butler", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Should we target surface vs intracellular antigens?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Intracellular Antigens", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marcus O. Butler ", "kol_full_name": "Marcus O. Butler " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Esophageal Neoplasms | Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454748", "session_name": "An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Margaret M. Lee", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "Victoria", "City": "Melbourne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Esophageal Neoplasms | Drug Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Margaret M. Lee ", "kol_full_name": "Margaret M. Lee " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454841", "session_name": "Treatment experience matters: integration of subcutaneous immunotherapy in the clinic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Margarita Majem", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Treatment experience matters: integration of subcutaneous immunotherapy in the clinic", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Margarita Majem ", "kol_full_name": "Margarita Majem " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiotherapy | Temozolomide | Glioblastoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454590", "session_name": "Final Results of Glasdegib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib/II GEINO 1602 trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Angeles Vaz Salgado", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Final Results of Glasdegib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib/II GEINO 1602 trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiotherapy | Temozolomide ", "rest_events_topic_count": 1, "rest_events_topic": " Glioblastoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Angeles Vaz Salgado ", "kol_full_name": "Maria Angeles Vaz Salgado " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nephrectomy | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454746", "session_name": "The role of cytoreductive nephrectomy in the immunotherapy era", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Carmen Mir Maresma", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of cytoreductive nephrectomy in the immunotherapy era", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Nephrectomy | Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Carmen Mir Maresma ", "kol_full_name": "Maria Carmen Mir Maresma " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "ErbB Receptors | Immunoconjugates | Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454408", "session_name": "ABBV-400, a c-Met Protein–Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) With Advanced EGFR Wildtype (WT) Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC): Results From a Phase 1 Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "María De Miguel", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ABBV-400", "rest_events_session_count": 2, "rest_events_session": " a c-Met Protein–Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) With Advanced EGFR Wildtype (WT) Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC): Results From a Phase 1 Study", "events_topic": "ErbB Receptors | Immunoconjugates ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Non-Small-Cell Lung", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
María De Miguel ", "kol_full_name": "María De Miguel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biomarkers | Trastuzumab Deruxtecan", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454633", "session_name": "Unraveling the mechanisms of action and resistance to Trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Fernanda Mosele", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Unraveling the mechanisms of action and resistance to Trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biomarkers | Trastuzumab Deruxtecan", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Fernanda Mosele ", "kol_full_name": "Maria Fernanda Mosele " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454490", "session_name": "The empowering leadership approach in oncology nursing according to work experience", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Giorgia D'Alonzo", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Puglia", "City": "Bari", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The empowering leadership approach in oncology nursing according to work experience", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Giorgia D'Alonzo ", "kol_full_name": "Maria Giorgia D'Alonzo " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454480", "session_name": "Working together: Multidisciplinary management of real-world metastatic breast cancer cases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Lapuente", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Working together: Multidisciplinary management of real-world metastatic breast cancer cases", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Lapuente ", "kol_full_name": "Maria Lapuente " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Translational Research, Biomedical", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454331", "session_name": "Activity and outcomes of a Translational Research Unit coordinated by Nursing.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Pilar Andueza", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Activity and outcomes of a Translational Research Unit coordinated by Nursing.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Translational Research, Biomedical", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Pilar Andueza ", "kol_full_name": "Maria Pilar Andueza " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antigens, Neoplasm", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454400", "session_name": "Tumour antigens derived from bacteria", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Rescigno", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Tumour antigens derived from bacteria", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Antigens, Neoplasm", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Rescigno ", "kol_full_name": "Maria Rescigno " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genes, ErbB-2 | Lymphocytes, Tumor-Infiltrating | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454478", "session_name": "TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maria Vittoria Dieci", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Veneto", "City": "Padova", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Genes, ErbB-2 | Lymphocytes, Tumor-Infiltrating ", "rest_events_topic_count": 1, "rest_events_topic": " Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maria Vittoria Dieci ", "kol_full_name": "Maria Vittoria Dieci " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454847", "session_name": "NSCLC metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Mariana Brandão", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Antwerpen", "City": "Arendonk", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NSCLC metastatic", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Mariana Brandão ", "kol_full_name": "Mariana Brandão " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lutetium Lu 177 Dotatate", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454252", "session_name": "A Multivariate Efficacy Analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marianne E. Pavel", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Bayern", "City": "Erlangen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A Multivariate Efficacy Analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lutetium Lu 177 Dotatate", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marianne E. Pavel ", "kol_full_name": "Marianne E. Pavel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Psychosocial Support Systems", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454730", "session_name": "Psychological support and resilience", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marije Van Der Lee", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Utrecht", "City": "Bilthoven", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Psychological support and resilience", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Psychosocial Support Systems", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marije Van Der Lee ", "kol_full_name": "Marije Van Der Lee " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Prostatic Neoplasms | Nursing Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454639", "session_name": "Comprehensive nursing care for prostate cancer patients: From diagnosis to long-term outcomes", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Mario Varandas", "middle_name": null, "last_name": null, "org_name": "", "Country": "Portugal", "Region": "Lisboa", "City": "Lisbon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Comprehensive nursing care for prostate cancer patients: From diagnosis to long-term outcomes", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Prostatic Neoplasms | Nursing Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Mario Varandas ", "kol_full_name": "Mario Varandas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Macrophages | Brain Neoplasms | Tumor Microenvironment | Lymphocytes, Tumor-Infiltrating", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454589", "session_name": "Characterization of Tumor-infiltrating Lymphocytes and Tumor-Associated Macrophages within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Markus Kleinberger", "middle_name": null, "last_name": null, "org_name": "", "Country": "Austria", "Region": "Wien", "City": "Vienna", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Characterization of Tumor-infiltrating Lymphocytes and Tumor-Associated Macrophages within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Macrophages | Brain Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Tumor Microenvironment | Lymphocytes, Tumor-Infiltrating", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Markus Kleinberger ", "kol_full_name": "Markus Kleinberger " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma, B-Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454371", "session_name": "Diffuse large B cell lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Martin Hutchings", "middle_name": null, "last_name": null, "org_name": "", "Country": "Denmark", "Region": "Kobenhavn", "City": "Copenhagen ", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Diffuse large B cell lymphoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lymphoma, B-Cell", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Martin Hutchings ", "kol_full_name": "Martin Hutchings " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genes, T-Cell Receptor | Pharmacokinetics", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454740", "session_name": "Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Martin Wermke", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Sachsen", "City": "Dresden", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Initial safety", "rest_events_session_count": 4, "rest_events_session": " pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation", "events_topic": "Genes, T-Cell Receptor | Pharmacokinetics", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Martin Wermke ", "kol_full_name": "Martin Wermke " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454561", "session_name": "Cost-effectiveness of optimized immunotherapy dosing", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Marzia Del Re", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Toscana", "City": "Pisa", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cost-effectiveness of optimized immunotherapy dosing", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Marzia Del Re ", "kol_full_name": "Marzia Del Re " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454268", "session_name": "PRO’s as endpoint in early phase clinical trials", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Massimo Di Maio", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Piemonte", "City": "Torino", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "PRO’s as endpoint in early phase clinical trials", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Trial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Massimo Di Maio ", "kol_full_name": "Massimo Di Maio " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radical Surgery | Pancreatic Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454722", "session_name": "Pancreatic NEN: Watchful wait vs radical surgery", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Massimo Falconi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Pancreatic NEN: Watchful wait vs radical surgery", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radical Surgery | Pancreatic Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Massimo Falconi ", "kol_full_name": "Massimo Falconi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Solid Tumors | Cyclin-Dependent Kinases", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454378", "session_name": "Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (Pts) With Advanced Solid Tumors: A Phase 1 Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Matteo Simonelli", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Emilia-Romagna", "City": "Piacenza", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Safety and Tolerability of INCB123667", "rest_events_session_count": 2, "rest_events_session": " a Selective CDK2 Inhibitor, in Patients (Pts) With Advanced Solid Tumors: A Phase 1 Study", "events_topic": "Solid Tumors | Cyclin-Dependent Kinases", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Matteo Simonelli ", "kol_full_name": "Matteo Simonelli " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oligopersistent", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454772", "session_name": "Consolidation in oligo-persistent", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Matthias Guckenberger", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Zurich", "City": "Zurich", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Consolidation in oligo-persistent", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oligopersistent", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Matthias Guckenberger ", "kol_full_name": "Matthias Guckenberger " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nursing Research | Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454497", "session_name": "Cancer nursing research priorities on supportive care in Europe: Results of a mixed methods study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maura Dowling", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Galway", "City": "Galway", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer nursing research priorities on supportive care in Europe: Results of a mixed methods study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Nursing Research | Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maura Dowling ", "kol_full_name": "Maura Dowling " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454229", "session_name": "EU HTA Regulation: State of play for cancer medicines", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Maya Matthews", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "EU HTA Regulation: State of play for cancer medicines", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Medicine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Maya Matthews ", "kol_full_name": "Maya Matthews " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urogenital Neoplasms | Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454827", "session_name": "Optimal biomarker testing in GU cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Melanie J. Costin", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Oxford", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Optimal biomarker testing in GU cancers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Urogenital Neoplasms | Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Melanie J. Costin ", "kol_full_name": "Melanie J. Costin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Mastectomy, Radical | Breast Neoplasms | Body Image", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454488", "session_name": "The Impact of Mindfulness-Based Meditation and Yoga on Stress, Body Image, Self- Esteem and Sexual Adjustment in Breast Cancer Patients Undergoing Modified Radical Mastectomy: A Randomized Controlled Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Melike Pehlivan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Kocaeli", "City": "Kocaeli", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The Impact of Mindfulness-Based Meditation and Yoga on Stress", "rest_events_session_count": 2, "rest_events_session": " Body Image, Self- Esteem and Sexual Adjustment in Breast Cancer Patients Undergoing Modified Radical Mastectomy: A Randomized Controlled Trial", "events_topic": "Mastectomy, Radical | Breast Neoplasms ", "rest_events_topic_count": 1, "rest_events_topic": " Body Image", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Melike Pehlivan ", "kol_full_name": "Melike Pehlivan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nasopharyngeal Carcinoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454422", "session_name": "Individualising induction and concurrent systemic therapy in locally advanced NPC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Melvin Lee Kiang Chua", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Individualising induction and concurrent systemic therapy in locally advanced NPC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Nasopharyngeal Carcinoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Melvin Lee Kiang Chua ", "kol_full_name": "Melvin Lee Kiang Chua " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial | Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454715", "session_name": "Utility of more comprehensive sequencing to identify biomarkers for early phase clinical trials", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Michael Berger", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "New York", "City": "New York", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Utility of more comprehensive sequencing to identify biomarkers for early phase clinical trials", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Trial | Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Michael Berger ", "kol_full_name": "Michael Berger " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Leukemia, Myeloid, Acute | Myelodysplastic Syndromes", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454379", "session_name": "AML/MDS", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Michael Heuser", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Niedersachsen", "City": "Hannover", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "AML/MDS", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Leukemia, Myeloid, Acute | Myelodysplastic Syndromes", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Michael Heuser ", "kol_full_name": "Michael Heuser " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Liquid Biopsy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454455", "session_name": "Liquid biopsy: Promises and challenges", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Michail Ignatiadis", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Liquid biopsy: Promises and challenges", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Liquid Biopsy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Michail Ignatiadis ", "kol_full_name": "Michail Ignatiadis " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454531", "session_name": "Side effects of immunotherapy, and how to deal with patients' health problems", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Michal Jarzab", "middle_name": null, "last_name": null, "org_name": "", "Country": "Poland", "Region": "Slaskie", "City": "Gliwice", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Side effects of immunotherapy", "rest_events_session_count": 1, "rest_events_session": " and how to deal with patients' health problems", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Michal Jarzab ", "kol_full_name": "Michal Jarzab " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cell- And Tissue-Based Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454468", "session_name": "Cellular therapies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Michal Lotem", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "Yerushalayim (Jerusalem)", "City": "Jerusalem", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cellular therapies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cell- And Tissue-Based Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Michal Lotem ", "kol_full_name": "Michal Lotem " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454409", "session_name": "Low dose versus standard dose pembrolizumab for treatment of stage 4 stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Michel Van Den Heuvel", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Gelderland", "City": "Nijmegen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Low dose versus standard dose pembrolizumab for treatment of stage 4 stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Michel Van Den Heuvel ", "kol_full_name": "Michel Van Den Heuvel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy | Neoadjuvant Therapy | Triple Negative Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454476", "session_name": "TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Miguel Martin Jimenez", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy | Neoadjuvant Therapy ", "rest_events_topic_count": 1, "rest_events_topic": " Triple Negative Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Miguel Martin Jimenez ", "kol_full_name": "Miguel Martin Jimenez " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454805", "session_name": "POWG 1: Biomarkers in everyday clinical practice", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Mila Petrova", "middle_name": null, "last_name": null, "org_name": "", "Country": "Bulgaria", "Region": "Sofiya", "City": "Sofia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "POWG 1: Biomarkers in everyday clinical practice", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Mila Petrova ", "kol_full_name": "Mila Petrova " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Stomach Neoplasms | Molecular Diagnostic Techniques | Esophageal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454471", "session_name": "Molecular testing in gastric and oesophageal cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Minsuk Kwon", "middle_name": null, "last_name": null, "org_name": "", "Country": "Korea, South", "Region": "Kyonggi-do", "City": "Suwon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Molecular testing in gastric and oesophageal cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Stomach Neoplasms | Molecular Diagnostic Techniques ", "rest_events_topic_count": 1, "rest_events_topic": " Esophageal Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Minsuk Kwon ", "kol_full_name": "Minsuk Kwon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Central Nervous System Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454799", "session_name": "CNS tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Monika E. Hegi", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CNS tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Central Nervous System Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Monika E. Hegi ", "kol_full_name": "Monika E. Hegi " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454876", "session_name": "Survivors of advanced melanoma: Management and support", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Mora Guardamagna", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Andalucia", "City": "Malaga", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Survivors of advanced melanoma: Management and support", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Mora Guardamagna ", "kol_full_name": "Mora Guardamagna " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Hematopoiesis | Receptors, Chimeric Antigen", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454240", "session_name": "CAR T cells reside in the bone marrow and inhibits healthy hematopoiesis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Myriam Ben Khelil", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Franche-Comte", "City": "Besancon", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CAR T cells reside in the bone marrow and inhibits healthy hematopoiesis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Hematopoiesis | Receptors, Chimeric Antigen", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Myriam Ben Khelil ", "kol_full_name": "Myriam Ben Khelil " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Randomized Controlled Trials As Topic | Terminal Cancer | Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454544", "session_name": "A multicenter, randomized controlled trial (RCT) on the efficacy of specialized rehabilitation using the Op-reha Guide for terminal cancer patients in palliative care units (PCUs)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nanako Nishiyama", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Osaka", "City": "Higashiosaka", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A multicenter", "rest_events_session_count": 1, "rest_events_session": " randomized controlled trial (RCT) on the efficacy of specialized rehabilitation using the Op-reha Guide for terminal cancer patients in palliative care units (PCUs)", "events_topic": "Randomized Controlled Trials As Topic | Terminal Cancer ", "rest_events_topic_count": 1, "rest_events_topic": " Palliative Care", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nanako Nishiyama ", "kol_full_name": "Nanako Nishiyama " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454653", "session_name": "Experiences from the war in Ukraine from a patient perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nataliia Hrad", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ukraine", "Region": "Misto Kyyiv", "City": "Kiev", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Experiences from the war in Ukraine from a patient perspective", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Patient Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nataliia Hrad ", "kol_full_name": "Nataliia Hrad " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Public Health", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454857", "session_name": "ESMO-MCBS: A practical tool with public health implications", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nathan I. Cherny", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "Yerushalayim (Jerusalem)", "City": "Jerusalem", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO-MCBS: A practical tool with public health implications", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Public Health", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nathan I. Cherny ", "kol_full_name": "Nathan I. Cherny " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Hematologic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454558", "session_name": "Two Hematological Precursors and Their Impact on Hematological Malignancies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nicholas J. Boddicker", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Minnesota", "City": "Rochester", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Two Hematological Precursors and Their Impact on Hematological Malignancies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Hematologic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nicholas J. Boddicker ", "kol_full_name": "Nicholas J. Boddicker " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Doxorubicin | Regorafenib | Placebos | Sarcoma | Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454718", "session_name": "EREMISS Trial: a double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of Regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts).", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nicolas Penel", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Nord-Pas-de-Calais", "City": "Lille", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "EREMISS Trial: a double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of Regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts).", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Doxorubicin | Regorafenib ", "rest_events_topic_count": 3, "rest_events_topic": " Placebos | Sarcoma | Drug Therapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nicolas Penel ", "kol_full_name": "Nicolas Penel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Antineoplastic Agents | Dug Exposure", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454560", "session_name": "The advantages of boosting studies to increase drug exposure of anticancer drugs", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nielka Van Erp", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Gelderland", "City": "Nijmegen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The advantages of boosting studies to increase drug exposure of anticancer drugs", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Antineoplastic Agents | Dug Exposure", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nielka Van Erp ", "kol_full_name": "Nielka Van Erp " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Multiple Myeloma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454380", "session_name": "Multiple myeloma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Niels W. Van De Donk", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Multiple myeloma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Multiple Myeloma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Niels W. Van De Donk ", "kol_full_name": "Niels W. Van De Donk " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasm Metastasis | Decision Making", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454744", "session_name": "Liquid profiling of molecular metastatic disease and impact on decision making", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Noelia Tarazona Llavero", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Liquid profiling of molecular metastatic disease and impact on decision making", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasm Metastasis | Decision Making", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Noelia Tarazona Llavero ", "kol_full_name": "Noelia Tarazona Llavero " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pseudoprogression | Radionecrosis", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454389", "session_name": "Radionecrosis and pseudoprogression", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Norbert Galldiks", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Nordrhein-Westfalen", "City": "Koeln", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Radionecrosis and pseudoprogression", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pseudoprogression | Radionecrosis", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Norbert Galldiks ", "kol_full_name": "Norbert Galldiks " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Spiritual Interventions", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454502", "session_name": "An Updated Evidence on the Effects of Spiritual Interventions in Cancer: A Systematic Review with Meta-analysis", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Nur Izgu", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Ankara", "City": "Ankara", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "An Updated Evidence on the Effects of Spiritual Interventions in Cancer: A Systematic Review with Meta-analysis", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Spiritual Interventions", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Nur Izgu ", "kol_full_name": "Nur Izgu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cell- And Tissue-Based Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454594", "session_name": "Non-cellular therapies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Olivier A. Michielin", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Geneve", "City": "Geneva", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Non-cellular therapies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cell- And Tissue-Based Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Olivier A. Michielin ", "kol_full_name": "Olivier A. Michielin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pancreatic Neoplasms | Somatic Mutation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454413", "session_name": "The somatic mutation landscape of the normal and malignant pancreas", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Pantelis A. Nicola", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The somatic mutation landscape of the normal and malignant pancreas", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pancreatic Neoplasms | Somatic Mutation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Pantelis A. Nicola ", "kol_full_name": "Pantelis A. Nicola " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Spartalizumab | Cutaneous Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454548", "session_name": "Phase 1 study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Paolo A. Ascierto", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Campania", "City": "Napoli", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase 1 study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Spartalizumab | Cutaneous Melanoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Paolo A. Ascierto ", "kol_full_name": "Paolo A. Ascierto " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Multiple Myeloma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454369", "session_name": "Myeloma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Paula Rodriguez-Otero", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Myeloma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Multiple Myeloma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Paula Rodriguez-Otero ", "kol_full_name": "Paula Rodriguez-Otero " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Precision Medicine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454843", "session_name": "Integrating precision medicine / ESCAT in your choice of treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Pawel Sobczuk", "middle_name": null, "last_name": null, "org_name": "", "Country": "Poland", "Region": "Mazowieckie", "City": "Warsaw", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Integrating precision medicine / ESCAT in your choice of treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Precision Medicine", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Pawel Sobczuk ", "kol_full_name": "Pawel Sobczuk " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454527", "session_name": "The European Cancer Patient Digital Centre", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Penilla Gunther", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Stockholms Lan", "City": "Stockholm", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The European Cancer Patient Digital Centre", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Penilla Gunther ", "kol_full_name": "Penilla Gunther " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nivolumab | Neoadjuvant Therapy | Colonic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454621", "session_name": "Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Peter G. De Gooyer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Nivolumab | Neoadjuvant Therapy ", "rest_events_topic_count": 1, "rest_events_topic": " Colonic Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Peter G. De Gooyer ", "kol_full_name": "Peter G. De Gooyer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms | Receptors, Estrogen", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454870", "session_name": "Incorporating novel treatment insights for ER+ early BC patients", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Petra Tesarova", "middle_name": null, "last_name": null, "org_name": "", "Country": "Czech Republic", "Region": "Hlavni Mesto Praha", "City": "Prague", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Incorporating novel treatment insights for ER+ early BC patients", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms | Receptors, Estrogen", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Petra Tesarova ", "kol_full_name": "Petra Tesarova " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms | Aromatase Inhibitors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454541", "session_name": "Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC).", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Pietro Lapidari", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC).", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms | Aromatase Inhibitors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Pietro Lapidari ", "kol_full_name": "Pietro Lapidari " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Axitinib | Avelumab | Cell Division | Gastrointestinal Stromal Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454261", "session_name": "Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: single-arm phase II study (AXAGIST)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Piotr Rutkowski", "middle_name": null, "last_name": null, "org_name": "", "Country": "Poland", "Region": "Mazowieckie", "City": "Warsaw", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: single-arm phase II study (AXAGIST)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Axitinib | Avelumab ", "rest_events_topic_count": 2, "rest_events_topic": " Cell Division | Gastrointestinal Stromal Tumors", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Piotr Rutkowski ", "kol_full_name": "Piotr Rutkowski " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Leukemia", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454644", "session_name": "Parents’ lived experience of children with leukemia", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Qasem Alnasser", "middle_name": null, "last_name": null, "org_name": "", "Country": "Saudi Arabia", "Region": "Ar Riyad", "City": "Riyadh", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Parents’ lived experience of children with leukemia", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Leukemia", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Qasem Alnasser ", "kol_full_name": "Qasem Alnasser " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Osteosarcoma | Antiangiogenics | Drug Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454262", "session_name": "The Final Results of Pulmonary Resectable Metastases of Osteosarcoma With Antiangiogenic and CHemotherapy (PROACH)： An open-label, single-arm phase 2 clinical trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Qiyuan Bao", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The Final Results of Pulmonary Resectable Metastases of Osteosarcoma With Antiangiogenic and CHemotherapy (PROACH)： An open-label", "rest_events_session_count": 1, "rest_events_session": " single-arm phase 2 clinical trial", "events_topic": "Osteosarcoma | Antiangiogenics ", "rest_events_topic_count": 1, "rest_events_topic": " Drug Therapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Qiyuan Bao ", "kol_full_name": "Qiyuan Bao " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Patient-Centered Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454513", "session_name": "Difference between patient-centred and person-centred care: Patient advocate perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rachel Giles", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Vlaardingen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Difference between patient-centred and person-centred care: Patient advocate perspective", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Patient-Centered Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rachel Giles ", "kol_full_name": "Rachel Giles " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Esophageal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454871", "session_name": "Management of oligometastatic gastroesophageal cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Radka L. Obermannova", "middle_name": null, "last_name": null, "org_name": "", "Country": "Czech Republic", "Region": "Jihomoravsky Kraj", "City": "Brno", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of oligometastatic gastroesophageal cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Esophageal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Radka L. Obermannova ", "kol_full_name": "Radka L. Obermannova " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biomarkers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454368", "session_name": "Biomarkers in daily practice", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Radu A. Vidra", "middle_name": null, "last_name": null, "org_name": "", "Country": "Romania", "Region": "Cluj", "City": "Cluj-Napoca", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Biomarkers in daily practice", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biomarkers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Radu A. Vidra ", "kol_full_name": "Radu A. Vidra " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Toxicity | Cancer Treatment", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454226", "session_name": "Time toxicity of cancer treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Raffaele Giusti", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lazio", "City": "Rome", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Time toxicity of cancer treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Toxicity | Cancer Treatment", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Raffaele Giusti ", "kol_full_name": "Raffaele Giusti " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454320", "session_name": "Social disparities in the survival of women with breast cancer in Brazil", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Raphael Manhaes Pessanha", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Pais Vasco", "City": "Vitoria", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Social disparities in the survival of women with breast cancer in Brazil", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Raphael Manhaes Pessanha ", "kol_full_name": "Raphael Manhaes Pessanha " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Hematologic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454655", "session_name": "Use of digital symptom reporting in haematological patients", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Raul Cordoba Mascunano", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Use of digital symptom reporting in haematological patients", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Hematologic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Raul Cordoba Mascunano ", "kol_full_name": "Raul Cordoba Mascunano " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Personalized Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454829", "session_name": "ESMO-SIOG: Working together in the era of personalized care for older adults with cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ravindran Kanesvaran", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ESMO-SIOG: Working together in the era of personalized care for older adults with cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Personalized Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ravindran Kanesvaran ", "kol_full_name": "Ravindran Kanesvaran " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cell-Free Nucleic Acids", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454416", "session_name": "Cancer treatment monitoring using cell-free DNA fragmentomes", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Remond Fijneman", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Cancer treatment monitoring using cell-free DNA fragmentomes", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cell-Free Nucleic Acids", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Remond Fijneman ", "kol_full_name": "Remond Fijneman " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Qualitative Research", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454328", "session_name": "Staying or Leaving the Pediatric Oncology Clinic: Nurses' Challenges in Care and Voices of Struggle: A Qualitative Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Remziye Semerci", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Istanbul", "City": "Istanbul", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Staying or Leaving the Pediatric Oncology Clinic: Nurses' Challenges in Care and Voices of Struggle: A Qualitative Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Qualitative Research", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Remziye Semerci ", "kol_full_name": "Remziye Semerci " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Liver Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454734", "session_name": "Patients with liver metastases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "René Adam", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Patients with liver metastases", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Liver Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
René Adam ", "kol_full_name": "René Adam " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tryptophan Depletion | Neoantigens", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454275", "session_name": "Neoantigens derived from tryptophan depletion", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Reuven Agami", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neoantigens derived from tryptophan depletion", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Tryptophan Depletion | Neoantigens", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Reuven Agami ", "kol_full_name": "Reuven Agami " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454642", "session_name": "Scoping review of the interventions for promoting dyadic adjustment in adult cancer patients and their partners", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Reyyan Gürel", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Ankara", "City": "Ankara", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Scoping review of the interventions for promoting dyadic adjustment in adult cancer patients and their partners", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Reyyan Gürel ", "kol_full_name": "Reyyan Gürel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Bone Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454733", "session_name": "Patients with bone metastases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Robbe Van Den Begin", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Antwerpen", "City": "Arendonk", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Patients with bone metastases", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Bone Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Robbe Van Den Begin ", "kol_full_name": "Robbe Van Den Begin " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Prevention", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454230", "session_name": "Prevention", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Robert Benamouzig", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Boulogne-Billancourt", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Prevention", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cancer Prevention", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Robert Benamouzig ", "kol_full_name": "Robert Benamouzig " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Research", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454349", "session_name": "How to utilise open data sources to start research projects?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rodrigo Dienstmann", "middle_name": null, "last_name": null, "org_name": "", "Country": "Brazil", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "How to utilise open data sources to start research projects?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Research", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rodrigo Dienstmann ", "kol_full_name": "Rodrigo Dienstmann " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Early Detection Of Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454342", "session_name": "Innovations in cancer screening: Emerging technologies and their clinical impact", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Roxana Albu", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Innovations in cancer screening: Emerging technologies and their clinical impact", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Early Detection Of Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Roxana Albu ", "kol_full_name": "Roxana Albu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Biomarkers | Artificial Intelligence | Clinical Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454550", "session_name": "Novel AI-enabled strategies in biomarker-informed clinical trials", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rudolf S. Fehrmann", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Groningen", "City": "Groningen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Novel AI-enabled strategies in biomarker-informed clinical trials", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Biomarkers | Artificial Intelligence ", "rest_events_topic_count": 1, "rest_events_topic": " Clinical Trial", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rudolf S. Fehrmann ", "kol_full_name": "Rudolf S. Fehrmann " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "CLDN18 Protein, Human | Immunoconjugates | Esophagogastric Junction", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454583", "session_name": "CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Rui-Hua Xu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Guangdong", "City": "Guangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "CLDN18.2 targeted antibody-drug conjugate (ADC)", "rest_events_session_count": 2, "rest_events_session": " SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study", "events_topic": "CLDN18 Protein, Human | Immunoconjugates ", "rest_events_topic_count": 1, "rest_events_topic": " Esophagogastric Junction", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Rui-Hua Xu ", "kol_full_name": "Rui-Hua Xu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Solid Tumors | Cetuximab | Pembrolizumab", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454290", "session_name": "Final results from Phase 1, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ruth Perets", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Final results from Phase 1", "rest_events_session_count": 5, "rest_events_session": " first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors", "events_topic": "Solid Tumors | Cetuximab ", "rest_events_topic_count": 1, "rest_events_topic": " Pembrolizumab", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ruth Perets ", "kol_full_name": "Ruth Perets " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Pembrolizumab | Sotigalimab | Melanoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454709", "session_name": "Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: a phase 1/2 trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Salah-Eddine Bentebibel", "middle_name": null, "last_name": null, "org_name": "", "Country": "United States", "Region": "Texas", "City": "Houston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: a phase 1/2 trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Pembrolizumab | Sotigalimab ", "rest_events_topic_count": 1, "rest_events_topic": " Melanoma", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Salah-Eddine Bentebibel ", "kol_full_name": "Salah-Eddine Bentebibel " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sotorasib | KRAS Protein, Human | Panitumumab | Colorectal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454623", "session_name": "Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Salvatore Siena", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sotorasib (soto)", "rest_events_session_count": 1, "rest_events_session": " panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study", "events_topic": "Sotorasib | KRAS Protein, Human ", "rest_events_topic_count": 2, "rest_events_topic": " Panitumumab | Colorectal Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Salvatore Siena ", "kol_full_name": "Salvatore Siena " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454881", "session_name": "Breast cancer, metastatic", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sandra Ximena Franco Millan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Colombia", "Region": "Distrito Capital", "City": "Bogota", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Breast cancer", "rest_events_session_count": 1, "rest_events_session": " metastatic", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sandra Ximena Franco Millan ", "kol_full_name": "Sandra Ximena Franco Millan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Testicular Germ Cell Tumor", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454509", "session_name": "From Surviving Cancer to Getting on With Life: Adult Testicular Germ Cell Tumor Survivors’ Perspectives on Transition From Follow-Up Care to Long-Term Survivorship", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sandrien Van Geel-Weda", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Utrecht", "City": "Utrecht", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "From Surviving Cancer to Getting on With Life: Adult Testicular Germ Cell Tumor Survivors’ Perspectives on Transition From Follow-Up Care to Long-Term Survivorship", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Testicular Germ Cell Tumor", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sandrien Van Geel-Weda ", "kol_full_name": "Sandrien Van Geel-Weda " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Service, Hospital | Patient-Centered Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454335", "session_name": "Optimizing the role of advanced practice nurses at the core of precision health: Achieving comprehensive, patient-centred cancer services", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sara Colomer-Lahiguera", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Vaud", "City": "Lausanne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Optimizing the role of advanced practice nurses at the core of precision health: Achieving comprehensive", "rest_events_session_count": 1, "rest_events_session": " patient-centred cancer services", "events_topic": "Oncology Service, Hospital | Patient-Centered Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sara Colomer-Lahiguera ", "kol_full_name": "Sara Colomer-Lahiguera " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454873", "session_name": "NETs and endocrine tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sara De Dosso", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Ticino", "City": "Bellinzona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NETs and endocrine tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sara De Dosso ", "kol_full_name": "Sara De Dosso " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Rehabilitation | Radiotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454661", "session_name": "Rehabilitation in radiotherapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sara Faithfull", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Rehabilitation in radiotherapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Rehabilitation | Radiotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sara Faithfull ", "kol_full_name": "Sara Faithfull " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Medicine Platform", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454355", "session_name": "WHO Novel Medicine Platform", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sarah Garner", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Geneve", "City": "Geneva", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "WHO Novel Medicine Platform", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Medicine Platform", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sarah Garner ", "kol_full_name": "Sarah Garner " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Self Care | Prostatic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454511", "session_name": "Health literacy and self-management behaviours among prostate cancer survivors: A systematic review", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sarah Sheehan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Ireland", "Region": "Dublin", "City": "Dublin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Health literacy and self-management behaviours among prostate cancer survivors: A systematic review", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Self Care | Prostatic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sarah Sheehan ", "kol_full_name": "Sarah Sheehan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Clinical Trial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454519", "session_name": "Are adaptive trial design and platform studies widely applicable? Tips from statistician", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Saskia Litiere", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Brussels", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Are adaptive trial design and platform studies widely applicable? Tips from statistician", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Clinical Trial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Saskia Litiere ", "kol_full_name": "Saskia Litiere " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Gastrointestinal Stromal Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454412", "session_name": "Landmark trials in GIST", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sebastian Bauer", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Nordrhein-Westfalen", "City": "Essen", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Landmark trials in GIST", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Gastrointestinal Stromal Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sebastian Bauer ", "kol_full_name": "Sebastian Bauer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors | Ramucirumab | Dacarbazine", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454251", "session_name": "Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sebastian Krug", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Sachsen", "City": "Leipzig", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neuroendocrine Tumors | Ramucirumab ", "rest_events_topic_count": 1, "rest_events_topic": " Dacarbazine", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sebastian Krug ", "kol_full_name": "Sebastian Krug " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454680", "session_name": "Neural influences on immunotherapies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sebastien Talbot", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Kingston", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neural influences on immunotherapies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sebastien Talbot ", "kol_full_name": "Sebastien Talbot " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncology Nursing", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454854", "session_name": "Building up resilience in cancer nursing: Strategies and skills", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Selma Islamcevic", "middle_name": null, "last_name": null, "org_name": "", "Country": "Croatia", "Region": "Grad Zagreb", "City": "Zagreb", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Building up resilience in cancer nursing: Strategies and skills", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oncology Nursing", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Selma Islamcevic ", "kol_full_name": "Selma Islamcevic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Fluorodeoxyglucose F18 | Positron Emission Tomography Computed Tomography | Lymphoma, Large B-Cell, Diffuse | Immunotherapy, Adoptive | Receptors, Chimeric Antigen", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454244", "session_name": "Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Seyed Ali Mirshahvalad", "middle_name": null, "last_name": null, "org_name": "", "Country": "Canada", "Region": "Ontario", "City": "Toronto", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Fluorodeoxyglucose F18 | Positron Emission Tomography Computed Tomography ", "rest_events_topic_count": 3, "rest_events_topic": " Lymphoma, Large B-Cell, Diffuse | Immunotherapy, Adoptive | Receptors, Chimeric Antigen", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Seyed Ali Mirshahvalad ", "kol_full_name": "Seyed Ali Mirshahvalad " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Palliative Care", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454867", "session_name": "Supportive and palliative care", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Shani Paluch-Shimon", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "Yerushalayim (Jerusalem)", "City": "Jerusalem", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Supportive and palliative care", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Palliative Care", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Shani Paluch-Shimon ", "kol_full_name": "Shani Paluch-Shimon " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Health Personnel", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454338", "session_name": "Talking about sex after cancer: Adapting, testing and evaluating an eLearning resource to enhance healthcare professional provision of sexual support for patients with cancer and their partners", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sharon L. Bingham", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "Northern Ireland", "City": "Belfast", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Talking about sex after cancer: Adapting", "rest_events_session_count": 1, "rest_events_session": " testing and evaluating an eLearning resource to enhance healthcare professional provision of sexual support for patients with cancer and their partners", "events_topic": "Health Personnel", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sharon L. Bingham ", "kol_full_name": "Sharon L. Bingham " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Randomized Controlled Trials As Topic | Smoking Cessation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454656", "session_name": "Efficacy of Digital Health Intervention in Smoking Cessation: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Shen Li", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Sichuan", "City": "Chengdu", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Efficacy of Digital Health Intervention in Smoking Cessation: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Randomized Controlled Trials As Topic | Smoking Cessation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Shen Li ", "kol_full_name": "Shen Li " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Paclitaxel | Carcinoma, Non-Small-Cell Lung | Chemoradiotherapy | Carboplatin", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454758", "session_name": "A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Shota Omori", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Oita", "City": "Oita", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Paclitaxel | Carcinoma, Non-Small-Cell Lung ", "rest_events_topic_count": 2, "rest_events_topic": " Chemoradiotherapy | Carboplatin", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Shota Omori ", "kol_full_name": "Shota Omori " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nasopharyngeal Carcinoma | Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454711", "session_name": "Longitudinal probing of combinatorial immunotherapy (anti-VEGF/anti-PD1) response in advanced nasopharyngeal carcinoma, at single cell resolution", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Shu-Mei Chia", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Longitudinal probing of combinatorial immunotherapy (anti-VEGF/anti-PD1) response in advanced nasopharyngeal carcinoma", "rest_events_session_count": 1, "rest_events_session": " at single cell resolution", "events_topic": "Nasopharyngeal Carcinoma | Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Shu-Mei Chia ", "kol_full_name": "Shu-Mei Chia " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Osimertinib | ErbB Receptors | Carcinoma, Non-Small-Cell Lung | Chemoradiotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454753", "session_name": "Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the Phase 3 LAURA study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Shun Lu", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the Phase 3 LAURA study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Osimertinib | ErbB Receptors ", "rest_events_topic_count": 2, "rest_events_topic": " Carcinoma, Non-Small-Cell Lung | Chemoradiotherapy", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Shun Lu ", "kol_full_name": "Shun Lu " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Fulvestrant | Triple Negative Breast Neoplasms | Endocrine Therapy | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454777", "session_name": "Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Shusen Wang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Guangdong", "City": "Guangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized", "rest_events_session_count": 3, "rest_events_session": " multicenter, double-blind, phase III study", "events_topic": "Fulvestrant | Triple Negative Breast Neoplasms ", "rest_events_topic_count": 2, "rest_events_topic": " Endocrine Therapy | Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Shusen Wang ", "kol_full_name": "Shusen Wang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Osteosarcoma | Sarcoma, Synovial", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454411", "session_name": "Landmark trials in bone and joint sarcomas", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Silvia Stacchiotti", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Landmark trials in bone and joint sarcomas", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Osteosarcoma | Sarcoma, Synovial", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Silvia Stacchiotti ", "kol_full_name": "Silvia Stacchiotti " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Genital Neoplasms, Female | Endometrial Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454804", "session_name": "Improving the experience of care for women with gynaecological cancers: Lessons from cervical and endometrial cancer policy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Silvija Piskorjanac", "middle_name": null, "last_name": null, "org_name": "", "Country": "Croatia", "Region": "Osjecko-Baranjska", "City": "Osijek", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Improving the experience of care for women with gynaecological cancers: Lessons from cervical and endometrial cancer policy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Genital Neoplasms, Female | Endometrial Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Silvija Piskorjanac ", "kol_full_name": "Silvija Piskorjanac " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454726", "session_name": "Ectopic cushing and neuroendocrine neoplasms", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Simona Glasberg", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "Yerushalayim (Jerusalem)", "City": "Jerusalem", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Ectopic cushing and neuroendocrine neoplasms", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Simona Glasberg ", "kol_full_name": "Simona Glasberg " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cancer Survivors | Randomized Controlled Trials As Topic | Fatigue", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454662", "session_name": "The Effect of an Empowerment Program on Ruminative Thoughts, Fatigue and Psychological Resilience of Cancer Survivors: A randomized controlled trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sinem Öcalan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Ankara", "City": "Ankara", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The Effect of an Empowerment Program on Ruminative Thoughts", "rest_events_session_count": 1, "rest_events_session": " Fatigue and Psychological Resilience of Cancer Survivors: A randomized controlled trial", "events_topic": "Cancer Survivors | Randomized Controlled Trials As Topic ", "rest_events_topic_count": 1, "rest_events_topic": " Fatigue", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sinem Öcalan ", "kol_full_name": "Sinem Öcalan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454773", "session_name": "Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sofia Rivera", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sofia Rivera ", "kol_full_name": "Sofia Rivera " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "CTLA-4 Antigen | Programmed Cell Death 1 Receptor", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454582", "session_name": "Moving on from PD-1-CTLA-4 blockade", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sophia Yien Ning Wong", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Moving on from PD-1-CTLA-4 blockade", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "CTLA-4 Antigen | Programmed Cell Death 1 Receptor", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sophia Yien Ning Wong ", "kol_full_name": "Sophia Yien Ning Wong " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454798", "session_name": "NETs and endocrine tumours", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sophie Leboulleux", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Geneve", "City": "Geneva", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "NETs and endocrine tumours", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Endocrine Gland Neoplasms | Neuroendocrine Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sophie Leboulleux ", "kol_full_name": "Sophie Leboulleux " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oligometastases", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454618", "session_name": "The role of the surgeon in resecting oligometastases", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Stefan Mönig", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Geneve", "City": "Geneva", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of the surgeon in resecting oligometastases", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Oligometastases", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Stefan Mönig ", "kol_full_name": "Stefan Mönig " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Disease Progression", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454699", "session_name": "What are the types of progression?", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Stephane Champiat", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "What are the types of progression?", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Disease Progression", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Stephane Champiat ", "kol_full_name": "Stephane Champiat " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Ovarian Function Tests | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454473", "session_name": "Ovarian Function Suppression in HR-positive, HER2-positive Breast Cancer: An Exploratory Analysis from the HERA Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sung Gwe Ahn", "middle_name": null, "last_name": null, "org_name": "", "Country": "Korea, South", "Region": "Kyonggi-do", "City": "Seoul", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Ovarian Function Suppression in HR-positive", "rest_events_session_count": 1, "rest_events_session": " HER2-positive Breast Cancer: An Exploratory Analysis from the HERA Trial", "events_topic": "Ovarian Function Tests | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sung Gwe Ahn ", "kol_full_name": "Sung Gwe Ahn " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiotherapy | Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454752", "session_name": "The role of radiotherapy in earlier stage NSCLC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Suresh Senan", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The role of radiotherapy in earlier stage NSCLC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiotherapy | Carcinoma, Non-Small-Cell Lung", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Suresh Senan ", "kol_full_name": "Suresh Senan " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiotherapy | Meningioma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454565", "session_name": "Controversies in radiotherapy for meningioma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Susan Short", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Leeds", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Controversies in radiotherapy for meningioma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiotherapy | Meningioma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Susan Short ", "kol_full_name": "Susan Short " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urinary Bladder Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454626", "session_name": "Histology subtypes (variants) of bladder cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Syed A. Hussain", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Sheffield", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Histology subtypes (variants) of bladder cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Urinary Bladder Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Syed A. Hussain ", "kol_full_name": "Syed A. Hussain " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Surgical Procedures, Operative", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454570", "session_name": "Impact on surgery: Extremities and other sites", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Sylvie Bonvalot", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Impact on surgery: Extremities and other sites", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Surgical Procedures, Operative", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Sylvie Bonvalot ", "kol_full_name": "Sylvie Bonvalot " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Organ Preservation | Adenocarcinoma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454432", "session_name": "Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Syrine Ben Dhia", "middle_name": null, "last_name": null, "org_name": "", "Country": "Tunisia", "Region": "Tunis", "City": "Tunis", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Organ Preservation | Adenocarcinoma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Syrine Ben Dhia ", "kol_full_name": "Syrine Ben Dhia " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Conflict, Psychological", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454654", "session_name": "Nursing with limited resources during an ongoing conflict", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Tamer J. Jafar", "middle_name": null, "last_name": null, "org_name": "", "Country": "Israel", "Region": "Yerushalayim (Jerusalem)", "City": "Palestine", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Nursing with limited resources during an ongoing conflict", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Conflict, Psychological", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Tamer J. Jafar ", "kol_full_name": "Tamer J. Jafar " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Gastrointestinal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454864", "session_name": "GI tumours, upper digestive", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Tania C. Fleitas", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Valenciana", "City": "Valencia", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "GI tumours", "rest_events_session_count": 1, "rest_events_session": " upper digestive", "events_topic": "Gastrointestinal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Tania C. Fleitas ", "kol_full_name": "Tania C. Fleitas " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Systemic Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454747", "session_name": "Systemic treatment options", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Teresa Alonso Gordoa", "middle_name": null, "last_name": null, "org_name": "", "Country": "Spain", "Region": "Madrid", "City": "Madrid", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Systemic treatment options", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Systemic Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Teresa Alonso Gordoa ", "kol_full_name": "Teresa Alonso Gordoa " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Diagnostic Imaging", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454417", "session_name": "Challenges and novel avenues of imaging ILC", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Thiemo Van Nijnatten", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Limburg", "City": "Maastricht", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Challenges and novel avenues of imaging ILC", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Diagnostic Imaging", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Thiemo Van Nijnatten ", "kol_full_name": "Thiemo Van Nijnatten " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endometrial Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454341", "session_name": "Improving the future of care for women with endometrial cancer – IHE report", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Thomas Hofmarcher", "middle_name": null, "last_name": null, "org_name": "", "Country": "Sweden", "Region": "Skane Lan", "City": "Lund", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Improving the future of care for women with endometrial cancer – IHE report", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Endometrial Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Thomas Hofmarcher ", "kol_full_name": "Thomas Hofmarcher " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Adjuvant Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454759", "session_name": "Update on adjuvant treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Tim Meyer", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "London", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Update on adjuvant treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Adjuvant Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Tim Meyer ", "kol_full_name": "Tim Meyer " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Artificial Intelligence", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454444", "session_name": "Artificial intelligence applications", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Tjalling Bosse", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Zuid-Holland", "City": "Leiden", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Artificial intelligence applications", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Artificial Intelligence", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Tjalling Bosse ", "kol_full_name": "Tjalling Bosse " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Endometrial Neoplasms | Uterine Cervical Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454286", "session_name": "ADCs in endometrial and cervical cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Toon Van Gorp", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Brussels", "City": "Leuven", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "ADCs in endometrial and cervical cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Endometrial Neoplasms | Uterine Cervical Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Toon Van Gorp ", "kol_full_name": "Toon Van Gorp " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms | Early Detection Of Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454299", "session_name": "The current state-of-the-art in lung cancer screening", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Torsten Blum", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Berlin", "City": "Berlin", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The current state-of-the-art in lung cancer screening", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Neoplasms | Early Detection Of Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Torsten Blum ", "kol_full_name": "Torsten Blum " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Esophageal Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454825", "session_name": "Management of oligometastatic gastroesophageal cancer", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Trevor Leong", "middle_name": null, "last_name": null, "org_name": "", "Country": "Australia", "Region": "Victoria", "City": "Melbourne", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Management of oligometastatic gastroesophageal cancer", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Esophageal Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Trevor Leong ", "kol_full_name": "Trevor Leong " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454323", "session_name": "'I thought I was probably going to die due to people's looking at me with pity’: A Phenomenological Qualitative Study on the Lived Cancer Stigma Experiences of Breast Cancer Patients", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Tugba Pehlivan Saribudak", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Istanbul", "City": "Istanbul", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "'I thought I was probably going to die due to people's looking at me with pity’: A Phenomenological Qualitative Study on the Lived Cancer Stigma Experiences of Breast Cancer Patients", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Tugba Pehlivan Saribudak ", "kol_full_name": "Tugba Pehlivan Saribudak " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Virtual Reality", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454327", "session_name": "The Effectiveness of Virtual Reality Use in Cancer Patients: A Systematic Review", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Tugce Ucgun", "middle_name": null, "last_name": null, "org_name": "", "Country": "Turkey", "Region": "Ankara", "City": "Ankara", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The Effectiveness of Virtual Reality Use in Cancer Patients: A Systematic Review", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Virtual Reality", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Tugce Ucgun ", "kol_full_name": "Tugce Ucgun " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Molecular Targeted Therapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454580", "session_name": "AI guided combinations using targeted therapy", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Udai Banerji", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Sutton", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "AI guided combinations using targeted therapy", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Molecular Targeted Therapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Udai Banerji ", "kol_full_name": "Udai Banerji " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms | Early Detection Of Cancer", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454859", "session_name": "Lung cancer interception: New approaches to lung cancer screening and prevention", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ugo Pastorino", "middle_name": null, "last_name": null, "org_name": "", "Country": "Italy", "Region": "Lombardia", "City": "Milano", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Lung cancer interception: New approaches to lung cancer screening and prevention", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Neoplasms | Early Detection Of Cancer", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ugo Pastorino ", "kol_full_name": "Ugo Pastorino " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Placebos | PIK3CA Protein, Human | Colonic Neoplasms | Aspirin", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454435", "session_name": "Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ulrich Güller", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Bern", "City": "Thun", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III", "rest_events_session_count": 1, "rest_events_session": " Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial", "events_topic": "Placebos | PIK3CA Protein, Human ", "rest_events_topic_count": 2, "rest_events_topic": " Colonic Neoplasms | Aspirin", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ulrich Güller ", "kol_full_name": "Ulrich Güller " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Urogenital Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454793", "session_name": "Genitourinary tumours, prostate", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Ursula Vogl", "middle_name": null, "last_name": null, "org_name": "", "Country": "Switzerland", "Region": "Ticino", "City": "Bellinzona", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Genitourinary tumours", "rest_events_session_count": 1, "rest_events_session": " prostate", "events_topic": "Urogenital Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Ursula Vogl ", "kol_full_name": "Ursula Vogl " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Nasopharyngeal Carcinoma | Pembrolizumab | Bevacizumab", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454450", "session_name": "Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Wan Qin Chong", "middle_name": null, "last_name": null, "org_name": "", "Country": "Singapore", "Region": null, "City": null, "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Nasopharyngeal Carcinoma | Pembrolizumab ", "rest_events_topic_count": 1, "rest_events_topic": " Bevacizumab", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Wan Qin Chong ", "kol_full_name": "Wan Qin Chong " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Epigenomics", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454449", "session_name": "Targeting epigenetic pathways", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Wilbert Zwart", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Targeting epigenetic pathways", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Epigenomics", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Wilbert Zwart ", "kol_full_name": "Wilbert Zwart " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454571", "session_name": "Impact on surgery: Other tumour locations", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Winan Van Houdt", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Impact on surgery: Other tumour locations", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Winan Van Houdt ", "kol_full_name": "Winan Van Houdt " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Rare Cancers", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454816", "session_name": "Rare cancers", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Winette T. Van Der Graaf", "middle_name": null, "last_name": null, "org_name": "", "Country": "Netherlands", "Region": "Noord-Holland", "City": "Amsterdam", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Rare cancers", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Rare Cancers", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Winette T. Van Der Graaf ", "kol_full_name": "Winette T. Van Der Graaf " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiologists", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454569", "session_name": "The radiologist point of view", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Wolfgang G. Kunz", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Bayern", "City": "Munich", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The radiologist point of view", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiologists", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Wolfgang G. Kunz ", "kol_full_name": "Wolfgang G. Kunz " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Ribociclib | Cyclin-Dependent Kinases | Drug Therapy | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454778", "session_name": "Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer– second interim efficacy analysis of the randomized Phase III DETECT V trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Wolfgang Janni", "middle_name": null, "last_name": null, "org_name": "", "Country": "Germany", "Region": "Baden-Wurttemberg", "City": "Ulm", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer– second interim efficacy analysis of the randomized Phase III DETECT V trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Ribociclib | Cyclin-Dependent Kinases ", "rest_events_topic_count": 2, "rest_events_topic": " Drug Therapy | Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Wolfgang Janni ", "kol_full_name": "Wolfgang Janni " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Hematologic Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454820", "session_name": "Haematological malignancies", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Won Seog Kim", "middle_name": null, "last_name": null, "org_name": "", "Country": "Korea, South", "Region": "Kyonggi-do", "City": "Seoul", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Haematological malignancies", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Hematologic Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Won Seog Kim ", "kol_full_name": "Won Seog Kim " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Drug Therapy | Ivonescimab | Triple Negative Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454775", "session_name": "The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Xiaojia Wang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Zhejiang", "City": "Hangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Drug Therapy | Ivonescimab ", "rest_events_topic_count": 1, "rest_events_topic": " Triple Negative Breast Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Xiaojia Wang ", "kol_full_name": "Xiaojia Wang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunogenicity, Vaccine | MRNA Vaccines | Lymphoma, T-Cell", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454553", "session_name": "An Exploratory Study to Assess the Safety, Immunogenicity, and Preliminary Anti-tumor Activity of the EBV mRNA vaccine (WGc-043 injection) in Patients with NK/T Cell Lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Xingchen Peng", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Sichuan", "City": "Chengdu", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "An Exploratory Study to Assess the Safety", "rest_events_session_count": 2, "rest_events_session": " Immunogenicity, and Preliminary Anti-tumor Activity of the EBV mRNA vaccine (WGc-043 injection) in Patients with NK/T Cell Lymphoma", "events_topic": "Immunogenicity, Vaccine | MRNA Vaccines ", "rest_events_topic_count": 1, "rest_events_topic": " Lymphoma, T-Cell", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Xingchen Peng ", "kol_full_name": "Xingchen Peng " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Radiotherapy | Lymphoma, Non-Hodgkin", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454554", "session_name": "Initial Results of the Multicenter Phase 2 Trial of a Novel Hypofractionated Low-dose Radiotherapy for Indolent non-Hodgkin Lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Xinyue Wang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Beijing", "City": "Beijing", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Initial Results of the Multicenter Phase 2 Trial of a Novel Hypofractionated Low-dose Radiotherapy for Indolent non-Hodgkin Lymphoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Radiotherapy | Lymphoma, Non-Hodgkin", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Xinyue Wang ", "kol_full_name": "Xinyue Wang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Chronic Pain | Breast Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454508", "session_name": "Prevention and treatment of chronic pain in breast cancer survivors: A transmural perspective", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yael Slaghmuylder", "middle_name": null, "last_name": null, "org_name": "", "Country": "Belgium", "Region": "Oost-Vlaanderen", "City": "Gent", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Prevention and treatment of chronic pain in breast cancer survivors: A transmural perspective", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Chronic Pain | Breast Neoplasms", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yael Slaghmuylder ", "kol_full_name": "Yael Slaghmuylder " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Avelumab | Solid Tumors | Regorafenib | Thyroid Neoplasms", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454247", "session_name": "Regomune study : A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yann Godbert", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Aquitaine", "City": "Bordeaux", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Regomune study : A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Avelumab | Solid Tumors ", "rest_events_topic_count": 2, "rest_events_topic": " Regorafenib | Thyroid Neoplasms", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yann Godbert ", "kol_full_name": "Yann Godbert " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoadjuvant Therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454755", "session_name": "Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase 2 POTENTIAL study.", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yasuhiro Tsutani", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Osaka", "City": "Osaka", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase 2 POTENTIAL study.", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoadjuvant Therapy | Nivolumab ", "rest_events_topic_count": 1, "rest_events_topic": " Carcinoma, Non-Small-Cell Lung", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yasuhiro Tsutani ", "kol_full_name": "Yasuhiro Tsutani " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncolytic Viruses | Solid Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454736", "session_name": "The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yinan Shen", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Zhejiang", "City": "Hangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "The updated report of phase I trial of VG2025", "rest_events_session_count": 2, "rest_events_session": " a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors", "events_topic": "Oncolytic Viruses | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yinan Shen ", "kol_full_name": "Yinan Shen " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Oncolytic Viruses | Solid Tumors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454735", "session_name": "A phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yingqi Hua", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Shanghai", "City": "Shanghai", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A phase 1", "rest_events_session_count": 3, "rest_events_session": " open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors", "events_topic": "Oncolytic Viruses | Solid Tumors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yingqi Hua ", "kol_full_name": "Yingqi Hua " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lung Neoplasms | Pirfenidone | Idiopathic Pulmonary Fibrosis", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454757", "session_name": "Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yukinobu Goto", "middle_name": null, "last_name": null, "org_name": "", "Country": "Japan", "Region": "Ibaraki", "City": "Tsukuba", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lung Neoplasms | Pirfenidone ", "rest_events_topic_count": 1, "rest_events_topic": " Idiopathic Pulmonary Fibrosis", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yukinobu Goto ", "kol_full_name": "Yukinobu Goto " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Glioblastoma | Injections, Spinal", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454256", "session_name": "A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yulun Huang", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Jiangsu", "City": "Suzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Glioblastoma | Injections, Spinal", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yulun Huang ", "kol_full_name": "Yulun Huang " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Cetuximab | Avelumab | Radiotherapy | Squamous Cell Carcinoma Of Head And Neck", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454454", "session_name": "Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): final analysis of randomized phase III GORTEC 2017-01 REACH trial", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yungan Tao", "middle_name": null, "last_name": null, "org_name": "", "Country": "France", "Region": "Ile-De-France", "City": "Paris", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): final analysis of randomized phase III GORTEC 2017-01 REACH trial", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Cetuximab | Avelumab ", "rest_events_topic_count": 2, "rest_events_topic": " Radiotherapy | Squamous Cell Carcinoma Of Head And Neck", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yungan Tao ", "kol_full_name": "Yungan Tao " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Tislelizumab | Programmed Cell Death 1 Receptor | Lymphoma | Hodgkin Disease", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454551", "session_name": "Efficacy and safety results from the phase 2 study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yuqin Song", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Beijing", "City": "Beijing", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Efficacy and safety results from the phase 2 study of Timdarpacept in combination with tislelizumab", "rest_events_session_count": 1, "rest_events_session": " in prior anti-PD-1 failed classical Hodgkin lymphoma", "events_topic": "Tislelizumab | Programmed Cell Death 1 Receptor ", "rest_events_topic_count": 2, "rest_events_topic": " Lymphoma | Hodgkin Disease", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yuqin Song ", "kol_full_name": "Yuqin Song " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Socioeconomic Factors", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454321", "session_name": "Socioeconomic Status and Cancer: An Umbrella Review and Burden Estimation Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Yuxin He", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Sichuan", "City": "Chengdu", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Socioeconomic Status and Cancer: An Umbrella Review and Burden Estimation Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Socioeconomic Factors", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Yuxin He ", "kol_full_name": "Yuxin He " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Lymphoma, T-Cell, Peripheral | Mitoxantrone | Liposomes", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454552", "session_name": "Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A phase l/II Study", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Zhiming Li", "middle_name": null, "last_name": null, "org_name": "", "Country": "China", "Region": "Guangdong", "City": "Guangzhou", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A phase l/II Study", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Lymphoma, T-Cell, Peripheral | Mitoxantrone ", "rest_events_topic_count": 1, "rest_events_topic": " Liposomes", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Zhiming Li ", "kol_full_name": "Zhiming Li " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Immunotherapy", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454505", "session_name": "Safe administration of subcutaneous immunotherapy: Operating procedures for nurses", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Zoe O’Neil", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Coventry", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Safe administration of subcutaneous immunotherapy: Operating procedures for nurses", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Immunotherapy", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Zoe O’Neil ", "kol_full_name": "Zoe O’Neil " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Neoplasms | Protein Degradation", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454741", "session_name": "Designing protein degraders for cancer treatment", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Zoran Rankovic", "middle_name": null, "last_name": null, "org_name": "", "Country": "United Kingdom", "Region": "England", "City": "Sutton", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Designing protein degraders for cancer treatment", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Neoplasms | Protein Degradation", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Zoran Rankovic ", "kol_full_name": "Zoran Rankovic " }, { "proj_kol_id": false, "eid": "128202", "event_topics": "Sacroma", "npi_num": "0", "hcp_pin_alias": "FU_HCP_5454779", "session_name": "Sacroma", "name": "2024 European Society for Medical Oncology Congress (ESMO)", "kol_id": "0", "first_name": "Zsuzsanna Papai", "middle_name": null, "last_name": null, "org_name": "", "Country": "Hungary", "Region": "Budapest", "City": "Budapest", "num_sess": "1", "opt_in_out_status": null, "url1": "https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session", "session_note": null, "events_session": "Sacroma", "rest_events_session_count": 0, "rest_events_session": "", "events_topic": "Sacroma", "rest_events_topic_count": 0, "rest_events_topic": "", "kol_name": "
\n\t\t\t\t\t \n\t\t\t\t\t
Zsuzsanna Papai ", "kol_full_name": "Zsuzsanna Papai " } ] } }